Document and Entity Information
Document and Entity Information - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Feb. 26, 2021 | Jun. 30, 2020 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2020 | ||
Document Fiscal Year Focus | 2020 | ||
Document Fiscal Period Focus | FY | ||
Trading Symbol | THRM | ||
Entity Registrant Name | GENTHERM INCORPORATED | ||
Entity Central Index Key | 0000903129 | ||
Entity Current Reporting Status | Yes | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Entity Common Stock, Shares Outstanding | 32,944,198 | ||
Entity Shell Company | false | ||
Entity File Number | 0-21810 | ||
Entity Tax Identification Number | 95-4318554 | ||
Entity Address, Address Line One | 21680 Haggerty Road | ||
Entity Address, City or Town | Northville | ||
Entity Address, State or Province | MI | ||
Entity Address, Postal Zip Code | 48167 | ||
City Area Code | 248 | ||
Local Phone Number | 504-0500 | ||
Entity Interactive Data Current | Yes | ||
Entity Incorporation, State or Country Code | MI | ||
Security Exchange Name | NASDAQ | ||
Title of 12(b) Security | Common Stock, no par value | ||
Document Transition Report | false | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Public Float | $ 1,264,214,873 | ||
Document Annual Report | true | ||
Documents Incorporated by Reference | DOCUMENTS INCORPORATED BY REFERENCE Portions of the proxy statement for the 2021 annual meeting of shareholders are incorporated by reference into Part III of this Report to the extent described herein. |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Current Assets: | ||
Cash and cash equivalents | $ 268,345 | $ 50,443 |
Restricted cash | 2,505 | |
Accounts receivable, net | 211,672 | 159,710 |
Inventory, net | 122,401 | 118,479 |
Other current assets | 41,188 | 42,726 |
Total current assets | 643,606 | 373,863 |
Property and equipment, net | 152,581 | 160,605 |
Goodwill | 68,024 | 64,572 |
Other intangible assets, net | 46,421 | 49,783 |
Operating lease right-of-use assets | 30,642 | 11,587 |
Deferred income tax assets | 73,912 | 69,096 |
Other non-current assets | 7,653 | 9,326 |
Total assets | 1,022,839 | 738,832 |
Current Liabilities: | ||
Accounts payable | 116,043 | 83,035 |
Current lease liabilities | 6,032 | 4,586 |
Current maturities of long-term debt | 2,500 | 2,500 |
Other current liabilities | 81,409 | 66,583 |
Total current liabilities | 205,984 | 156,704 |
Long-term debt, less current maturities | 189,934 | 78,124 |
Non-current lease liabilities | 24,233 | 6,751 |
Pension benefit obligation | 8,163 | 8,057 |
Other non-current liabilities | 8,194 | 5,100 |
Total liabilities | 436,508 | 254,736 |
Common Stock: | ||
No par value; 55,000,000 shares authorized 32,921,341 and 32,674,354 issued and outstanding at December 31, 2020 and December 31, 2019, respectively | 121,073 | 102,507 |
Paid-in capital | 7,458 | 10,852 |
Accumulated other comprehensive loss | (14,982) | (42,355) |
Accumulated earnings | 472,782 | 413,092 |
Total shareholders’ equity | 586,331 | 484,096 |
Total liabilities and shareholders’ equity | $ 1,022,839 | $ 738,832 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2020 | Dec. 31, 2019 |
Statement Of Financial Position [Abstract] | ||
Common Stock, par value | ||
Common Stock, shares authorized | 55,000,000 | 55,000,000 |
Common Stock, shares issued | 32,921,341 | 32,674,354 |
Common Stock, shares outstanding | 32,921,341 | 32,674,354 |
Consolidated Statements of Inco
Consolidated Statements of Income - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income Statement [Abstract] | |||
Product revenues | $ 913,098 | $ 971,684 | $ 1,048,505 |
Type of Revenue [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember |
Cost of sales | $ 644,994 | $ 683,349 | $ 743,647 |
Gross margin | 268,104 | 288,335 | 304,858 |
Operating expenses: | |||
Research and development expenses | 81,968 | 91,033 | 98,663 |
Reimbursed research and development expenses | (13,928) | (18,557) | (18,763) |
Net research and development expenses | 68,040 | 72,476 | 79,900 |
Selling, general and administrative expenses | 105,044 | 118,680 | 137,398 |
Restructuring expenses | 5,803 | 12,919 | 14,772 |
Total operating expenses | 178,887 | 204,075 | 232,070 |
Operating income | 89,217 | 84,260 | 72,788 |
Interest expense, net | (4,559) | (4,763) | (4,942) |
Foreign currency (loss) gain | (5,439) | 2,326 | 622 |
Impairment loss | (21,206) | (11,476) | |
Net loss on divestitures | (1,587) | ||
Other income | 2,337 | 121 | 1,127 |
Earnings before income tax | 81,556 | 59,151 | 58,119 |
Income tax expense | 21,866 | 10,285 | 16,220 |
Net income | $ 59,690 | $ 48,866 | $ 41,899 |
Basic earnings per share | $ 1.83 | $ 1.48 | $ 1.17 |
Diluted earnings per share | $ 1.81 | $ 1.47 | $ 1.16 |
Weighted average number of shares – basic | 32,666,025 | 33,120,076 | 35,920,782 |
Weighted average number of shares – diluted | 33,028,104 | 33,297,589 | 36,177,144 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Statement Of Income And Comprehensive Income [Abstract] | |||
Net income | $ 59,690 | $ 48,866 | $ 41,899 |
Other comprehensive income (loss): | |||
Cumulative effect of accounting change due to ASU 2018-02 | (40) | ||
Pension benefit obligations | (80) | (1,032) | 76 |
Foreign currency translation adjustments | 27,242 | (2,722) | (19,602) |
Unrealized gain on foreign currency derivative securities, net of tax | 211 | 899 | 796 |
Unrealized loss on commodity derivative securities, net of tax | (286) | ||
Other comprehensive income (loss), net of tax | 27,373 | (2,855) | (19,056) |
Comprehensive income | $ 87,063 | $ 46,011 | $ 22,843 |
Consolidated Statements of Chan
Consolidated Statements of Changes In Shareholders' Equity - USD ($) $ in Thousands | Total | Cumulative Effect of Accounting Change Due to Adoption of ASU | Common Stock | Paid-in Capital | AOCI Attributable to Parent | AOCI Attributable to ParentCumulative Effect of Accounting Change Due to Adoption of ASU | Retained Earnings | Retained EarningsCumulative Effect of Accounting Change Due to Adoption of ASU |
Beginning Balance at Dec. 31, 2017 | $ 553,874 | $ 265,048 | $ 15,625 | $ (20,444) | $ 293,645 | |||
Beginning Balance (ASU 2014-09) at Dec. 31, 2017 | $ (3,264) | $ (3,264) | ||||||
Beginning Balance (ASU 2016-16) at Dec. 31, 2017 | 31,645 | 31,645 | ||||||
Beginning Balance (ASU 2018-02) at Dec. 31, 2017 | $ (40) | 40 | ||||||
Beginning Balance (in shares) at Dec. 31, 2017 | 36,761,000 | |||||||
Net income | 41,899 | 41,899 | ||||||
Other comprehensive income (loss) | (19,056) | |||||||
Other comprehensive loss | (19,016) | (19,016) | ||||||
Stock compensation, net | 22,635 | $ 23,326 | (691) | |||||
Stock repurchase | (148,074) | $ (148,074) | ||||||
Stock repurchase (in shares) | (3,470,000) | |||||||
Ending Balance at Dec. 31, 2018 | 479,699 | $ 140,300 | 14,934 | (39,500) | 363,965 | |||
Ending Balance (ASU 2016-02) at Dec. 31, 2018 | $ 261 | $ 261 | ||||||
Ending Balance (in shares) at Dec. 31, 2018 | 33,857,000 | |||||||
Stock compensation, net, shares | 566,000 | |||||||
Net income | 48,866 | 48,866 | ||||||
Other comprehensive income (loss) | (2,855) | (2,855) | ||||||
Stock compensation, net | 21,408 | $ 25,490 | (4,082) | |||||
Stock repurchase | (63,283) | $ (63,283) | ||||||
Stock repurchase (in shares) | (1,595,000) | |||||||
Ending Balance at Dec. 31, 2019 | $ 484,096 | $ 102,507 | 10,852 | (42,355) | 413,092 | |||
Ending Balance (in shares) at Dec. 31, 2019 | 32,674,354 | 32,674,000 | ||||||
Stock compensation, net, shares | 412,000 | |||||||
Net income | $ 59,690 | 59,690 | ||||||
Other comprehensive income (loss) | 27,373 | 27,373 | ||||||
Stock compensation, net | 24,264 | $ 27,658 | (3,394) | |||||
Stock repurchase | (9,092) | $ (9,092) | ||||||
Stock repurchase (in shares) | (246,000) | |||||||
Ending Balance at Dec. 31, 2020 | $ 586,331 | $ 121,073 | $ 7,458 | $ (14,982) | $ 472,782 | |||
Ending Balance (in shares) at Dec. 31, 2020 | 32,921,341 | 32,921,000 | ||||||
Stock compensation, net, shares | 493,000 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Operating Activities: | |||
Net income | $ 59,690 | $ 48,866 | $ 41,899 |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 41,114 | 44,246 | 50,638 |
Deferred income taxes | 849 | (7,743) | 6,699 |
Non-cash stock based compensation | 8,829 | 6,253 | 9,047 |
Change in defined benefit pension plans | (748) | (570) | 82 |
Loss on sale of property and equipment | 683 | 462 | 2,602 |
Operating lease expense | 7,157 | 6,173 | |
Gain on sale of patents | (1,978) | ||
Impairment loss | 21,206 | 11,476 | |
Net loss on divestitures | 1,587 | ||
Other | 1,612 | ||
Changes in assets and liabilities: | |||
Accounts receivable, net | (46,742) | 7,154 | 3,023 |
Inventory | (814) | (3,859) | (7,689) |
Other assets | (18,240) | 7,996 | (4,428) |
Accounts payable | 29,960 | (10,253) | 12,380 |
Other liabilities | 30,935 | (4,327) | (7,295) |
Net cash provided by operating activities | 110,695 | 118,803 | 118,434 |
Investing Activities: | |||
Purchases of property and equipment | (17,219) | (23,729) | (41,541) |
Acquisition of intangible assets | (3,141) | ||
Proceeds from the sale of patents and property and equipment | 2,140 | 219 | 799 |
Proceeds from divestiture of businesses, net | 44,173 | ||
Acquisition of subsidiary, net of cash acquired | (14,823) | (15) | |
Net cash (used in) provided by investing activities | (18,220) | 5,840 | (40,757) |
Financing Activities: | |||
Borrowing of debt | 201,194 | 37,812 | 94,679 |
Repayments of debt | (91,439) | (96,999) | (99,460) |
Cash paid for the repurchase of Common Stock | (9,092) | (63,283) | (148,074) |
Proceeds from the exercise of Common Stock options | 16,552 | 16,557 | 14,777 |
Cash paid for the cancellation of restricted stock | (1,117) | (1,402) | (1,188) |
Acquisition contingent consideration payment | (618) | ||
Cash paid for financing costs | (1,278) | ||
Net cash provided by (used in) financing activities | 115,480 | (108,593) | (139,266) |
Foreign currency effect | 7,442 | (2,722) | (1,963) |
Net increase (decrease) in cash, cash equivalents and restricted cash | 215,397 | 13,328 | (63,552) |
Cash, cash equivalents and restricted cash at beginning of period | 52,948 | 39,620 | 103,172 |
Cash, cash equivalents and restricted cash at end of period | 268,345 | 52,948 | 39,620 |
Supplemental disclosure of cash flow information: | |||
Cash paid for taxes | 5,013 | 11,008 | 23,159 |
Cash paid for interest | $ 4,204 | $ 4,462 | $ 5,027 |
Overview
Overview | 12 Months Ended |
Dec. 31, 2020 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Overview | Note 1 — Overview Gentherm Incorporated is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Unless the context otherwise requires, the terms “Gentherm”, “Company”, “we”, “us” and “our” used herein refer to Gentherm Incorporated and its consolidated subsidiaries. Our products provide solutions for automotive passenger climate comfort and convenience, battery thermal management and cell connecting systems, as well as patient temperature management within the health care industry. Our automotive products can be found on the vehicles of nearly all major automotive manufacturers operating in North America and Europe and several major automotive manufacturers in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. The Company is also developing a number of new technologies and products that is expected to help enable improvements to existing products and to create new product applications for existing and new markets. On February 1, 2019, the Company completed the divestiture of its environmental test equipment business, Cincinnati Sub Zero industrial chamber business (“CSZ-IC”) and on October 1, 2019, the Company completed the divestiture of its remote power generation systems business, Gentherm Global Power Technologies (“GPT”). The Company’s consolidated financial statements herein include the results of CSZ-IC and GPT through their respective dates of divestiture. Impact of COVID-19 The COVID-19 pandemic has significantly disrupted global economic activity, including the automotive market. The COVID-19 pandemic was first identified in China around December 2019. The impact of the outbreak quickly expanded beyond China and its surrounding region and has significantly and adversely impacted the entire global economy and automotive market in 2020. During the first quarter of 2020, customer plants in North America and Europe were closed beginning in the second half of March due to the pandemic. This resulted in temporary, partial closures of several of our manufacturing facilities in North America and Europe by the end of March 2020. Customer plants and our manufacturing facilities in Asia were closed for several weeks in February and operated at reduced volumes in March, resuming production to near full capacity by the end of the first quarter, which continued throughout the second quarter. However, during the second quarter of 2020, our manufacturing facilities in North America and Europe remained closed until the last week in May due to the pandemic, gradually resuming production to near full capacity in North America, and to about 70% capacity in Europe by the end of June. During the second half of 2020, our customers’ plants were open, and our production volumes were stronger than pre-COVID levels at our manufacturing facilities. The Company has implemented additional health and safety precautions and protocols in response to the pandemic and government guidelines to help ensure the safety and health of all its employees, and it continues to assess and update business continuity plans in the context of this pandemic. The consequences of the pandemic and adverse impact to the economy continue to evolve and the future adverse impact on our business and financial statements remains subject to significant uncertainty as of the date of this filing. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Note 2 — Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain prior period amounts have been reclassified to conform to current period presentation. In 2020, the Industrial reporting segment was renamed the Medical reporting segment to reflect the patient temperature management business as the focus and strategic direction of this segment, and the advanced research and development organization was moved to the Automotive segment. See below under “Segment Reporting” in this footnote and Note 20, “Segment Reporting” for further details. Revision of Prior Period Financial Statements During the fourth quarter of 2020, management determined that certain deferred tax assets were not properly evaluated for realizability under ASC Topic 740, Income Taxes which resulted in an immaterial error that affected previously issued financial statements for the year ended December 31, 2019. In accordance with ASC 250: Accounting Changes and Error Corrections (“ASC 250”), w e have corrected the error by revising the historical consolidated financial statements and related disclosures for the year ended December 31, 2019 . Management evaluated the effect of the adjustment on the Company’s financial statements under provision ASC 250, Staff Accounting Bulletin No. 99: Materiality, and Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements and concluded that the adjustment made was immaterial to the previously issued financial statements for the year ended December 31, 2019. The impact to the consolidated statements of income for the year ended December 31, 2019 and the consolidated balance sheet as of December 31, 2019 is as follows: Year Ended December 31, 2019 As Reported Adjustment As Revised Income Statement: Earnings before income tax $ 59,151 $ — $ 59,151 Income tax expense 21,645 (11,360 ) 10,285 Net income 37,506 11,360 48,866 Basic EPS $ 1.13 $ 0.35 $ 1.48 Diluted EPS $ 1.13 $ 0.34 $ 1.47 December 31, 2019 As Reported Adjustment As Revised Balance Sheet: Deferred income tax asset - long term $ 57,650 $ 11,446 $ 69,096 Total non-current assets 353,523 11,446 364,969 Total assets 727,386 11,446 738,832 Accumulated other comprehensive (loss) income (42,441 ) 86 (42,355 ) Accumulated earnings 401,732 11,360 413,092 Total shareholders' equity $ 727,386 $ 11,446 $ 738,832 Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. Investments in affiliates in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20%), investments in affiliates are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Use of Estimates In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. Segment Reporting The Company has two reportable segments: Automotive Medical In 2018 and 2019, our Industrial reporting segment represented the combined results from our patient temperature management systems business (“Medical”), remote power generation systems business, Gentherm Global Power Technologies (“GPT”) (through its divestiture on October 1, 2019), environmental test equipment business, Cincinnati Sub Zero industrial chamber business (“CSZ-IC”) (through its divestiture on February 1, 2019) and our advanced research and development division. The operating results from these businesses and division previously were presented together as one reporting segment because of their historical joint concentration on identifying new markets and product applications based on thermal management technologies. In 2020, the Industrial reporting segment was renamed the Medical reporting segment to reflect the patient temperature management business as the focus and strategic direction of this segment. Also, during 2020, the advanced research and development costs not associated with the Medical segment were moved to the Automotive segment, as this organization primarily supports the Automotive related research and development activities following the divestitures of GPT and CSZ-IC. Revenue Recognition Revenue is recognized from agreements containing enforceable rights and obligations, when promised goods are delivered or services are completed. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from Product revenues. Shipping and handling fees billed to customers are included in Product revenues, while costs of shipping and handling are included in Cost of sales. Automotive Revenues The Company provides production parts to its customers under long-term supply agreements (“LTAs”). The duration of an LTA is generally consistent with the life cycle of a vehicle; however, an LTA does not reach the level of a performance obligation until Gentherm receives either a purchase order and/or a materials release from the customer for a specific number of production parts at a specified price, at which point an enforceable contract exists. Revenue is recognized when control of the production parts has transferred to the customer according to the terms of the contract, which typically occurs when the parts are shipped or delivered to the customer’s premises. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring production parts. Certain LTAs provide for annual price reductions over the production life of the vehicle. Agreements that are determined to provide customers with purchase option discounts that would not be received without entering into the contract are considered to contain a material right (for example, a discount given to a customer that is incremental to the range of discounts typically given to that class of customer). The material right represents a purchase option that provides the customer with the ability to purchase additional production parts at a set price in the future and is accounted for as a separate performance obligation. Under these circumstances, each transfer of production parts under the LTA requires allocation of the purchase price to the production part and the purchase option. As a practical alternative to estimating the standalone selling price of an option, the Company allocates transaction price to the purchase option by reference to the production part volumes expected to be ordered and the consideration expected to be received over the life of the vehicle program. The production part’s relative standalone selling price observed under the LTA is subtracted from the total amount of consideration expected to be received in exchange for transferring of parts under the current contract and the difference is allocated to the purchase option. Revenue from options containing a material right is recognized when the amounts billed by the customer for production parts transferred, under the LTA, is less than the standalone selling price of those production parts. Medical Revenues Revenues from our patient temperature management business unit are generated from the sale of products and equipment. Our medical products and equipment focus on body and blood temperature management. The Company sells medical products and equipment primarily through distributor and group purchasing organization agreements. These agreements allow member participants to the distributor or group purchasing organization to make purchases at discounted prices negotiated by the distributor or group purchasing organization. A rebate is incurred at the point in time a member participant purchases product covered under these types of agreements. Rebates are accounted for as variable consideration, using an expected value, probability weighted approach, based on the level of sales to the distributor and the time lag between the initial sale and the rebate claim in determining the transaction price of a contract. Revenue is recognized at the point in time the medical products or equipment is transferred to the customer. GPT and CSZ-IC Revenues Revenues from our divested businesses, GPT and CSZ-IC, were generated from the sale of products and services. GPT and CSZ-IC customers commonly entered into multiple-element agreements for the purchase of products and services. Installation services, for example, were separate and distinct performance obligations that were often included in contracts to purchase customized environmental test chambers. Depending on the application, delivery of an environmental test chamber or remote power generation system to the customer’s place of business could range from two weeks to nine months from commencement of the contract. Installation services, while reliant on the specifications and timing from the customer, rarely remained incomplete more than two months after delivery. Revenues allocated to environmental test chambers or remote power systems were based on the stand-alone selling price of the products themselves. Judgement was used to determine the degree to which early pay discounts and other credits were utilized in the calculation of standalone selling price, and only included to the extent it was probable that a significant reversal of any incremental revenue would not occur. Revenues were recognized at the point in time the chamber or power system was shipped to the customer. For contracts that also included a promise for installation, the portion of total transaction price allocated to the installation was recognized as revenue at the point in time the installation was complete. GPT and CSZ-IC often required milestone payments for contracts to provide environmental test chambers or remote power systems to customers. Milestone payments did not provide the Company with a right to payment for the work completed to date and did not represent the satisfaction of a performance obligation. Milestone payments were deferred and reported within unearned revenue until construction was complete and the unit had been delivered or was installed. If the environmental test chamber contract included a separate promise to provide installation services, any installation-related payments received from the customer were deferred until the point in time the installation was complete. Assets Recognized from the Costs to Obtain a Contract with a Customer We recognize an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year. Total capitalized costs to obtain a contract were $1,805 and $1,893 as of December 31, 2020 and 2019, respectively. These amounts are recorded in Other current assets and are being amortized into Product revenues over the expected production life of the program. During the year ended December 31, 2020 and 2019, $263 and $1,006, respectively, was amortized into Product revenues. Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with original maturities of less than 90 days to be cash equivalents. Cash balances in individual banks may exceed the federally insured limit by the Federal Deposit Insurance Corporation. The Company had Cash and cash equivalents of $106,598 and $35,735 held in foreign jurisdictions as of December 31, 2020 and 2019, respectively. Restricted cash includes cash that is legally restricted as to use or withdrawal. Disclosures About Fair Value of Financial Instruments The carrying amounts of financial instruments comprising cash and cash equivalents, short-term investments and accounts receivable approximate fair value because of the short maturities of these instruments. The carrying amount of the Company’s U.S. Revolving Note approximates its fair value because interest charged on the loan balance is variable. See Note 14 for information about the techniques used to assess the fair value of financial assets and liabilities, including our fixed rate debt instruments. Concentration of Credit Risk Financial assets, which subject the Company to concentration of credit risk, consist primarily of cash equivalents, short-term investments and accounts receivable. Cash equivalents consist primarily of money market funds managed by major financial services companies. The credit risk for these cash equivalents is considered low. The Company does not require collateral from its customers. As of December 31, 2020, Lear and Adient both individually represented 18% of the Company’s accounts receivable balance. As of December 31, 2019, Lear and Adient both individually represented 21% of the Company’s accounts receivable balance. These accounts are currently in good standing. Accounts Receivable Accounts receivable are stated at the invoiced amount, less allowance for doubtful accounts for estimated amounts not expected to be collected, and do not bear interest. The Company determines the allowances based on historical write-off experience by industry and regional economic data, current expectations of future credit losses and historical cash discounts. Inventory The Company’s inventory is measured at the lower of cost or net realizable value, with cost being determined using the first-in first-out basis. Raw materials, consumables and commodities are measured at cost of purchase and unfinished and finished goods are measured at cost of production, using the weighted average method. If the net realizable value expected on the reporting date is below cost, a write-down is recorded to adjust inventory to its net realizable value. We recognize a reserve for obsolete and slow-moving inventories based on estimates of future sales and an inventory item’s capacity to be repurposed for a different use. We consider the number of months supply on hand based on current planned requirements, uncommitted future projections and historical usage in estimating the inventory reserve. Property and Equipment Property and equipment, including additions and improvements, are recorded at cost less accumulated depreciation. Expenditures for general repairs and maintenance are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded as Operating income or expense. Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s Property and equipment are as follows: Asset Category Useful Life Buildings and improvements 2 to 50 years Plant and equipment 1 to 20 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 10 years The Company recognized depreciation expense of $31,037, $33,639 and $36,270 for the years ended December 31, 2020, 2019 and 2018, respectively. Tooling The Company incurs costs related to tooling used in the manufacture of products sold to its customers. In some cases, the Company enters into contracts with its customers whereby the Company incurs the costs to design, develop and purchase tooling and is then reimbursed by the customer under a reimbursement contract. Tooling costs that will be reimbursed by customers are included in Other current assets at the lower of accumulated cost or the customer reimbursable amount. As of December 31, 2020 and 2019, respectively, $4,831 and $5,347 of reimbursable tooling was capitalized within Other current assets. Company-owned tooling is included in Property and equipment and depreciated over its expected useful life, generally two to ten years. Management periodically evaluates the recoverability of tooling costs, based on estimated future cash flows, and makes provisions, where appropriate, for tooling costs that will not be recovered. Goodwill and Other Intangible Assets Goodwill and other intangible assets recorded in conjunction with business combinations are based on the Company’s estimate of fair value, as of the date of acquisition. Amortization is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 6 to 15 years Technology 4 to 8 years Product development costs 1 to 15 years Trade names Indefinite Our business strategy largely centers on designing products based upon internally developed and purchased technology, and we protect certain technology with patents that have value to our business strategy. Our policy is to expense all costs associated with the development and issuance of new patents as incurred. Such costs are classified as research and development expenses in our consolidation statements of income. Patents purchased as part of a business combination are capitalized based on their fair values. Periodically we review the recoverability and remaining lives of our capitalized patents. If necessary, we make adjustments to reported amounts based upon unfavorable impacts from market conditions, the emergence of competitive technologies or changes in our projected business plans. Impairments of Long-Lived Assets, Other Intangible Assets and Goodwill Goodwill is tested for impairment at least annually as of December 31 and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In conducting our annual impairment assessment testing, we first perform a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount. If not, no further goodwill impairment testing is performed. If it is more likely than not that a reporting unit’s fair value is less than its carrying amount, or if we elect not to perform a qualitative assessment of a reporting unit, we then compare the fair value of the reporting unit to the related net book value. If the net book value of a reporting unit exceeds its fair value, an impairment loss is measured and recognized. The Company utilizes an income statement approach to estimate the fair value of a reporting unit and a market valuation approach to further support this analysis (level 3). The income statement approach is based on projected debt-free cash flow that is discounted to the present value using discount factors that consider the timing and risk of cash flows. We believe that this approach is appropriate because it provides a fair value estimate based on the reporting unit’s expected long-term operating cash flow performance. This approach also mitigates the impact of cyclical trends that occur in the industry. Fair value is estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used is the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital is adjusted to reflect a risk factor, if necessary. Other significant assumptions include terminal value growth rates, terminal value margin rates, future capital expenditures and changes in future working capital requirements. While there are inherent uncertainties related to the assumptions used and to management’s application of these assumptions to this analysis, we believe that the income statement approach provides a reasonable estimate of the fair value of a reporting unit. The Company performs its indefinite-lived intangible asset impairment assessment annually as of December 31, and between annual assessments if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount . Accrued Warranty Costs The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including claims already filed by customers, the warranty accrual is adjusted quarterly to reflect management’s best estimate of future claims. Research and Development Expenses Research and development activities are expensed as incurred. The Company groups development and prototype costs and related reimbursements in Research and development. The Company recognizes amounts due as reimbursements for expenses as these expenses are incurred. Leases The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. We also have operating leases for office equipment and automobiles. Excluding land leases, our leases have remaining lease terms ranging from less than 1 year to 11 years and may include options to extend the lease. Land leases have remaining lease terms that range from 40 to 42 years and some which specify that the end of the lease term is at the discretion of the lessee. We do not have lease arrangements with related parties. The Company determines whether a contractual arrangement is or contains a lease at inception. Leases that are operating in nature are recognized in Operating lease right-of-use assets, Current lease liabilities and Non-current lease liabilities on our consolidated balance sheets. Gentherm is not currently party to any leases that qualify as financing leases. Lease liabilities are measured initially at the present value of the sum of the future minimum rental payments at the commencement date of the lease. Lease payments that will vary in the future due to changes in facts and circumstances are excluded from the calculation of rental payments, unless those variable payments are based on an index or rate. Rental payments are discounted using an incremental borrowing rate based on the Company’s credit rating, determined on a fully collateralized loan basis from information available at commencement date, and the duration of the lease term (the “reference rate”). Judgement is used to assess the importance of risk factor inputs during the computation of the Company’s credit rating. For leases at foreign subsidiaries denominated in U.S. Dollars, a risk premium associated with the borrower subsidiary’s country is added to the reference rate. For significant leases at foreign subsidiaries denominated in a foreign currency, the U.S. Dollar risk free rate with a duration similar to that of the lease term is subtracted from the reference rate and a corresponding foreign currency risk free rate with a duration similar to that of the lease term is added to the reference rate. Operating lease right-of-use assets are measured at the amount of the lease liability, adjusted for prepaid or accrued lease payments, lease incentive received, and initial direct costs incurred, as applicable. Periods covered by an option to extend the lease are initially included in the measurement of an operating lease right-of-use asset and lease liability only when it is reasonably certain we will exercise the option. Gentherm’s lease agreements do not contain residual value guarantees or impose restrictions or covenants on the Company. For all classes of underlying assets, the Company accounts for leases that contain separate lease and non-lease components as containing a single lease component. The Company does not recognize lease right-of-use assets and lease liabilities from leases with an original lease term of 12 months or less and, instead, recognizes rent payments on a straight-line basis over the lease term in the consolidated statements of income. Income Taxes The Company records income tax expense using the liability method which specifies that deferred tax assets and liabilities be measured each year based on the difference between the financial statement and tax base of assets and liabilities at the applicable enacted tax rates. A valuation allowance is provided for deferred tax assets when management considers it more likely than not that the asset will not be realized. At December 31, 2020 and 2019, a valuation allowance has been provided for certain deferred tax assets which the Company has concluded are more likely than not to not be realized. If future annual taxable income were to be significantly less than current and projected levels, there is a risk that certain of our deferred tax assets not already provided for by the valuation allowance would expire prior to utilization. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in Income tax expense. Derivative Financial Instruments – Hedge Accounting The Company accounts for some of its derivative financial instruments as cash flow hedges. For derivative contracts which can be classified as a cash flow hedge, the effective potion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive income in the consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive income is recorded in earnings in the consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. Any ineffective portion of the gain or loss is recognized in the consolidated statements of income under Foreign currency (loss) gain. These hedging transactions and the respective correlations meet the requirements for hedge accounting. Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of Common Stock outstanding during the respective period. The Company’s diluted earnings per common share give effect to all potential shares of Common Stock outstanding during a period that are not anti-dilutive. In computing the number of diluted shares outstanding, the treasury stock method is used in order to arrive at a net number of shares created upon the conversion of Common Stock equivalents. Stock Based Compensation Share based payments that involve the issuance of Common Stock to employees, including grants of employee stock options, restricted stock, and time-based and performance-based restricted stock units, are recognized in the financial statements as compensation expense based upon the fair value on the date of grant. Performance-based restricted stock unit awards are measured based on either a target return on invested capital ratio (“ROIC”), as defined in the award agreement, for a specified fiscal year, or the Company’s common stock market price returning a target total shareholder return (“TSR”), as defined, during a specific three-year measurement period. Performance-based restricted stock units cliff vest after three years based on the achievement of performance measurements. Share based payments that are satisfied only by the payment of cash, such as stock appreciation rights, are accounted for as liabilities. The liability is reported at market value of the vested portion of the underlying units. During each period, the change in the liability is recorded as compensation expense during periods when the liability increases or income during periods in which the liability decreases. Pension Plans The Company’s obligations and expenses for its pension plans are dependent on the Company’s selection of discount rate, expected long-term rate of return on plan assets and other assumptions used by actuaries to calculate these amounts. |
New Accounting Pronouncements
New Accounting Pronouncements | 12 Months Ended |
Dec. 31, 2020 | |
New Accounting Pronouncements And Changes In Accounting Principles [Abstract] | |
New Accounting Pronouncements | Note 3 — New Accounting Pronouncements Recently Adopted Accounting Pronouncements Expected Credit Losses In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets held. The Company adopted ASU 2016-13 as of January 1, 2020 and there was no significant impact on its consolidated condensed financial statements and related disclosures as a result. The Company considered, among other things, the current and expected future economic and market conditions related to the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. Cloud Computing Arrangements That Are Service Contracts In August 2018, the FASB issued ASU 2018-15, “Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” ASU 2018-15 requires implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement if those costs would be capitalized by the customer in a software licensing arrangement under the internal-use software guidance. The Company adopted ASU 2018-15 as of January 1, 2020 and there was no significant impact on its consolidated condensed financial statements and related disclosures as a result. Fair Value Measurement In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 removes certain disclosure requirements, including (i) the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, (ii) the policy for timing of transfer between levels, and (iii) the valuation processes for Level 3 fair value measurements. ASU 2018-13 also adds new disclosure requirements, including (i) the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The Company adopted ASU 2018-13 as of January 1, 2020 and there was no significant impact on its consolidated condensed financial statements and related disclosures as a result. Retirement Benefits In August 2018, the FASB issued ASU 2018-14, “Compensation – Retirement Benefits – Defined Benefit Plans – General (Subtopic 715-20): Disclosure Framework – Changes to the Disclosure Requirements for Defined Benefit Plans.” ASU 2018-14 removes certain disclosure requirements, including (i) the amounts in accumulated other comprehensive income expected to be recognized as components of net periodic benefit cost over the next fiscal year, and (ii) the amount and timing of plan assets expected to be returned to the employer. ASU 2018-14 also adds new disclosure requirements, including (i) the weighted-average interest crediting rates for cash balance plans and other plans with promised interest crediting rates and (ii) an explanation of the reasons for significant gains and losses related to changes in the benefit obligation for the period. The Company adopted ASU 2018-14 as of December 31, 2020 and there was no significant impact on its consolidated condensed financial statements and related disclosures as a result. Recently Issued Accounting Pronouncements Not Yet Adopted Income Taxes In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes". This ASU simplifies the accounting for income taxes by removing certain exceptions previously included in the guidance. In addition, the ASU amends existing guidance to improve consistent application. ASU 2019-12 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within those reporting periods. Early adoption of the amendments in this update is permitted. The adoption of this standard is not expected to have a significant impact on the Company’s financial statements or financial disclosures Reference Rate Reform In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of Effects of Reference Rate Reform on Financial Reporting”. ASU 2020-04 provides practical expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments in this update apply only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued as a result of reference rate reform. These amendments are not applicable to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. ASU No. 2020-04 is effective as of March 12, 2020 through December 31, 2022 and may be applied to contract modifications and hedging relationships from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company will adopt this standard when LIBOR is discontinued and does not expect a material impact to its consolidated financial statements. |
Acquisitions and Divestitures
Acquisitions and Divestitures | 12 Months Ended |
Dec. 31, 2020 | |
Business Combinations [Abstract] | |
Acquisitions and Divestitures | Note 4 – Acquisitions and Divestitures In June 2018, Gentherm announced a new strategic plan. An important element of the strategy was the elimination of investments in non-core areas, including GPT and CSZ-IC. The strategy also identified several product categories the Company exited in 2018, including furniture, aviation, battery management electronics, industrial battery packs, automotive thermoelectric generators and other non-core electronics. During the year ended December 31, 2018, Gentherm determined that GPT and CSZ-IC met the held for sale criteria and recognized $11,476 of asset impairment charges, consisting of $6,151 of goodwill impairment charges, $3,135 of other intangible asset impairment charges and $2,190 of impairment on assets held for sale. These impairment charges are reported within the Medical segment and are classified as Impairment loss within the consolidated statements of income. Divestiture of CSZ-IC On February 1, 2019, the Company completed the sale of CSZ-IC and former Cincinnati Sub-Zero headquarters facility to Weiss Technik North America, Inc. for total cash proceeds of $47,500, including $2,500 of cash proceeds placed into an escrow account for a period of up to one year as partial security for the Company’s obligations under the sale agreement. During the year ended December 31, 2020, the Company resolved its remaining obligations under the sale agreement, and the amounts in escrow were released net of settlement for obligations under the sale agreement. Divestiture of GPT During 2019, the Company continued to assess the fair value of the GPT disposal group, less costs to sell, at each reporting period. As a result of these fair value measurements, the Company recognized additional impairment losses of $21,206 consisting of $4,486 of impairment of an equity investment that met the held for sale criteria during 2019 and $16,720 of impairment on assets held for sale. These impairment charges are classified as Impairment loss within the consolidated statements of income. On October 1, 2019, the Company completed the sale of GPT for a nominal amount and recognized a $5,885 loss on sale for the year ended December 31, 2019, which included $1,500 related to a loan to the buyer that was considered uncollectible, which is classified as Net loss on divestitures within the consolidated statements of income. Acquisition of Stihler Electronic GmbH On April 1, 2019, Gentherm acquired Stihler Electronic GmbH (“Stihler”), a leading developer and manufacturer of patient and blood temperature management systems, for a purchase price of $15,476, net of cash acquired and including $653 of contingent consideration to be paid upon achievement of a milestone that was completed in September 2020. In addition, the purchase agreement included a contingent payment of $653 paid for the selling shareholder remaining employed by Stihler through December 2020. This was completed and the payment was recorded as a component of Selling, general and administrative expenses ratably over the service period. The results of operations of Stihler are reported within the Company’s Medical segment from the date of acquisition. During the year ended December 31, 2019, the Company incurred acquisition-related costs of approximately $324. These amounts were recorded as incurred, within the consolidated statements of income. The acquisition was accounted for as a business combination. The purchase price and related allocation to the acquired net assets of Stihler, based on their estimated fair values as of the acquisition date, are shown below: Purchase price, cash consideration, net of cash acquired $ 14,823 Purchase price, fair value of contingent consideration 653 Total purchase price, net of cash acquired 15,476 Accounts receivable 883 Inventory 1,698 Prepaid expenses and other assets 241 Operating lease right-of-use assets 263 Property and equipment 260 Other intangible assets 4,380 Goodwill 9,816 Assumed liabilities (2,065 ) Net assets acquired $ 15,476 Other intangible assets primarily include amounts recognized for the fair value of customer-related intangible assets, which will be amortized over their estimated useful lives of approximately 9 years. The estimated fair value of these assets was based on third- party valuations and management’s estimates, generally utilizing an income approach. Goodwill recognized in this transaction is primarily attributable to intangible assets that do not qualify for separate recognition. A total of $ 2,524 of the goodwill recognized was deductible for income tax purposes . The pro forma effect of the Stihler acquisition does not materially impact the Company’s reported results for any period presented, and as a result no pro forma financial statements are presented. |
Restructuring
Restructuring | 12 Months Ended |
Dec. 31, 2020 | |
Restructuring And Related Activities [Abstract] | |
Restructuring | Note 5 — Manufacturing Footprint Rationalization On September 23, 2019, the Company committed to a restructuring plan to improve the Company’s manufacturing productivity and rationalize its footprint. Under this plan, the Company will relocate and consolidate certain existing automotive manufacturing and, as a result, reduce the number of plants by two. On March 20, 2020, the Company announced the initial phase of this restructuring plan, which includes the consolidation of all North American electronics manufacturing to Celaya, Mexico. This will result in the closure of the Burlington, Canada facility, and the transfer of electronics manufacturing from Acuña, Mexico. During the second quarter of 2020, due to circumstances arising from the COVID-19 pandemic, management adjusted the plan to proactively manage its cash position. Adjustments to the plan have resulted in changes to the estimated number of employee separations and total costs to execute the plan. On December 10, 2020, the Company announced the consolidation of our electronics manufacturing in Asia to Bantian, Shenzhen, China, which will result in the closure of our Longgang, Shenzhen, China facility that is expected to be completed by the end of 2021. During the year ended December 31, 2020, the Company recognized restructuring expense of $(832) for employee separation costs, $687 for accelerated depreciation and $332 for other costs. The net activity for the year ended December 31, 2020 is primarily related to a reduction in the estimates of previously recognized employee separation costs. During the year ended December 31, 2019, the Company recognized restructuring expense of $4,863 for employee separation costs, and $2,087 of accelerated depreciation and fixed asset impairment. The Company has recorded approximately $7,137 of restructuring expenses since the inception of this program. Under the revised restructuring plan, the Company expects to incur total costs of between $16,000 and $19,000, of which between $13,000 and $16,000 are expected to be cash expenditures. The total expected costs include employee separation costs of between $6,500 and $7,500, capital expenditures of between $3,500 and $4,500 and non-cash expenses for accelerated depreciation and impairment of fixed assets of approximately $3,000. The Company also expects to incur other transition costs including recruiting, relocation, and machinery and equipment move and set up costs of between $3,000 and $4,000. The actions under this plan are expected to be substantially completed by the end of 2021. The actual timing, costs and savings of the plan may differ materially from the Company’s current expectations and estimates. Other Restructuring Activities As part of the Company’s continued efforts to optimize its cost structure, the Company has undertaken several discrete restructuring actions. During the years ended December 31, 2020, 2019 and 2018, the Company recognized $5,382, $2,942 and $6,598 of employee separation costs, respectively, and $234, $1,360 and $2,869 of other related costs, respectively. These restructuring expenses were primarily associated with restructuring actions focused on optimizing our manufacturing and engineering footprint and the reduction of global overhead costs. Advanced Research and Development Rationalization and Site Consolidation In June 2018, Gentherm completed the sale of its battery management systems division located in Irvine, California. A loss on the sale of $1,107 was recognized in restructuring expenses during the year ended December 31, 2018. An additional asset impairment loss of $425 was recognized during the year ended December 31, 2019. During the year ended December 31, 2018, Gentherm recognized employee separation costs of $1,094, and $643 of other related costs associated with the closure of two leased facilities located in Azusa, California. The Company also recognized $1,400 in restructuring expenses for the year ended for the disposal of long-lived assets controlled and used in Azusa, California. The Company has recorded approximately $4,669 of restructuring expenses since inception of this program and it is considered complete. GPT and CSZ-IC During 2018, Gentherm launched a program to actively market GPT and CSZ-IC. Costs associated with the divestiture process were classified as restructuring. During the year ended December 31, 2019 and 2018 The Company has recorded approximately $2,303 of restructuring expenses since inception of this program and it is considered complete. Restructuring Expenses By Reporting Segment Restructuring expense by reporting segment for the years ended December 31, 2020, 2019 and 2018 was as follows: Year Ended December 31, 2020 2019 2018 Automotive $ 5,075 $ 9,353 $ 5,548 Medical 112 1,838 5,607 Corporate 616 1,728 3,617 Total $ 5,803 $ 12,919 $ 14,772 Restructuring Liability The following table summarizes restructuring activity for all restructuring initiatives for the years ended December 31, 2020 and 2019: Employee Separation Costs Accelerated Depreciation and Asset Impairment Charges Other Related Costs Total Balance at December 31, 2018 $ 2,079 $ — $ 468 $ 2,547 Additions, charged to restructuring expenses 8,056 2,512 2,351 12,919 Cash payments (4,118 ) — (2,636 ) (6,754 ) Non-cash utilization — (2,512 ) — (2,512 ) Reclassification to lease liability — — (112 ) (112 ) Currency translation (23 ) — — (23 ) Balance at December 31, 2019 5,994 — 71 6,065 Additions, charged to restructuring expenses 6,932 687 584 8,203 Change in estimate (2,382 ) — (18 ) (2,400 ) Cash payments (5,052 ) — (757 ) (5,809 ) Non-cash utilization — (687 ) — (687 ) Currency translation 135 — 120 255 Balance at December 31, 2020 $ 5,627 $ — $ — $ 5,627 |
Details of Certain Financial St
Details of Certain Financial Statement Components | 12 Months Ended |
Dec. 31, 2020 | |
Financial Statement Components [Abstract] | |
Details of Certain Financial Statement Components | Note 6 — Details of Certain Financial Statement Components December 31, 2020 2019 Inventory: Raw materials, net of reserve $ 68,362 $ 61,323 Work in process, net of reserve 8,247 7,444 Finished goods, net of reserve 45,792 49,712 Total inventory, net $ 122,401 $ 118,479 Other current assets: Notes receivable $ 19,200 $ 9,963 Income tax and other tax receivable 10,514 17,057 Billable tooling 4,831 5,194 Prepaid expenses 3,930 7,022 Other 2,713 3,490 Total other current assets $ 41,188 $ 42,726 Property and equipment: Machinery and equipment $ 142,833 $ 137,813 Buildings and improvements 99,011 90,675 Information technology 30,338 27,697 Production tooling 22,783 19,906 Leasehold improvements 11,762 11,116 Construction in progress 8,968 2,856 Total property and equipment 315,695 290,063 Less: accumulated depreciation (163,114 ) (129,458 ) Total property and equipment, net $ 152,581 $ 160,605 Other current liabilities: Accrued employee liabilities $ 26,612 $ 26,019 Liabilities from discounts and rebates 22,910 16,593 Income tax and other taxes payable 14,714 3,693 Restructuring 5,627 6,065 Accrued warranty 2,391 4,596 Other 9,155 9,617 Total other current liabilities $ 81,409 $ 66,583 |
Goodwill and Other Intangibles
Goodwill and Other Intangibles | 12 Months Ended |
Dec. 31, 2020 | |
Goodwill And Intangible Assets Disclosure [Abstract] | |
Goodwill and Other Intangibles | Note 7 — Goodwill and Other Intangibles Goodwill Changes in the carrying amount of goodwill, by reportable segment, for the years ended December 31, 2020 and 2019 were as follows: Automotive Medical Total December 31, 2018 $ 37,533 $ 17,778 $ 55,311 Stihler acquisition — 9,816 9,816 Exchange rate impact (595 ) 40 (555 ) Balance as of December 31, 2019 $ 36,938 $ 27,634 $ 64,572 Exchange rate impact 2,557 895 3,452 Balance as of December 31, 2020 $ 39,495 $ 28,529 $ 68,024 Other Intangible Assets Other intangible assets and accumulated amortization balances as of December 31, 2020 and 2019 were as follows: Gross Carrying Value Accumulated Amortization Net Carrying Value Definite-lived: Customer relationships $ 97,815 $ (63,432 ) $ 34,383 Technology 30,615 (24,075 ) 6,540 Product development costs 22,164 (21,336 ) 828 Indefinite-lived: Tradenames 4,670 — 4,670 Balance as of December 31, 2020 $ 155,264 $ (108,843 ) $ 46,421 Gross Carrying Value Accumulated Amortization Net Carrying Value Definite-lived: Customer relationships $ 89,208 $ (50,687 ) $ 38,521 Technology 25,106 (19,866 ) 5,240 Product development costs 19,911 (18,559 ) 1,352 Indefinite-lived: Tradenames 4,670 — 4,670 Balance as of December 31, 2019 $ 138,895 $ (89,112 ) $ 49,783 On February 28, 2020, Gentherm acquired the automotive patents and technology of a development-stage technology company for $3,141. The investment was accounted for as an asset acquisition of defensive intangible assets and will be amortized over six years. On June 19, 2020, Gentherm sold patents from a non-core business for $2,055. The gain on sale of $1,978 was recorded in Other income in the consolidated statements of income. In connection with the acquisition of Stihler, the Company recorded intangible assets including customer relationships and technology of $3,420 and $538, respectively. These definite-lived assets are being amortized using the straight-line method over their estimated useful lives of approximately 9 years and 7 years, respectively. A total of $9,226, $10,068 and $14,043 in other intangible assets were amortized in 2020, 2019 and 2018, respectively. An estimate of other intangible asset amortization by year, is as follows: 2021 $ 8,316 2022 7,803 2023 4,385 2024 3,245 2025 3,229 Impairment Charges During 2018, Gentherm determined GPT and CSZ-IC met the held for sale criteria, described above, and recorded an impairment loss on assets held for sale, goodwill and other intangible assets of $2,190, $6,151 and $3,135, respectively. |
Leases
Leases | 12 Months Ended |
Dec. 31, 2020 | |
Leases [Abstract] | |
Leases | Note 8 — Leases Components of lease expense for the years ended December Year Ended December 31, 2020 2019 Lease cost: Operating lease cost $ 6,773 $ 5,899 Short-term lease cost 1,834 3,444 Sublease income (158 ) (128 ) Total lease cost $ 8,449 $ 9,215 Other information related to leases is as follows: Year Ended December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 6,817 $ 6,059 Right-of-use lease assets obtained in exchange for lease obligations: Operating leases $ 25,161 $ 4,111 Gain on sale and leaseback transactions, net $ 207 December 31, 2020 December 31, 2019 Weighted average remaining lease term: Operating leases 5.4 years 4.5 years Weighted average discount rate: Operating leases 4.65 % 5.46 % A summary of operating leases as of December 31, 2020, under all non-cancellable operating leases with terms exceeding one year is as follows: . 2021 $ 7,316 2022 6,033 2023 4,016 2024 3,829 2025 3,648 2026 or later 10,461 Total future minimum lease payments 35,303 Less imputed interest (5,038 ) Total $ 30,265 |
Debt
Debt | 12 Months Ended |
Dec. 31, 2020 | |
Debt Disclosure [Abstract] | |
Debt | Note 9 — The following table summarizes the Company’s debt as of December 31, 2020 and 2019: December 31, 2020 2019 Interest Rate Principal Balance Interest Rate Principal Balance Amended Credit Agreement: U.S. Revolving Note (U.S. Dollar Denominations) 1.65 % $ 171,500 3.05 % $ 50,000 U.S. Revolving Note (Euro Denominations) 1.50 % 14,684 1.25 % 21,874 DEG Vietnam Loan 5.21 % 6,250 5.21 % 8,750 Total debt 192,434 80,624 Current maturities (2,500 ) (2,500 ) Long-term debt, less current maturities $ 189,934 $ 78,124 Amended Credit Agreement The Company, together with certain direct and indirect subsidiaries, had a credit agreement dated August 7, 2014, as amended On June 27, 2019, the Company entered into an Amended and Restated Credit Agreement (the “Amended Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent. The Amended Credit Agreement amended and restated in its entirety the Credit Agreement. The outstanding principal and interest of the U.S. Revolving Note under the Credit Agreement continued and constitute obligations under the Amended Credit Agreement. The Amended Credit Agreement increased the U.S. Revolving Note from $350,000 to $475,000 and extended the maturity from March 17, 2021 to June 27, 2024. The Amended Credit Agreement also provides $15,000 availability for the issuance of letters of credit and a maximum of $40,000 for swing line borrowing. Any amount of the facility utilized for letters of credit or swing line loans outstanding will reduce the amount available under the Amended Credit Agreement. The Company had no outstanding letters of credit issued under the Amended Credit Agreement as of December 31, 2020 and 2019. The U.S. borrowers and guarantors participating in the Amended Credit Agreement also entered into a related amended and restated pledge and security agreement. The amended and restated pledge and security agreement grants a security interest to the lenders in substantially all of the personal property of the Company and its U.S. subsidiaries designated as borrowers to secure their respective obligations under the Amended Credit Agreement, including the stock and membership interests of specified subsidiaries (limited to 66% of the stock in the case of certain non-U.S. subsidiaries). In addition to the security obligations, all obligations under the Amended Credit Agreement are unconditionally guaranteed by certain of the Company’s subsidiaries. The Amended Credit Agreement restricts, among other things, the amount of dividend payments the Company can make to shareholders. The Amended Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets, merge with other companies or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and Consolidated Leverage Ratio (based on consolidated EBITDA for the applicable trailing 12-month period as defined in the Amended Credit Agreement) as of the end of any fiscal quarter. The Amended Credit Agreement also contains customary events of default. As of December 31 Under the Amended Credit Agreement, U.S. Dollar denominated loans bear interest at either a base rate (“Base Rate Loans”) or Eurocurrency rate (“Eurocurrency Rate Loans”), plus a margin (“Applicable Rate”). The rate for Base Rate Loans is equal to the highest of the Federal Funds Rate (0.09% at December 31, 2020) plus 0.50%, Bank of America’s prime rate (3.25% at December 31, 2020), or the Eurocurrency rate plus 1.00%. The rate for Eurocurrency Rate Loans denominated in U.S. Dollars is equal to the London Interbank Offered Rate (0.14% at December 31, 2020). All loans denominated in a currency other than the U.S. Dollar must be Eurocurrency Rate Loans. Interest is payable at least quarterly. The Applicable Rate varies based on the Consolidated Leverage Ratio reported by the Company. As long as the Company is not in default of the terms and conditions of the Amended Credit Agreement, the lowest and highest possible Applicable Rate is 1.25% and 2.25%, respectively, for Eurocurrency Rate Loans and 0.25% and 1.25%, respectively, for Base Rate Loans. In March 2020, the Company increased its borrowings under the Amended Credit Agreement by $169,546 as a safeguard to increase its cash position and provide additional financial flexibility due to the COVID-19 pandemic. The proceeds were used for working capital and for other general corporate purposes permitted by the Amended Credit Agreement. After the drawdown in March 2020 and through December 31, 2020, the Company repaid a net amount of $41,180 of the amounts outstanding under the Amended Credit Agreement. As of December 31, 2020, inclusive of the net new borrowings in 2020, $186,184 was outstanding under the Borrowing availability is subject to, among other things, the Company’s compliance with the . $288,776 remained available as of December 31, 2020 for additional borrowings under the subject to specified conditions that Gentherm currently satisfies. In connection with the Amended Credit Agreement, the Company incurred debt issuance costs of $1,278 which have been capitalized and will be amortized into interest expense over the term of the credit facility. DEG Vietnam Loan The Company also has a fixed interest rate loan with the German Investment Corporation (“DEG”), a subsidiary of KfW Banking Group, a Germany government-owned development bank. The fixed interest rate senior loan agreement with DEG was used to finance the construction and set up of the Vietnam production facility (“DEG Vietnam Loan”). The DEG Vietnam Loan is subject to semi-annual principal payments that began November, 2017 and will end May, 2023. Under the terms of the DEG Vietnam Loan, the Company must maintain a minimum Enhanced Equity Ratio, as defined by the DEG Vietnam Loan agreement, based on the financial statements of Gentherm’s wholly owned subsidiary, Gentherm Vietnam Co. Ltd. As of December 31, 2020, the Company was in compliance with all terms as outlined in the DEG Vietnam Loan. The scheduled principal maturities of our debt as of December 31, 2020 were as follows: DEG Vietnam Note U.S. Revolving Note Total 2021 $ 2,500 $ — $ 2,500 2022 2,500 — 2,500 2023 1,250 — 1,250 2024 — 186,184 186,184 Total $ 6,250 $ 186,184 $ 192,434 |
Pension and Other Post Retireme
Pension and Other Post Retirement Benefit Plans | 12 Months Ended |
Dec. 31, 2020 | |
Compensation And Retirement Disclosure [Abstract] | |
Pension and Other Post Retirement Benefit Plans | Note 10 — The Company maintains a U.S. defined benefit pension plan covering its former Chief Executive Officer (“U.S. Plan”) and a German defined benefit pension plan covering certain retired executive employees of the Company’s wholly owned subsidiary, Gentherm GmbH (“German Plan”). The components of net periodic benefit cost for the Company’s defined benefit plans for the years ended December 31, 2020, 2019 and 2018 were as follows: U.S. Plan German Plan Year Ended December 31, Year Ended December 31, 2020 2019 2018 2020 2019 2018 Net periodic benefit cost: Service cost $ — $ — $ — $ — $ — $ — Interest cost 85 127 114 88 147 147 Expected return on plan assets — — — (121 ) (126 ) (130 ) Amortization of prior service cost and actuarial loss 7 — — 124 72 73 Net periodic benefit cost $ 92 $ 127 $ 114 $ 91 $ 93 $ 90 Assumptions: Discount rate 2.40 % 3.65 % 2.95 % 1.08 % 1.06 % 2.04 % Long-term return on assets N/A N/A N/A 2.90 % 3.10 % 3.40 % A reconciliation of the change in benefit obligation and the change in plan assets for the years ended December 31, 2020 and 2019 is as follows: U.S. Plan German Plan As of December 31, As of December 31, 2020 2019 2020 2019 Change in projected benefit obligation: Balance at beginning of year $ 3,871 $ 3,832 $ 8,353 $ 7,529 Interest cost 85 127 88 147 Paid pension distributions (342 ) (342 ) (294 ) (285 ) Actuarial losses 233 254 40 1,116 Exchange rate impact — — 747 (154 ) Balance at end of year $ 3,847 $ 3,871 $ 8,934 $ 8,353 Change in plan assets: Balance at beginning of year — $ — 3,825 3,808 Actual return on plan assets — — 121 126 Contributions — — 294 284 Paid pension distributions — — (294 ) (284 ) Actuarial losses — — (25 ) (30 ) Exchange rate impact — — 355 (79 ) Balance at end of year $ — $ — $ 4,276 $ 3,825 Underfunded Status $ (3,847 ) $ (3,871 ) $ (4,658 ) $ (4,528 ) Balance sheet classification: Other current liabilities (342 ) (342 ) — — Pension benefit obligation (3,505 ) (3,529 ) (4,658 ) (4,528 ) Accumulated other comprehensive loss (pre-tax): Actuarial losses 701 476 3,644 3,398 Assumptions: Discount rate 1.20 % 2.40 % 1.08 % 1.06 % Pre-tax amounts included in AOCI that are expected to be recognized in net periodic benefit cost during the year ended December 31, 2021 are as follows: U.S Plan German Plan Actuarial losses $ 26 $ 126 The accumulated benefit obligations were as follows: U.S. Plan German Plan As of December 31, As of December 31, 2020 2019 2020 2019 Accumulated benefit obligation $ 3,847 $ 3,871 $ 8,934 $ 8,529 Interest costs are recognized in Selling, general and administrative expenses in the consolidated statements of income and actuarial gains and losses are included the consolidated balance sheet as part of Accumulated other comprehensive loss within shareholders’ equity. Actuarial gains or losses are amortized to Selling, general and administrative expense in the consolidated statements of income based on the average future life of the Plan using the corridor method. Prior service cost is included in Selling, general and administrative expenses in the consolidated statements of income. Plan assets – German Plan Plan assets are comprised of Gentherm GmbH’s pension insurance policies and are pledged to the beneficiaries of the German Plan. A market valuation technique, based on observable underlying insurance charges, is used to determine the fair value of the pension plan assets (Level 2). The expected return on plan assets assumption used to calculate Gentherm GmbH’s pension benefit obligation was determined using actual returns realized on plan assets in the prior year. Other assets Although the U.S. Plan is not funded, the Company has established a separate trust having the sole purpose of paying benefits under the U.S. Plan. The only asset of the trust is a corporate-owned life insurance policy (“COLI”). The COLI is valued at fair value using quoted prices listed in active markets (Level 1). The policy value of the COLI was $2,966 and $2,592 as of December 31, 2020 and 2019, respectively, and is included in Other non-current assets in the Company’s consolidated balance sheets. Contributions We do not expect contributions to be paid to the U.S. Plan or the German Plan during the next fiscal year. The schedule of future expected pension payments is as follows: Projected Pension Benefit Payments Year U.S Plan German Plan 2021 $ 342 $ 296 2022 342 291 2023 342 301 2024 342 295 2025 342 287 2026-2030 1,710 2,886 Total $ 3,420 $ 4,356 Defined contribution plans The Company also sponsors defined contribution plans for eligible employees. On a discretionary basis, the Company matches a portion of the employee contributions and or makes additional discretionary contributions. Gentherm recognized costs of $1,275, $1,384 and $1,471 related to contributions to its defined contribution plans during the years ended December 31, 2020, 2019 and 2018, respectively. |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2020 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 11 — The Company may be subject to various legal actions and claims in the ordinary course of its business, including those arising out of breach of contracts, product warranties, product liability, intellectual property rights, environmental matters, regulatory matters and employment-related matters. The Company establishes accruals for matters which it believes that losses are probable and can be reasonably estimated. Although it is not possible to predict with certainty the outcome of these matters, the Company is of the opinion that the ultimate resolution of these matters will not have a material adverse effect on its consolidated results of operations or financial position. Purchase commitments for materials, supplies, services and property and equipment as part of the normal course of business was immaterial as of December 31, 2020. Product liability and warranty reserves are recorded separately from legal reserves, as described below. Product Liability and Warranty Matters The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including claims already filed by customers, the warranty accrual is adjusted quarterly to reflect management’s best estimate of future claims. The Company maintains liability insurance coverage at levels based on commercial norms and historical claims experience. The Company can provide no assurances that it will not experience material claims in the future or that it will not incur significant costs to defend such claims. The following is a reconciliation of the changes in accrued warranty costs: Year Ended December 31, 2020 2019 Balance at beginning of year $ 4,596 $ 4,514 Warranty claims paid (2,598 ) (584 ) Warranty expense for products shipped during the current period 1,223 2,370 Adjustments to warranty estimates from prior periods (893 ) (1,660 ) Acquisition of business — 21 Adjustments due to currency translation 63 (65 ) Balance at end of year $ 2,391 $ 4,596 Employees Approximately 25% of the Company’s workforce are members of industrial trade unions and are employed under the terms of various labor agreements. None of these agreements expire in 2021. |
Earnings Per Share
Earnings Per Share | 12 Months Ended |
Dec. 31, 2020 | |
Earnings Per Share [Abstract] | |
Earnings per Share | Note 12 — Basic earnings per share are computed by dividing net income by the weighted average number of shares of Common Stock outstanding during the period. The Company’s diluted earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the diluted earnings per share, the treasury stock method is used in determining the number of shares assumed to be issued from the exercise of Common Stock equivalents. The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Year Ended December 31, 2020 2019 2018 Net income $ 59,690 $ 48,866 $ 41,899 Basic weighted average shares of Common Stock outstanding 32,666,025 33,120,076 35,920,782 Dilutive effect of stock options, restricted stock awards and restricted stock units 362,079 177,513 256,362 Diluted weighted average shares of Common Stock outstanding 33,028,104 33,297,589 36,177,144 Basic earnings per share $ 1.83 $ 1.48 $ 1.17 Diluted earnings per share $ 1.81 $ 1.47 $ 1.16 The following table represents Common Stock issuable upon the exercise of certain stock options that have been excluded from the diluted earnings calculation because the effect of their inclusion would be anti-dilutive. Year Ended December 31, 2020 2019 2018 Anti-dilutive securities share impact 12,000 214,000 898,250 See Note 17 for information about the Company’s different equity incentive plans. |
Financial Instruments
Financial Instruments | 12 Months Ended |
Dec. 31, 2020 | |
Derivative Instruments And Hedging Activities Disclosure [Abstract] | |
Financial Instruments | Note 13 —Financial Instruments Cash, cash equivalents and restricted cash As of December 31, 2019, the Company had cash that was legally restricted as to use or withdrawal. A reconciliation of cash and cash equivalents on the consolidated balance sheets to cash, cash equivalents and restricted cash presented on the consolidated statements of cash flows is as follows: As of December 31, 2020 2019 Cash and cash equivalents presented in the consolidated balance sheets $ 268,345 $ 50,443 Restricted cash — 2,505 Cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows $ 268,345 $ 52,948 Derivative Financial Instruments The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and commodity price fluctuations. Market risks for changes in interest rates relate primarily to its debt obligations under the Amended Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won and Vietnamese Dong. The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The maximum length of time over which the Company hedges its exposure to foreign currency exchange risks is twelve months. The Company had foreign currency derivative contracts with a notional value of $13,299 and $14,449 outstanding at December 31, 2020 and 2019, respectively. The principal currency hedged by the Company was the Mexican Peso. The Company does not enter into derivative financial instruments for speculative or trading purposes. The Company’s hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive loss in the consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of foreign currency hedging instruments, if any, to Foreign currency gain (loss) in the consolidated statements of income. The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounts such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term. Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2020 is as follows: Asset Derivatives Liability Derivatives Hedge Designation Fair Value Hierarchy Balance Sheet Location Fair Value Balance Sheet Location Fair Value Net Asset/ (Liabilities) Foreign currency derivatives Cash flow hedge Level 2 Other current assets $ 1,513 Other current liabilities $ — $ 1,513 Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2019 is as follows: Asset Derivatives Liability Derivatives Hedge Designation Fair Value Hierarchy Balance Sheet Location Fair Value Balance Sheet Location Fair Value Net Asset/ (Liabilities) Foreign currency derivatives Cash flow hedge Level 2 Other current assets $ 1,242 Other current liabilities $ — $ 1,242 Information related to the effect of derivative instruments in the consolidated statements of income is as follows: Year Ended December 31, Location 2020 2019 Foreign currency derivatives Cost of sales $ (1,629 ) $ 1,976 Other comprehensive income 272 1,151 Foreign currency loss (118 ) (46 ) Total foreign currency derivatives $ (1,475 ) $ 3,081 The Company did not incur any hedge ineffectiveness during the years ended December 31, 2020 and 2019. |
Fair Value Measurement
Fair Value Measurement | 12 Months Ended |
Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurement | Note 14 — Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on one or more of the following three valuation techniques: Market : This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. Income : This approach uses valuation techniques to convert future amounts to a single present value amount based on current market expectations. Cost : This approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost). The Company uses the following fair value hierarchy to measure fair value into three broad levels, which are described below: Level 1 : Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 : Inputs, other than quoted market prices included in Level 1, that are observable either directly or indirectly for the asset or liability. Level 3 : Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. Items Measured at Fair Value on a Recurring Basis Except for derivative financial instruments (see Note 13), pension plan assets (see Note 10) and a corporate owned life insurance policy (see Note 10), the Company has no material financial assets and liabilities that are carried at fair value at December 31, 2020 and 2019. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and also considers counterparty credit risk in its assessment of fair value. Items Measured at Fair Value on a Nonrecurring Basis The Company measures certain assets and liabilities at fair value on a non-recurring basis. As these nonrecurring fair value measurements are generally determined using unobservable inputs, these fair value measurements are classified within Level 3 of the fair value hierarchy. As further described in “Note 4, “Acquisitions and Divestitures", the Company utilized a third-party to assist in the Level 3 fair value estimates of $4,380 related to other intangible assets. The estimated fair values of these assets were based on third-party valuations and management’s estimates, generally utilizing the income approach. As of December 31, 2020 and 2019, there were no additional significant assets or liabilities measured at fair value on a non-recurring basis. Items Not Carried at Fair Value The Company uses an income valuation technique to measure the fair values of its debt instruments by converting amounts of future cash flows to a single present value amount using rates based on current market expectations (Level 2 inputs). As of December 31, 2020 and 2019, the carrying values of the Company’s Credit Agreement indebtedness were not materially different than their estimated fair values because the interest rates on variable rate debt approximated rates currently available to the Company (see Note 9). Discount rates used to measure the fair value of Gentherm’s DEG Vietnam Loan are based on quoted swap rates. As of December 31, 2020, the carrying value of the DEG Vietnam Loan was $6,250, as compared to an estimated fair value of $6,360. As of December 31, 2019, the carrying value of the DEG Vietnam Loan was $8,750 as compared to an estimated fair value of $8,785. |
Equity
Equity | 12 Months Ended |
Dec. 31, 2020 | |
Stockholders Equity Note [Abstract] | |
Equity | Note 15 — Equity Common Stock The Company is authorized to issue up to 59,991,000 shares, of which 55,000,000 shares shall be common stock, without par value, and 4,991,000 shall be Preferred Stock, without par value. As of December 31, 2020, an aggregate of 32,921,341 shares of its common stock were issued and outstanding. As of December 31, 2020, there are no preferred stock shares issued or outstanding. The Company’s common stock is listed on the Nasdaq Global Select Market under the symbol, “THRM”, and has the following rights and privileges: ▪ Voting rights. All shares of the Company’s common stock have identical rights and privileges. With limited exceptions, holders of common stock are entitled to one vote for each outstanding share of common stock held of record by each shareholder on all matters properly submitted for the vote of the Company’s shareholders. ▪ Dividend rights . Subject to applicable law, any contractual restrictions and the rights of the holders of outstanding preferred stock, if any, holders of common stock are entitled to receive ratably such dividends and other distributions that the Company’s Board of Directors, in its discretion, declares from time to time. ▪ Liquidation rights . Upon the dissolution, liquidation or winding up of the Company, subject to the rights of the holders of outstanding preferred stock, if any, holders of common stock are entitled to receive ratably the assets of the Company available for distribution to the Company’s shareholders in proportion to the number of shares of common stock held by each shareholder. ▪ Conversion, Redemption and Preemptive Rights . Holders of common stock have no conversion, redemption, sinking fund, preemptive, subscription or similar rights. Stock Repurchase Program In December 2016, the Board of Directors of Gentherm Incorporated (“Board of Directors”) authorized a three-year three-year Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. Repurchases may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. During the year ended December 31, 2020, the Company repurchased approximately $9,092 of shares under the Stock Repurchase Program with an average price paid per share of $36.93. The Stock Repurchase Program had $74,226 of repurchase authorization remaining at expiration. The Company did not make any repurchases under either stock repurchase program during the second, third and fourth quarters of 2020. |
Reclassifications Out of Accumu
Reclassifications Out of Accumulated Other Comprehensive Income (Loss) | 12 Months Ended |
Dec. 31, 2020 | |
Equity [Abstract] | |
Reclassifications Out of Accumulated Other Comprehensive Income (Loss) | N ote 16 – Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Reclassification adjustments and other activities impacting accumulated other comprehensive income (loss) during the years ended December 31, 2020, 2019 and 2018 are as follows: Defined Benefit Pension Plans Foreign Currency Translation Adjustments Foreign Currency Hedge Derivatives Total Balance at December 31, 2019 $ (3,371 ) $ (39,879 ) $ 895 $ (42,355 ) Other comprehensive (loss) income before reclassifications (328 ) 27,147 (1,751 ) 25,068 Income tax effect of other comprehensive income before reclassifications 117 95 381 593 Amounts reclassified from accumulated other comprehensive loss into net income 131 2,023 a 2,154 Income taxes reclassified into net income — (442 ) (442 ) Net current period other comprehensive (loss) income (80 ) 27,242 211 27,373 Balance at December 31, 2020 $ (3,451 ) $ (12,637 ) $ 1,106 $ (14,982 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income. Defined Benefit Pension Plans Foreign Currency Translation Adjustments Foreign Currency Hedge Derivatives Total Balance at December 31, 2018 $ (2,339 ) $ (37,157 ) $ (4 ) $ (39,500 ) Other comprehensive (loss) income before reclassifications (1,264 ) (2,329 ) 2,259 $ (1,334 ) Income tax effect of other comprehensive income (loss) before reclassifications 232 (393 ) (493 ) $ (654 ) Amounts reclassified from accumulated other comprehensive loss into net income — — (1,108 ) a $ (1,108 ) Income taxes reclassified into net income — — 241 $ 241 Net current period other comprehensive (loss) income (1,032 ) (2,722 ) 899 (2,855 ) Balance at December 31, 2019 $ (3,371 ) $ (39,879 ) $ 895 $ (42,355 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income. Defined Benefit Pension Plans Foreign Currency Translation Adjustments Commodity Hedge Derivatives Foreign Currency Hedge Derivatives Total Balance at December 31, 2017 $ (2,366 ) $ (17,555 ) $ 277 $ (800 ) $ (20,444 ) Cumulative effect of accounting change due to adoption of ASU 2018-02 (49 ) — 9 — (40 ) Other comprehensive income (loss) before reclassifications 18 (19,212 ) — 1,342 (17,852 ) Income tax effect of other comprehensive loss before reclassifications (15 ) (390 ) — (337 ) (742 ) Amounts reclassified from accumulated other comprehensive loss into net income 73 — (218 ) a (246 ) a (391 ) Income taxes reclassified into net income — — (68 ) 37 (31 ) Net current period other comprehensive income (loss) 27 (19,602 ) (277 ) 796 (19,056 ) Balance at December 31, 2018 $ (2,339 ) $ (37,157 ) $ — $ (4 ) $ (39,500 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income. We expect all of the existing gains and losses related to foreign currency and commodity derivatives reported in Accumulated other comprehensive income (loss) as of December 31, 2020 to be reclassified into earnings during the twelve-month period ending December 31, 2021. |
Accounting for Stock Based Comp
Accounting for Stock Based Compensation | 12 Months Ended |
Dec. 31, 2020 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Accounting for Stock Based Compensation | Note 17 — On May 16, 2013, the Compensation Committee of the Company’s Board of Directors (the “Board”) approved the Gentherm Incorporated 2013 Equity Incentive Plan (the “2013 Plan”), covering 3,500,000 shares of our Common Stock. The 2013 Plan was amended on May 19, 2017 to increase the number of available shares by 2,000,000 and further amended on May 21, 2020 to increase the number of available shares by 2,450,000. The 2013 Plan permits the granting of various awards including stock options (including both nonqualified options and incentive options), stock appreciation rights (“SARs”), restricted stock and restricted stock units, performance shares and certain other awards to employees, outside directors and consultants and advisors of the Company. All shares of our Common Stock that remained available for issuance under the Amended and Restated 2006 Stock Incentive Plan (the “2006 Plan”) and the Gentherm Incorporated 2011 Equity Incentive Plan (the “2011 Plan), were reduced to zero; however, some options under the 2006 Plan are still outstanding. As of December 31, 2020, the Company had an aggregate of 3,021,451 shares of Common Stock available to issue under the 2013 Plan. All equity plans are administered by the Compensation Committee of the Board. During the three-year period ended December 31, 2020, the Company has outstanding stock options, SARs, restricted stock awards and restricted stock units to employees, directors and consultants. These awards become available to the recipient upon the satisfaction of a vesting condition, either based on a period of service or based on the performance of a specific achievement. For equity-based awards with a service condition, the requisite service period typically ranges between three to four years for employees and consultants and one year for directors. As of December 31, 2020, there were 315,834 performance-based restricted stock units (“PSUs”) outstanding. These awards cliff vest after three-years three-year Under FASB ASC Topic 718, the provisions of the PSUs that vest upon the achievement of relative TSR are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this portion award. A third party was engaged to complete a “Monte Carlo simulation” to account for the market condition. That simulation takes into account the beginning stock price of our common stock, the expected volatilities for the TSR comparator group, the expected volatilities for the Company’s stock price, correlation coefficients, the expected risk-free rate of return and the expected dividend yield of the Company and the comparator group. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the relative TSR feature. The grant date fair value of the other PSUs and RSUs are calculated as the closing price of our common stock as quoted on Nasdaq on the grant date multiplied by the number of shares subject to the award. ROIC is considered a performance condition and the grant-date fair value for ROIC PSUs corresponds with management's expectation of the probable outcome of the performance condition as of the grant date. Total unrecognized compensation cost related to non-vested options, restricted stock, restricted stock units and PSUs outstanding under all of the Company’s equity plans was $13,604 and $13,168 as of December 31, 2020 and 2019, respectively. That cost is expected to be recognized over a weighted average period of two years. Compensation expense for the years ended December 31, 2020, 2019 and 2018 was $14,323, $8,589 and $12,177, respectively, and the related deferred tax benefit was $3,002, $1,573 and $2,434, respectively. If Gentherm were to realize expired shared-based payment arrangements, they would be reported as a forfeit in the activity roll forward tables below. Stock Options The following table summarizes stock option activity during the years ended December 31, 2020, 2019 and 2018: Options Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2017 2,652,142 $ 35.34 4.76 $ 6,964 Granted — — Exercised (615,358 ) 24.01 Forfeited (383,784 ) 39.59 Outstanding at December 31, 2018 1,653,000 $ 38.53 4.28 $ 3,610 Granted — — Exercised (428,250 ) 38.66 Forfeited (355,750 ) 39.99 Outstanding at December 31, 2019 869,000 $ 37.87 3.51 $ 5,172 Granted — — Exercised (434,250 ) 38.12 Forfeited (6,750 ) 38.05 Outstanding at December 31, 2020 428,000 $ 37.61 3.20 $ 11,815 Exercisable at December 31, 2020 338,625 $ 37.87 3.11 $ 9,261 The fair value of each option is estimated on the date of grant using the Black-Scholes option-pricing model in order to measure the compensation cost associated with the award. This model incorporates certain assumptions for inputs including a risk-free interest rate, expected dividend yield of the underlying Common Stock, expected option life and expected volatility in the market value of the underlying Common Stock. Expected volatilities are based on the historical volatility of the Company’s Common Stock. The Company uses historical exercise data and several other factors in developing an assumption for the expected lives of stock options, including the average holding period of outstanding options and their remaining terms. The risk-free interest rate is based upon quoted market yields for United States Treasury debt securities. The expected dividend yield is based upon the Company’s history of having never issued a dividend, the limitations to issue a dividend under terms of the Amended Credit Agreement and management’s current expectation regarding future dividends. We do not expect any of the options granted to be forfeited for purposes of computing fair value. There were no stock options granted during the years ended December 31, 2020, 2019 and 2018. The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018 was $5,317, $1,681 and $5,061, respectively. Restricted Stock The following table summarizes restricted stock activity during the years ended December 31, 2020, 2019 and 2018: Unvested Restricted Shares Shares Weighted-Average Grant Date Fair Value Outstanding at December 31, 2017 282,100 $ 38.06 Granted 21,681 35.00 Vested (130,684 ) 38.62 Forfeited (36,531 ) 37.60 Outstanding at December 31, 2018 136,566 $ 37.16 Granted 19,920 40.16 Vested (91,566 ) 37.09 Forfeited (30,000 ) 38.05 Outstanding at December 31, 2019 34,920 $ 38.31 Granted 32,406 39.96 Vested (32,420 ) 38.33 Forfeited — — Outstanding at December 31, 2020 34,906 $ 39.82 The compensation cost associated with restricted shares is estimated on the date of grant using quoted market prices (Level 1 input). The total fair value of restricted shares vested in 2020, 2019 and 2018 was $1,499, $3,697 and $4,599, respectively. Restricted Stock Units The following table summarizes restricted stock unit activity during the years ended December 31, 2020, 2019 and 2018: Performance-Based Awards Unvested Restricted Stock Units Time Vesting Shares ROIC Target Shares TSR Target Shares Total Outstanding at December 31, 2017 — — — — Granted 86,392 64,785 64,792 215,969 Vested — — — — Forfeited — — — — Outstanding at December 31, 2018 86,392 64,785 64,792 215,969 Granted 107,391 56,380 56,375 220,146 Vested (23,956 ) — — (23,956 ) Forfeited (28,086 ) (26,124 ) (26,128 ) (80,338 ) Outstanding at December 31, 2019 141,741 95,041 95,039 331,821 Granted 132,864 77,967 77,967 288,798 Vested (50,953 ) — — (50,953 ) Forfeited (14,747 ) (15,090 ) (15,090 ) (44,927 ) Outstanding at December 31, 2020 208,905 157,918 157,916 524,739 The total intrinsic value of restricted stock units vested during the years ended December 31, 2020, 2019 and 2018 was $2,214, $1,000 and $0, respectively. Stock Appreciation Rights The following table summarizes SARs activity during the years ended December 31, 2020, 2019 and 2018: Stock Appreciation Rights Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2017 1,192,350 $ 38.17 4.36 $ 2,278 Granted — — Exercised (204,250 ) 26.35 Forfeited — — Outstanding at December 31, 2018 988,100 $ 40.61 3.57 $ 2,064 Granted — — Exercised (179,500 ) 32.84 Forfeited (254,350 ) 42.63 Outstanding at December 31, 2019 554,250 $ 39.41 2.84 $ 2,981 Granted — — Exercised (342,150 ) 38.22 Forfeited (40,500 ) 44.39 Outstanding at December 31, 2020 171,600 $ 40.60 2.44 $ 4,224 Exercisable at December 31, 2020 131,350 $ 41.39 2.22 3,131 The total intrinsic value of SARs exercised during the years ended December 31, 2020, 2019 and 2018 was $4,164, $1,588 and $3,532, respectively. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Note 18 — The income tax provisions were calculated based upon the following components of (loss) earnings before income tax for the years ended December 31, 2020, 2019 and 2018: Year Ended December 31, 2020 2019 2018 (Loss) earnings before income tax: Domestic $ (11,374 ) $ 74,531 $ 10,092 Foreign 92,930 (15,380 ) 48,027 Earnings before income tax $ 81,556 $ 59,151 $ 58,119 The components of the provision for income taxes for the years ended December 31, 2020, 2019 and 2018 are summarized as follows: Year Ended December 31, 2020 2019 2018 Current income tax expense (benefit): Federal $ 784 $ 262 $ 340 State and local 83 94 (71 ) Foreign 20,150 17,672 9,224 Total current income tax expense 21,017 18,028 9,493 Deferred income tax expense (benefit): Federal (2,302 ) (2,490 ) (1,422 ) State and local 32 (1 ) 20 Foreign 3,119 (5,252 ) 8,129 Total deferred income tax expense 849 (7,743 ) 6,727 Total income tax expense $ 21,866 $ 10,285 $ 16,220 As of December 31, 2020, deferred income taxes have not been provided on the undistributed earnings of the Company’s foreign subsidiaries since these earnings will not be taxable upon repatriation to the United States. These earnings will be primarily treated as previously taxed income from either the one-time transition tax or global intangible low-taxed income (“GILTI”) provision, or they will be offset with a 100% dividend received deduction. However, the Company continues to provide a deferred tax liability for foreign withholding tax that will be incurred with respect to the undistributed foreign earnings that are not permanently reinvested. The deferred tax assets and deferred tax liabilities and related valuation allowance were comprised of the following as of December 31, 2020 and 2019: December 31, 2020 2019 Deferred tax assets: Net operating losses $ 22,658 $ 17,881 Intangible assets 29,145 33,743 Research and development credits 10,773 9,752 Depreciation 7,426 7,223 Valuation reserves and accrued liabilities 7,131 7,196 Stock compensation 4,200 3,485 Defined benefit obligation 1,974 2,027 Inventory 1,571 1,284 Other credits 12,068 11,753 Unrealized foreign currency exchange loss 1,431 — Other 64 113 Total deferred tax asset 98,441 94,457 Valuation allowance (17,197 ) (17,316 ) Deferred tax liabilities: Unrealized foreign currency exchange gains — (674 ) Undistributed profits of subsidiary (5,727 ) (4,629 ) Property and equipment (2,758 ) (3,366 ) Other (572 ) (733 ) Total deferred tax liability (9,057 ) (9,402 ) Net deferred tax asset $ 72,187 $ 67,739 Reconciliations between the statutory Federal income tax rate and the effective rate of income tax expense for the years ended December 31, 2020, 2019 and 2018 are as follows: Year Ended December 31, 2020 2019 2018 Statutory Federal income tax rate 21.0 % 21.0 % 21.0 % Increase (decrease) resulting from: Change in valuation allowance (0.4 )% 11.5 % (6.6 )% Effect of different tax rates of foreign jurisdictions (4.7 )% (24.8 )% (6.6 )% Audit settlements and statute expirations 3.9 % 0.6 % (1.1 )% US tax reform items 2.5 % 4.3 % 10.8 % Research and development credits (1.4 )% (2.3 )% (2.5 )% Non-deductible expenses 2.1 % 2.1 % 3.4 % Foreign, state and local tax, net of Federal benefit 1.4 % 1.7 % 1.8 % Tax effects of intercompany transfers 1.4 % 1.5 % 0.8 % Undistributed profit of subsidiaries 0.9 % 1.2 % 1.2 % Other 0.1 % 0.6 % 5.7 % Effective rate 26.8 % 17.4 % 27.9 % The Company has Net Operating Loss (“NOL”) carryforwards as follows: Jurisdiction Amount as of December 31, 2020 Years of Expiration U.S. state income tax $ 106,987 2021-2040 Foreign $ 7,441 2021-2025 Foreign $ 161,851 Never We have incurred NOLs in various states associated with the benefits of the state dividends received reduction along with the foreign royalty exclusion. The state NOL carryforwards expire at various dates from 2021 to 2040. Management has concluded that it is more likely than not that a majority of these NOLs will not be utilized, and thus has not recognized the benefit of these NOLs. At December 31, 2020, certain non-U.S. subsidiaries had net operating loss carryforwards totaling $169,293. This amount included $7,441 in NOLs that expire at various dates from 2021 through 2025 and the remaining $161,851 have no expiration date. The Company had a valuation allowance recorded against $5,787 of the total non-U.S. subsidiaries’ net operating loss carryforwards as of December 31, 2020. The Company is subject to taxation in the United States and various state and foreign jurisdictions. As of December 31, 2020, the Company was no longer subject to U.S. Federal examinations by tax authorities for tax years before 2016 and was no longer subject to foreign examinations by tax authorities for tax years before 2014. During 2015, to entice the Company to construct a new facility in North Macedonia, the government of North Macedonia granted the Company a tax holiday, in combination with state aid, which released the Company from the obligation to pay corporate income taxes for a ten year period, subject to certain limitations. The amount of corporate income tax savings realized by the Company as a result of this tax holiday during 2020, 2019 and 2018, respectively, was zero as a result of operating losses generated during previous periods. The aggregate dollar effect and per share effect of the corporate income tax holiday during 2020, 2019 and 2018 was, therefore, immaterial. At December 31, 2020, 2019 and 2018, the Company had total unrecognized tax benefits of $4,967, $3,795 and $2,819, respectively, all of which, if recognized, would affect the effective income tax rates. The reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended December 31, 2020 2019 2018 Balance at beginning of year $ 3,795 $ 2,819 $ 3,812 Additions based on tax position related to current year 1,489 661 221 Additions based on tax position related to prior year 179 352 423 Reductions from settlements and statute of limitation expiration (650 ) — (1,469 ) Effect of foreign currency translation 154 (37 ) (168 ) Balance at end of year $ 4,967 $ 3,795 $ 2,819 The Company classifies income tax-related penalties and net interest as income tax expense. In the years ended December 31, 2020, 2019 and 2018, income tax related interest and penalties were not material. It is reasonably possible that audit settlements, the conclusions of current examinations or the expiration of the statute of limitations in several jurisdictions could impact the Company’s unrecognized tax benefits. If recognized, all the Company’s gross unrecognized tax benefits would affect the Company’s effective tax rate. |
Revenue Recognition
Revenue Recognition | 12 Months Ended |
Dec. 31, 2020 | |
Revenue Recognition And Deferred Revenue [Abstract] | |
Revenue Recognition | Note 19 –Revenue Recognition The principal activity from which the Company generates its revenue is the manufacturing of production parts for automotive OEMs and automotive suppliers, as well as the sale of medical products and equipment primarily through distributor and group purchasing organization agreements. Contract Balances We record a receivable when revenue is recognized at the time of invoicing and unearned revenue when revenue is recognized subsequent to invoicing. For contracts where control of the goods or service is transferred to the customer over time, or whose terms required the customer to make milestone payments throughout the fulfillment period, the timing of revenue recognition is likely to differ from the timing of invoicing to customers. Most of Gentherm’s unearned revenue pertains to LTAs containing a material right. In the early periods of an LTA containing a material right, when payments collected from the customer are greater than the standalone selling price of the production parts, revenue associated with the material right is deferred. In future periods, when amounts collected from customers as payment is less than the standalone selling price of the production parts delivered, the deferred revenue is reversed into revenue. For LTAs containing a material right and, thus, the timing of revenue recognition is likely to differ from the timing of invoicing to customer, the aggregate amount of transaction price allocated to material rights that remained unsatisfied under LTAs as of December 31, 2020 was $181 within our Automotive segment. We expect to recognize into revenue 32% of this balance in 2021, 48% in 2022 and the remaining 20% in 2023 Revenue allocated to remaining performance obligations represent contracted revenue that has not yet been recognized, which includes unearned revenue and amounts that will be invoiced and recognized as revenue in future periods. |
Segment Reporting
Segment Reporting | 12 Months Ended |
Dec. 31, 2020 | |
Segment Reporting [Abstract] | |
Segment Reporting | Note 20 — Segment information is used by management for making operating decisions for the Company. Management evaluates the performance of the Company’s segments based primarily on operating income or loss. The Company’s reportable segments are as follows: • Automotive — this segment represents the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronic and software systems. • Medical — this segment represents the combined results from our Medical business, GPT (through October 1, 2019), CSZ-IC (through February 1, 2019) and non-automotive expenses from Gentherm’s advanced research and development division (through December 31, 2019). The operating results from these businesses and division are presented together as one reporting segment because of their historical joint concentration on identifying new markets and product applications based on thermal management technologies. With the remaining temperature management business being the primary focus now in this segment, we have renamed it to reflect the strategic direction of this segment. • Corporate — includes corporate costs, selling, general and administrative costs and acquisition transaction costs. This segment has been renamed this year to better align with the costs allocated to this segment. It was previously named ‘Reconciling Items’. In 2018 and 2019, our Industrial reporting segment represented the combined results from our patient temperature management systems business, GPT (through its divestiture on October 1, 2019), CSZ-IC (through its divestiture on February 1, 2019) and non-automotive expenses from our advanced research and development division (through December 31, 2019). The operating results from these businesses and division previously were presented together as one reporting segment because of their historical joint concentration on identifying new markets and product applications based on thermal management technologies. In 2020, the Industrial reporting segment was renamed the Medical reporting segment to reflect the patient temperature management business as the focus and strategic direction of this segment. Also, during 2020, the advanced research and development costs not associated with the Medical segment were moved to the Automotive segment, as this organization now primarily supports the Automotive related development activities following the divestitures of GPT and CSZ-IC. For comparability to the prior years, we have moved the portion of advanced research and development costs to the Automotive segment that were focused on technologies related to automotive in 2018 and 2019 in both the Depreciation and amortization and Operating income (loss) lines in the table below. The tables below present segment information about the reported product revenues and operating income of the Company for years ended December 31, 2020, 2019 and 2018. With the exception of goodwill, asset information by segment is not reported since the Company does not manage assets at a segment level. Automotive Medical Corporate Total 2020: Product revenues $ 869,998 $ 43,100 $ — $ 913,098 Depreciation and amortization 37,662 2,366 1,086 $ 41,114 Operating income (loss) 138,410 971 (50,164 ) $ 89,217 2019: Product revenues $ 920,225 $ 51,459 $ — $ 971,684 Depreciation and amortization 40,923 1,621 1,702 $ 44,246 Operating income (loss) 141,206 (5,735 ) (51,211 ) $ 84,260 2018: Product revenues $ 957,824 $ 90,681 $ — $ 1,048,505 Depreciation and amortization 44,246 3,759 2,633 $ 50,638 Operating income (loss) 136,421 (6,900 ) (56,733 ) $ 72,788 Automotive and Medical segment product revenues by product category for each of the years ended December 31, 2020, 2019 and 2018 are as follows: Year Ended December 31, 2020 2019 2018 Climate Control Seat (CCS) $ 342,550 $ 359,355 $ 373,945 Seat Heaters 249,665 284,174 305,337 Steering Wheel Heaters 76,272 65,426 69,845 Automotive Cables 73,997 88,031 98,931 Electronics 53,238 47,542 56,783 Battery Performance Solutions (BPS) (a) 50,901 41,498 28,472 Other Automotive 23,375 34,199 24,511 Subtotal Automotive segment 869,998 920,225 957,824 Medical 43,100 36,860 30,108 GPT — 11,181 19,520 CSZ-IC — 3,418 41,053 Subtotal Medical segment 43,100 51,459 90,681 Total Company $ 913,098 $ 971,684 $ 1,048,505 (a) Battery Performance Solutions (BPS) was renamed from Battery Thermal Management (BTM), to better represent our product offerings included within this product category. Revenue (based on shipment destination) by geographic area for each of the years ended December 31, 2020, 2019 and 2018 is as follows: Year Ended December 31, 2020 2019 2018 United States $ 377,577 $ 440,316 $ 488,926 China 101,039 71,461 93,628 South Korea 88,745 63,339 58,717 Germany 58,536 81,315 88,366 Japan 57,785 76,197 62,633 Czech Republic 37,542 38,888 42,665 Other 191,874 200,168 213,570 Total Non-U.S. 535,521 531,368 559,579 Total Company $ 913,098 $ 971,684 $ 1,048,505 The table below lists the percentage of total product revenues generated from sales to customers which contributed 10% or more to the Company’s total consolidated product revenue for the years ended December 31, 2020, 2019 and 2018: Year Ended December 31, 2020 2019 2018 Lear 15 % 16 % 17 % Adient 14 % 15 % 16 % Property and equipment, net, for each of the geographic areas in which the Company operates as of December 31, 2020 and 2019 is as follows: December 31, Property and equipment, net 2020 2019 Macedonia $ 38,273 $ 38,989 Vietnam 21,080 21,452 China 20,375 23,721 United States 19,011 21,280 Mexico 16,034 19,982 Germany 15,641 10,515 Ukraine 9,364 11,727 Hungary 8,401 6,803 Other 4,402 6,136 Total $ 152,581 $ 160,605 |
Valuation and Qualifying Accoun
Valuation and Qualifying Accounts | 12 Months Ended |
Dec. 31, 2020 | |
Valuation And Qualifying Accounts [Abstract] | |
Valuation and Qualifying Accounts | GENTHERM INCORPORATED SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS For the Years Ended December 31, 2020, 2019 and 2018 (In thousands) Description Balance at Beginning of Period Charged to Costs and Expenses Charged to Other Accounts Deductions from Reserves Balance at End of Period Allowance for Doubtful Accounts Year Ended December 31, 2020 1,193 1,298 33 (1,363 ) 1,161 Year Ended December 31, 2019 851 969 (8 ) (619 ) 1,193 Year Ended December 31, 2018 973 1,005 (121 ) (1,006 ) 851 Allowance for Deferred Income Tax Assets Year Ended December 31, 2020 17,316 — 139 (258 ) 17,197 Year Ended December 31, 2019 9,977 7,830 (491 ) — 17,316 Year Ended December 31, 2018 27,578 — (14,009 ) (3,592 ) 9,977 Reserve for Inventory Year Ended December 31, 2020 6,073 1,768 214 (914 ) 7,141 Year Ended December 31, 2019 6,270 1,679 (56 ) (1,820 ) 6,073 Year Ended December 31, 2018 7,887 2,712 (1,047 ) (3,282 ) 6,270 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Impact of COVID-19 | Impact of COVID-19 The COVID-19 pandemic has significantly disrupted global economic activity, including the automotive market. The COVID-19 pandemic was first identified in China around December 2019. The impact of the outbreak quickly expanded beyond China and its surrounding region and has significantly and adversely impacted the entire global economy and automotive market in 2020. During the first quarter of 2020, customer plants in North America and Europe were closed beginning in the second half of March due to the pandemic. This resulted in temporary, partial closures of several of our manufacturing facilities in North America and Europe by the end of March 2020. Customer plants and our manufacturing facilities in Asia were closed for several weeks in February and operated at reduced volumes in March, resuming production to near full capacity by the end of the first quarter, which continued throughout the second quarter. However, during the second quarter of 2020, our manufacturing facilities in North America and Europe remained closed until the last week in May due to the pandemic, gradually resuming production to near full capacity in North America, and to about 70% capacity in Europe by the end of June. During the second half of 2020, our customers’ plants were open, and our production volumes were stronger than pre-COVID levels at our manufacturing facilities. The Company has implemented additional health and safety precautions and protocols in response to the pandemic and government guidelines to help ensure the safety and health of all its employees, and it continues to assess and update business continuity plans in the context of this pandemic. The consequences of the pandemic and adverse impact to the economy continue to evolve and the future adverse impact on our business and financial statements remains subject to significant uncertainty as of the date of this filing. |
Basis of Presentation | Basis of Presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain prior period amounts have been reclassified to conform to current period presentation. In 2020, the Industrial reporting segment was renamed the Medical reporting segment to reflect the patient temperature management business as the focus and strategic direction of this segment, and the advanced research and development organization was moved to the Automotive segment. See below under “Segment Reporting” in this footnote and Note 20, “Segment Reporting” for further details. |
Revision of Prior Period Financial Statements | Revision of Prior Period Financial Statements During the fourth quarter of 2020, management determined that certain deferred tax assets were not properly evaluated for realizability under ASC Topic 740, Income Taxes which resulted in an immaterial error that affected previously issued financial statements for the year ended December 31, 2019. In accordance with ASC 250: Accounting Changes and Error Corrections (“ASC 250”), w e have corrected the error by revising the historical consolidated financial statements and related disclosures for the year ended December 31, 2019 . Management evaluated the effect of the adjustment on the Company’s financial statements under provision ASC 250, Staff Accounting Bulletin No. 99: Materiality, and Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements and concluded that the adjustment made was immaterial to the previously issued financial statements for the year ended December 31, 2019. The impact to the consolidated statements of income for the year ended December 31, 2019 and the consolidated balance sheet as of December 31, 2019 is as follows: Year Ended December 31, 2019 As Reported Adjustment As Revised Income Statement: Earnings before income tax $ 59,151 $ — $ 59,151 Income tax expense 21,645 (11,360 ) 10,285 Net income 37,506 11,360 48,866 Basic EPS $ 1.13 $ 0.35 $ 1.48 Diluted EPS $ 1.13 $ 0.34 $ 1.47 December 31, 2019 As Reported Adjustment As Revised Balance Sheet: Deferred income tax asset - long term $ 57,650 $ 11,446 $ 69,096 Total non-current assets 353,523 11,446 364,969 Total assets 727,386 11,446 738,832 Accumulated other comprehensive (loss) income (42,441 ) 86 (42,355 ) Accumulated earnings 401,732 11,360 413,092 Total shareholders' equity $ 727,386 $ 11,446 $ 738,832 |
Principles of Consolidation | Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. Investments in affiliates in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20%), investments in affiliates are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. |
Use of Estimates | Use of Estimates In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. |
Segment Reporting | Segment Reporting The Company has two reportable segments: Automotive Medical In 2018 and 2019, our Industrial reporting segment represented the combined results from our patient temperature management systems business (“Medical”), remote power generation systems business, Gentherm Global Power Technologies (“GPT”) (through its divestiture on October 1, 2019), environmental test equipment business, Cincinnati Sub Zero industrial chamber business (“CSZ-IC”) (through its divestiture on February 1, 2019) and our advanced research and development division. The operating results from these businesses and division previously were presented together as one reporting segment because of their historical joint concentration on identifying new markets and product applications based on thermal management technologies. In 2020, the Industrial reporting segment was renamed the Medical reporting segment to reflect the patient temperature management business as the focus and strategic direction of this segment. Also, during 2020, the advanced research and development costs not associated with the Medical segment were moved to the Automotive segment, as this organization primarily supports the Automotive related research and development activities following the divestitures of GPT and CSZ-IC. |
Revenue Recognition | Revenue Recognition Revenue is recognized from agreements containing enforceable rights and obligations, when promised goods are delivered or services are completed. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from Product revenues. Shipping and handling fees billed to customers are included in Product revenues, while costs of shipping and handling are included in Cost of sales. Automotive Revenues The Company provides production parts to its customers under long-term supply agreements (“LTAs”). The duration of an LTA is generally consistent with the life cycle of a vehicle; however, an LTA does not reach the level of a performance obligation until Gentherm receives either a purchase order and/or a materials release from the customer for a specific number of production parts at a specified price, at which point an enforceable contract exists. Revenue is recognized when control of the production parts has transferred to the customer according to the terms of the contract, which typically occurs when the parts are shipped or delivered to the customer’s premises. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring production parts. Certain LTAs provide for annual price reductions over the production life of the vehicle. Agreements that are determined to provide customers with purchase option discounts that would not be received without entering into the contract are considered to contain a material right (for example, a discount given to a customer that is incremental to the range of discounts typically given to that class of customer). The material right represents a purchase option that provides the customer with the ability to purchase additional production parts at a set price in the future and is accounted for as a separate performance obligation. Under these circumstances, each transfer of production parts under the LTA requires allocation of the purchase price to the production part and the purchase option. As a practical alternative to estimating the standalone selling price of an option, the Company allocates transaction price to the purchase option by reference to the production part volumes expected to be ordered and the consideration expected to be received over the life of the vehicle program. The production part’s relative standalone selling price observed under the LTA is subtracted from the total amount of consideration expected to be received in exchange for transferring of parts under the current contract and the difference is allocated to the purchase option. Revenue from options containing a material right is recognized when the amounts billed by the customer for production parts transferred, under the LTA, is less than the standalone selling price of those production parts. Medical Revenues Revenues from our patient temperature management business unit are generated from the sale of products and equipment. Our medical products and equipment focus on body and blood temperature management. The Company sells medical products and equipment primarily through distributor and group purchasing organization agreements. These agreements allow member participants to the distributor or group purchasing organization to make purchases at discounted prices negotiated by the distributor or group purchasing organization. A rebate is incurred at the point in time a member participant purchases product covered under these types of agreements. Rebates are accounted for as variable consideration, using an expected value, probability weighted approach, based on the level of sales to the distributor and the time lag between the initial sale and the rebate claim in determining the transaction price of a contract. Revenue is recognized at the point in time the medical products or equipment is transferred to the customer. GPT and CSZ-IC Revenues Revenues from our divested businesses, GPT and CSZ-IC, were generated from the sale of products and services. GPT and CSZ-IC customers commonly entered into multiple-element agreements for the purchase of products and services. Installation services, for example, were separate and distinct performance obligations that were often included in contracts to purchase customized environmental test chambers. Depending on the application, delivery of an environmental test chamber or remote power generation system to the customer’s place of business could range from two weeks to nine months from commencement of the contract. Installation services, while reliant on the specifications and timing from the customer, rarely remained incomplete more than two months after delivery. Revenues allocated to environmental test chambers or remote power systems were based on the stand-alone selling price of the products themselves. Judgement was used to determine the degree to which early pay discounts and other credits were utilized in the calculation of standalone selling price, and only included to the extent it was probable that a significant reversal of any incremental revenue would not occur. Revenues were recognized at the point in time the chamber or power system was shipped to the customer. For contracts that also included a promise for installation, the portion of total transaction price allocated to the installation was recognized as revenue at the point in time the installation was complete. GPT and CSZ-IC often required milestone payments for contracts to provide environmental test chambers or remote power systems to customers. Milestone payments did not provide the Company with a right to payment for the work completed to date and did not represent the satisfaction of a performance obligation. Milestone payments were deferred and reported within unearned revenue until construction was complete and the unit had been delivered or was installed. If the environmental test chamber contract included a separate promise to provide installation services, any installation-related payments received from the customer were deferred until the point in time the installation was complete. Assets Recognized from the Costs to Obtain a Contract with a Customer We recognize an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year. Total capitalized costs to obtain a contract were $1,805 and $1,893 as of December 31, 2020 and 2019, respectively. These amounts are recorded in Other current assets and are being amortized into Product revenues over the expected production life of the program. During the year ended December 31, 2020 and 2019, $263 and $1,006, respectively, was amortized into Product revenues. |
Cash and Cash Equivalents and Restricted Cash | Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with original maturities of less than 90 days to be cash equivalents. Cash balances in individual banks may exceed the federally insured limit by the Federal Deposit Insurance Corporation. The Company had Cash and cash equivalents of $106,598 and $35,735 held in foreign jurisdictions as of December 31, 2020 and 2019, respectively. Restricted cash includes cash that is legally restricted as to use or withdrawal. |
Disclosures About Fair Value of Financial Instruments | Disclosures About Fair Value of Financial Instruments The carrying amounts of financial instruments comprising cash and cash equivalents, short-term investments and accounts receivable approximate fair value because of the short maturities of these instruments. The carrying amount of the Company’s U.S. Revolving Note approximates its fair value because interest charged on the loan balance is variable. See Note 14 for information about the techniques used to assess the fair value of financial assets and liabilities, including our fixed rate debt instruments. |
Concentration of Credit Risk | Concentration of Credit Risk Financial assets, which subject the Company to concentration of credit risk, consist primarily of cash equivalents, short-term investments and accounts receivable. Cash equivalents consist primarily of money market funds managed by major financial services companies. The credit risk for these cash equivalents is considered low. The Company does not require collateral from its customers. As of December 31, 2020, Lear and Adient both individually represented 18% of the Company’s accounts receivable balance. As of December 31, 2019, Lear and Adient both individually represented 21% of the Company’s accounts receivable balance. These accounts are currently in good standing. |
Accounts Receivable | Accounts Receivable Accounts receivable are stated at the invoiced amount, less allowance for doubtful accounts for estimated amounts not expected to be collected, and do not bear interest. The Company determines the allowances based on historical write-off experience by industry and regional economic data, current expectations of future credit losses and historical cash discounts. |
Inventory | Inventory The Company’s inventory is measured at the lower of cost or net realizable value, with cost being determined using the first-in first-out basis. Raw materials, consumables and commodities are measured at cost of purchase and unfinished and finished goods are measured at cost of production, using the weighted average method. If the net realizable value expected on the reporting date is below cost, a write-down is recorded to adjust inventory to its net realizable value. We recognize a reserve for obsolete and slow-moving inventories based on estimates of future sales and an inventory item’s capacity to be repurposed for a different use. We consider the number of months supply on hand based on current planned requirements, uncommitted future projections and historical usage in estimating the inventory reserve. |
Property and Equipment | Property and Equipment Property and equipment, including additions and improvements, are recorded at cost less accumulated depreciation. Expenditures for general repairs and maintenance are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded as Operating income or expense. Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s Property and equipment are as follows: Asset Category Useful Life Buildings and improvements 2 to 50 years Plant and equipment 1 to 20 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 10 years The Company recognized depreciation expense of $31,037, $33,639 and $36,270 for the years ended December 31, 2020, 2019 and 2018, respectively. |
Tooling | Tooling The Company incurs costs related to tooling used in the manufacture of products sold to its customers. In some cases, the Company enters into contracts with its customers whereby the Company incurs the costs to design, develop and purchase tooling and is then reimbursed by the customer under a reimbursement contract. Tooling costs that will be reimbursed by customers are included in Other current assets at the lower of accumulated cost or the customer reimbursable amount. As of December 31, 2020 and 2019, respectively, $4,831 and $5,347 of reimbursable tooling was capitalized within Other current assets. Company-owned tooling is included in Property and equipment and depreciated over its expected useful life, generally two to ten years. Management periodically evaluates the recoverability of tooling costs, based on estimated future cash flows, and makes provisions, where appropriate, for tooling costs that will not be recovered. |
Goodwill and Other Intangible Assets | Goodwill and Other Intangible Assets Goodwill and other intangible assets recorded in conjunction with business combinations are based on the Company’s estimate of fair value, as of the date of acquisition. Amortization is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 6 to 15 years Technology 4 to 8 years Product development costs 1 to 15 years Trade names Indefinite Our business strategy largely centers on designing products based upon internally developed and purchased technology, and we protect certain technology with patents that have value to our business strategy. Our policy is to expense all costs associated with the development and issuance of new patents as incurred. Such costs are classified as research and development expenses in our consolidation statements of income. Patents purchased as part of a business combination are capitalized based on their fair values. Periodically we review the recoverability and remaining lives of our capitalized patents. If necessary, we make adjustments to reported amounts based upon unfavorable impacts from market conditions, the emergence of competitive technologies or changes in our projected business plans. |
Impairments of Long-Lived Assets, Other Intangible Assets and Goodwill | Impairments of Long-Lived Assets, Other Intangible Assets and Goodwill Goodwill is tested for impairment at least annually as of December 31 and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In conducting our annual impairment assessment testing, we first perform a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount. If not, no further goodwill impairment testing is performed. If it is more likely than not that a reporting unit’s fair value is less than its carrying amount, or if we elect not to perform a qualitative assessment of a reporting unit, we then compare the fair value of the reporting unit to the related net book value. If the net book value of a reporting unit exceeds its fair value, an impairment loss is measured and recognized. The Company utilizes an income statement approach to estimate the fair value of a reporting unit and a market valuation approach to further support this analysis (level 3). The income statement approach is based on projected debt-free cash flow that is discounted to the present value using discount factors that consider the timing and risk of cash flows. We believe that this approach is appropriate because it provides a fair value estimate based on the reporting unit’s expected long-term operating cash flow performance. This approach also mitigates the impact of cyclical trends that occur in the industry. Fair value is estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used is the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital is adjusted to reflect a risk factor, if necessary. Other significant assumptions include terminal value growth rates, terminal value margin rates, future capital expenditures and changes in future working capital requirements. While there are inherent uncertainties related to the assumptions used and to management’s application of these assumptions to this analysis, we believe that the income statement approach provides a reasonable estimate of the fair value of a reporting unit. The Company performs its indefinite-lived intangible asset impairment assessment annually as of December 31, and between annual assessments if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount . |
Accrued Warranty Costs | Accrued Warranty Costs The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including claims already filed by customers, the warranty accrual is adjusted quarterly to reflect management’s best estimate of future claims. |
Research and Development Expenses | Research and Development Expenses Research and development activities are expensed as incurred. The Company groups development and prototype costs and related reimbursements in Research and development. The Company recognizes amounts due as reimbursements for expenses as these expenses are incurred. |
Leases | Leases The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. We also have operating leases for office equipment and automobiles. Excluding land leases, our leases have remaining lease terms ranging from less than 1 year to 11 years and may include options to extend the lease. Land leases have remaining lease terms that range from 40 to 42 years and some which specify that the end of the lease term is at the discretion of the lessee. We do not have lease arrangements with related parties. The Company determines whether a contractual arrangement is or contains a lease at inception. Leases that are operating in nature are recognized in Operating lease right-of-use assets, Current lease liabilities and Non-current lease liabilities on our consolidated balance sheets. Gentherm is not currently party to any leases that qualify as financing leases. Lease liabilities are measured initially at the present value of the sum of the future minimum rental payments at the commencement date of the lease. Lease payments that will vary in the future due to changes in facts and circumstances are excluded from the calculation of rental payments, unless those variable payments are based on an index or rate. Rental payments are discounted using an incremental borrowing rate based on the Company’s credit rating, determined on a fully collateralized loan basis from information available at commencement date, and the duration of the lease term (the “reference rate”). Judgement is used to assess the importance of risk factor inputs during the computation of the Company’s credit rating. For leases at foreign subsidiaries denominated in U.S. Dollars, a risk premium associated with the borrower subsidiary’s country is added to the reference rate. For significant leases at foreign subsidiaries denominated in a foreign currency, the U.S. Dollar risk free rate with a duration similar to that of the lease term is subtracted from the reference rate and a corresponding foreign currency risk free rate with a duration similar to that of the lease term is added to the reference rate. Operating lease right-of-use assets are measured at the amount of the lease liability, adjusted for prepaid or accrued lease payments, lease incentive received, and initial direct costs incurred, as applicable. Periods covered by an option to extend the lease are initially included in the measurement of an operating lease right-of-use asset and lease liability only when it is reasonably certain we will exercise the option. Gentherm’s lease agreements do not contain residual value guarantees or impose restrictions or covenants on the Company. For all classes of underlying assets, the Company accounts for leases that contain separate lease and non-lease components as containing a single lease component. The Company does not recognize lease right-of-use assets and lease liabilities from leases with an original lease term of 12 months or less and, instead, recognizes rent payments on a straight-line basis over the lease term in the consolidated statements of income. |
Income Taxes | Income Taxes The Company records income tax expense using the liability method which specifies that deferred tax assets and liabilities be measured each year based on the difference between the financial statement and tax base of assets and liabilities at the applicable enacted tax rates. A valuation allowance is provided for deferred tax assets when management considers it more likely than not that the asset will not be realized. At December 31, 2020 and 2019, a valuation allowance has been provided for certain deferred tax assets which the Company has concluded are more likely than not to not be realized. If future annual taxable income were to be significantly less than current and projected levels, there is a risk that certain of our deferred tax assets not already provided for by the valuation allowance would expire prior to utilization. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in Income tax expense. |
Derivative Financial Instruments - Hedge Accounting | Derivative Financial Instruments – Hedge Accounting The Company accounts for some of its derivative financial instruments as cash flow hedges. For derivative contracts which can be classified as a cash flow hedge, the effective potion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive income in the consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive income is recorded in earnings in the consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. Any ineffective portion of the gain or loss is recognized in the consolidated statements of income under Foreign currency (loss) gain. These hedging transactions and the respective correlations meet the requirements for hedge accounting. |
Earnings Per Share | Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of Common Stock outstanding during the respective period. The Company’s diluted earnings per common share give effect to all potential shares of Common Stock outstanding during a period that are not anti-dilutive. In computing the number of diluted shares outstanding, the treasury stock method is used in order to arrive at a net number of shares created upon the conversion of Common Stock equivalents. |
Stock Based Compensation | Stock Based Compensation Share based payments that involve the issuance of Common Stock to employees, including grants of employee stock options, restricted stock, and time-based and performance-based restricted stock units, are recognized in the financial statements as compensation expense based upon the fair value on the date of grant. Performance-based restricted stock unit awards are measured based on either a target return on invested capital ratio (“ROIC”), as defined in the award agreement, for a specified fiscal year, or the Company’s common stock market price returning a target total shareholder return (“TSR”), as defined, during a specific three-year measurement period. Performance-based restricted stock units cliff vest after three years based on the achievement of performance measurements. Share based payments that are satisfied only by the payment of cash, such as stock appreciation rights, are accounted for as liabilities. The liability is reported at market value of the vested portion of the underlying units. During each period, the change in the liability is recorded as compensation expense during periods when the liability increases or income during periods in which the liability decreases. |
Pension Plans | Pension Plans The Company’s obligations and expenses for its pension plans are dependent on the Company’s selection of discount rate, expected long-term rate of return on plan assets and other assumptions used by actuaries to calculate these amounts. |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements Expected Credit Losses In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets held. The Company adopted ASU 2016-13 as of January 1, 2020 and there was no significant impact on its consolidated condensed financial statements and related disclosures as a result. The Company considered, among other things, the current and expected future economic and market conditions related to the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. Cloud Computing Arrangements That Are Service Contracts In August 2018, the FASB issued ASU 2018-15, “Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” ASU 2018-15 requires implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement if those costs would be capitalized by the customer in a software licensing arrangement under the internal-use software guidance. The Company adopted ASU 2018-15 as of January 1, 2020 and there was no significant impact on its consolidated condensed financial statements and related disclosures as a result. Fair Value Measurement In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 removes certain disclosure requirements, including (i) the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, (ii) the policy for timing of transfer between levels, and (iii) the valuation processes for Level 3 fair value measurements. ASU 2018-13 also adds new disclosure requirements, including (i) the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The Company adopted ASU 2018-13 as of January 1, 2020 and there was no significant impact on its consolidated condensed financial statements and related disclosures as a result. Retirement Benefits In August 2018, the FASB issued ASU 2018-14, “Compensation – Retirement Benefits – Defined Benefit Plans – General (Subtopic 715-20): Disclosure Framework – Changes to the Disclosure Requirements for Defined Benefit Plans.” ASU 2018-14 removes certain disclosure requirements, including (i) the amounts in accumulated other comprehensive income expected to be recognized as components of net periodic benefit cost over the next fiscal year, and (ii) the amount and timing of plan assets expected to be returned to the employer. ASU 2018-14 also adds new disclosure requirements, including (i) the weighted-average interest crediting rates for cash balance plans and other plans with promised interest crediting rates and (ii) an explanation of the reasons for significant gains and losses related to changes in the benefit obligation for the period. The Company adopted ASU 2018-14 as of December 31, 2020 and there was no significant impact on its consolidated condensed financial statements and related disclosures as a result. |
Recently Issued Accounting Pronouncements Not Yet Adopted | Recently Issued Accounting Pronouncements Not Yet Adopted Income Taxes In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes". This ASU simplifies the accounting for income taxes by removing certain exceptions previously included in the guidance. In addition, the ASU amends existing guidance to improve consistent application. ASU 2019-12 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within those reporting periods. Early adoption of the amendments in this update is permitted. The adoption of this standard is not expected to have a significant impact on the Company’s financial statements or financial disclosures Reference Rate Reform In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of Effects of Reference Rate Reform on Financial Reporting”. ASU 2020-04 provides practical expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments in this update apply only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued as a result of reference rate reform. These amendments are not applicable to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. ASU No. 2020-04 is effective as of March 12, 2020 through December 31, 2022 and may be applied to contract modifications and hedging relationships from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company will adopt this standard when LIBOR is discontinued and does not expect a material impact to its consolidated financial statements. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Summary of Revision of Prior Period Financial Statements | The impact to the consolidated statements of income for the year ended December 31, 2019 and the consolidated balance sheet as of December 31, 2019 is as follows: Year Ended December 31, 2019 As Reported Adjustment As Revised Income Statement: Earnings before income tax $ 59,151 $ — $ 59,151 Income tax expense 21,645 (11,360 ) 10,285 Net income 37,506 11,360 48,866 Basic EPS $ 1.13 $ 0.35 $ 1.48 Diluted EPS $ 1.13 $ 0.34 $ 1.47 December 31, 2019 As Reported Adjustment As Revised Balance Sheet: Deferred income tax asset - long term $ 57,650 $ 11,446 $ 69,096 Total non-current assets 353,523 11,446 364,969 Total assets 727,386 11,446 738,832 Accumulated other comprehensive (loss) income (42,441 ) 86 (42,355 ) Accumulated earnings 401,732 11,360 413,092 Total shareholders' equity $ 727,386 $ 11,446 $ 738,832 |
Estimated Useful Lives of Property and Equipment | Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s Property and equipment are as follows: Asset Category Useful Life Buildings and improvements 2 to 50 years Plant and equipment 1 to 20 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 10 years |
Fair Value and Corresponding Useful Lives for Acquired Intangibles Assets | Amortization is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 6 to 15 years Technology 4 to 8 years Product development costs 1 to 15 years Trade names Indefinite |
Acquisitions and Divestitures (
Acquisitions and Divestitures (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Stihler Electronic GmbH | |
Business Acquisition [Line Items] | |
Summary of Purchase Price Allocation | The purchase price and related allocation to the acquired net assets of Stihler, based on their estimated fair values as of the acquisition date, are shown below: Purchase price, cash consideration, net of cash acquired $ 14,823 Purchase price, fair value of contingent consideration 653 Total purchase price, net of cash acquired 15,476 Accounts receivable 883 Inventory 1,698 Prepaid expenses and other assets 241 Operating lease right-of-use assets 263 Property and equipment 260 Other intangible assets 4,380 Goodwill 9,816 Assumed liabilities (2,065 ) Net assets acquired $ 15,476 |
Restructuring (Tables)
Restructuring (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Restructuring And Related Activities [Abstract] | |
Summary of Restructuring Expense by Reportable Segment | Restructuring expense by reporting segment for the years ended December 31, 2020, 2019 and 2018 was as follows: Year Ended December 31, 2020 2019 2018 Automotive $ 5,075 $ 9,353 $ 5,548 Medical 112 1,838 5,607 Corporate 616 1,728 3,617 Total $ 5,803 $ 12,919 $ 14,772 |
Summary of Restructuring Activity for All Restructuring Initiatives | The following table summarizes restructuring activity for all restructuring initiatives for the years ended December 31, 2020 and 2019: Employee Separation Costs Accelerated Depreciation and Asset Impairment Charges Other Related Costs Total Balance at December 31, 2018 $ 2,079 $ — $ 468 $ 2,547 Additions, charged to restructuring expenses 8,056 2,512 2,351 12,919 Cash payments (4,118 ) — (2,636 ) (6,754 ) Non-cash utilization — (2,512 ) — (2,512 ) Reclassification to lease liability — — (112 ) (112 ) Currency translation (23 ) — — (23 ) Balance at December 31, 2019 5,994 — 71 6,065 Additions, charged to restructuring expenses 6,932 687 584 8,203 Change in estimate (2,382 ) — (18 ) (2,400 ) Cash payments (5,052 ) — (757 ) (5,809 ) Non-cash utilization — (687 ) — (687 ) Currency translation 135 — 120 255 Balance at December 31, 2020 $ 5,627 $ — $ — $ 5,627 |
Details of Certain Financial _2
Details of Certain Financial Statement Components (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Financial Statement Components [Abstract] | |
Details of Certain Financial Statement Components | December 31, 2020 2019 Inventory: Raw materials, net of reserve $ 68,362 $ 61,323 Work in process, net of reserve 8,247 7,444 Finished goods, net of reserve 45,792 49,712 Total inventory, net $ 122,401 $ 118,479 Other current assets: Notes receivable $ 19,200 $ 9,963 Income tax and other tax receivable 10,514 17,057 Billable tooling 4,831 5,194 Prepaid expenses 3,930 7,022 Other 2,713 3,490 Total other current assets $ 41,188 $ 42,726 Property and equipment: Machinery and equipment $ 142,833 $ 137,813 Buildings and improvements 99,011 90,675 Information technology 30,338 27,697 Production tooling 22,783 19,906 Leasehold improvements 11,762 11,116 Construction in progress 8,968 2,856 Total property and equipment 315,695 290,063 Less: accumulated depreciation (163,114 ) (129,458 ) Total property and equipment, net $ 152,581 $ 160,605 Other current liabilities: Accrued employee liabilities $ 26,612 $ 26,019 Liabilities from discounts and rebates 22,910 16,593 Income tax and other taxes payable 14,714 3,693 Restructuring 5,627 6,065 Accrued warranty 2,391 4,596 Other 9,155 9,617 Total other current liabilities $ 81,409 $ 66,583 |
Goodwill and Other Intangibles
Goodwill and Other Intangibles (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Goodwill And Intangible Assets Disclosure [Abstract] | |
Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment | Changes in the carrying amount of goodwill, by reportable segment, for the years ended December 31, 2020 and 2019 were as follows: Automotive Medical Total December 31, 2018 $ 37,533 $ 17,778 $ 55,311 Stihler acquisition — 9,816 9,816 Exchange rate impact (595 ) 40 (555 ) Balance as of December 31, 2019 $ 36,938 $ 27,634 $ 64,572 Exchange rate impact 2,557 895 3,452 Balance as of December 31, 2020 $ 39,495 $ 28,529 $ 68,024 |
Summary of Other Intangible Assets and Accumulated Amortization Balances | Other intangible assets and accumulated amortization balances as of December 31, 2020 and 2019 were as follows: Gross Carrying Value Accumulated Amortization Net Carrying Value Definite-lived: Customer relationships $ 97,815 $ (63,432 ) $ 34,383 Technology 30,615 (24,075 ) 6,540 Product development costs 22,164 (21,336 ) 828 Indefinite-lived: Tradenames 4,670 — 4,670 Balance as of December 31, 2020 $ 155,264 $ (108,843 ) $ 46,421 Gross Carrying Value Accumulated Amortization Net Carrying Value Definite-lived: Customer relationships $ 89,208 $ (50,687 ) $ 38,521 Technology 25,106 (19,866 ) 5,240 Product development costs 19,911 (18,559 ) 1,352 Indefinite-lived: Tradenames 4,670 — 4,670 Balance as of December 31, 2019 $ 138,895 $ (89,112 ) $ 49,783 |
Summary of Estimate of Other Intangible Asset Amortization | An estimate of other intangible asset amortization by year, is as follows: 2021 $ 8,316 2022 7,803 2023 4,385 2024 3,245 2025 3,229 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Leases [Abstract] | |
Components of Lease Expense and Other Information | Components of lease expense for the years ended December Year Ended December 31, 2020 2019 Lease cost: Operating lease cost $ 6,773 $ 5,899 Short-term lease cost 1,834 3,444 Sublease income (158 ) (128 ) Total lease cost $ 8,449 $ 9,215 Other information related to leases is as follows: Year Ended December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 6,817 $ 6,059 Right-of-use lease assets obtained in exchange for lease obligations: Operating leases $ 25,161 $ 4,111 Gain on sale and leaseback transactions, net $ 207 December 31, 2020 December 31, 2019 Weighted average remaining lease term: Operating leases 5.4 years 4.5 years Weighted average discount rate: Operating leases 4.65 % 5.46 % |
Summary of Operating Leases Under all Non-Cancellable Operating Leases | A summary of operating leases as of December 31, 2020, under all non-cancellable operating leases with terms exceeding one year is as follows: . 2021 $ 7,316 2022 6,033 2023 4,016 2024 3,829 2025 3,648 2026 or later 10,461 Total future minimum lease payments 35,303 Less imputed interest (5,038 ) Total $ 30,265 |
Debt (Tables)
Debt (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Debt Disclosure [Abstract] | |
Summary of Company's Debt | The following table summarizes the Company’s debt as of December 31, 2020 and 2019: December 31, 2020 2019 Interest Rate Principal Balance Interest Rate Principal Balance Amended Credit Agreement: U.S. Revolving Note (U.S. Dollar Denominations) 1.65 % $ 171,500 3.05 % $ 50,000 U.S. Revolving Note (Euro Denominations) 1.50 % 14,684 1.25 % 21,874 DEG Vietnam Loan 5.21 % 6,250 5.21 % 8,750 Total debt 192,434 80,624 Current maturities (2,500 ) (2,500 ) Long-term debt, less current maturities $ 189,934 $ 78,124 |
Principal Maturities of Debt | The scheduled principal maturities of our debt as of December 31, 2020 were as follows: DEG Vietnam Note U.S. Revolving Note Total 2021 $ 2,500 $ — $ 2,500 2022 2,500 — 2,500 2023 1,250 — 1,250 2024 — 186,184 186,184 Total $ 6,250 $ 186,184 $ 192,434 |
Pension and Other Post Retire_2
Pension and Other Post Retirement Benefit Plans (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Compensation And Retirement Disclosure [Abstract] | |
Components of Net Periodic Benefit Cost for Company's Defined Benefit Plans | The components of net periodic benefit cost for the Company’s defined benefit plans for the years ended December 31, 2020, 2019 and 2018 were as follows: U.S. Plan German Plan Year Ended December 31, Year Ended December 31, 2020 2019 2018 2020 2019 2018 Net periodic benefit cost: Service cost $ — $ — $ — $ — $ — $ — Interest cost 85 127 114 88 147 147 Expected return on plan assets — — — (121 ) (126 ) (130 ) Amortization of prior service cost and actuarial loss 7 — — 124 72 73 Net periodic benefit cost $ 92 $ 127 $ 114 $ 91 $ 93 $ 90 Assumptions: Discount rate 2.40 % 3.65 % 2.95 % 1.08 % 1.06 % 2.04 % Long-term return on assets N/A N/A N/A 2.90 % 3.10 % 3.40 % |
Reconciliation of Change in Benefit Obligation, Change in Plan Assets and Balance Sheet Classification | A reconciliation of the change in benefit obligation and the change in plan assets for the years ended December 31, 2020 and 2019 is as follows: U.S. Plan German Plan As of December 31, As of December 31, 2020 2019 2020 2019 Change in projected benefit obligation: Balance at beginning of year $ 3,871 $ 3,832 $ 8,353 $ 7,529 Interest cost 85 127 88 147 Paid pension distributions (342 ) (342 ) (294 ) (285 ) Actuarial losses 233 254 40 1,116 Exchange rate impact — — 747 (154 ) Balance at end of year $ 3,847 $ 3,871 $ 8,934 $ 8,353 Change in plan assets: Balance at beginning of year — $ — 3,825 3,808 Actual return on plan assets — — 121 126 Contributions — — 294 284 Paid pension distributions — — (294 ) (284 ) Actuarial losses — — (25 ) (30 ) Exchange rate impact — — 355 (79 ) Balance at end of year $ — $ — $ 4,276 $ 3,825 Underfunded Status $ (3,847 ) $ (3,871 ) $ (4,658 ) $ (4,528 ) Balance sheet classification: Other current liabilities (342 ) (342 ) — — Pension benefit obligation (3,505 ) (3,529 ) (4,658 ) (4,528 ) Accumulated other comprehensive loss (pre-tax): Actuarial losses 701 476 3,644 3,398 Assumptions: Discount rate 1.20 % 2.40 % 1.08 % 1.06 % |
Summary of Pre-tax Amounts in AOCI Expected to Be Recognized in Net Periodic Benefit Cost | Pre-tax amounts included in AOCI that are expected to be recognized in net periodic benefit cost during the year ended December 31, 2021 are as follows: U.S Plan German Plan Actuarial losses $ 26 $ 126 |
Summary of Accumulated Benefit Obligations | The accumulated benefit obligations were as follows: U.S. Plan German Plan As of December 31, As of December 31, 2020 2019 2020 2019 Accumulated benefit obligation $ 3,847 $ 3,871 $ 8,934 $ 8,529 |
Schedule of Future Expected Pension Payments | The schedule of future expected pension payments is as follows: Projected Pension Benefit Payments Year U.S Plan German Plan 2021 $ 342 $ 296 2022 342 291 2023 342 301 2024 342 295 2025 342 287 2026-2030 1,710 2,886 Total $ 3,420 $ 4,356 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Commitments And Contingencies Disclosure [Abstract] | |
Reconciliation of Changes in Accrued Warranty Costs | The following is a reconciliation of the changes in accrued warranty costs: Year Ended December 31, 2020 2019 Balance at beginning of year $ 4,596 $ 4,514 Warranty claims paid (2,598 ) (584 ) Warranty expense for products shipped during the current period 1,223 2,370 Adjustments to warranty estimates from prior periods (893 ) (1,660 ) Acquisition of business — 21 Adjustments due to currency translation 63 (65 ) Balance at end of year $ 2,391 $ 4,596 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Earnings Per Share [Abstract] | |
Earnings per Share and Weighted Average Shares Outstanding Used in Calculating Basic and Diluted Earnings per Share | The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Year Ended December 31, 2020 2019 2018 Net income $ 59,690 $ 48,866 $ 41,899 Basic weighted average shares of Common Stock outstanding 32,666,025 33,120,076 35,920,782 Dilutive effect of stock options, restricted stock awards and restricted stock units 362,079 177,513 256,362 Diluted weighted average shares of Common Stock outstanding 33,028,104 33,297,589 36,177,144 Basic earnings per share $ 1.83 $ 1.48 $ 1.17 Diluted earnings per share $ 1.81 $ 1.47 $ 1.16 |
Common Stock Issuable upon Exercise of Certain Stock Options | The following table represents Common Stock issuable upon the exercise of certain stock options that have been excluded from the diluted earnings calculation because the effect of their inclusion would be anti-dilutive. Year Ended December 31, 2020 2019 2018 Anti-dilutive securities share impact 12,000 214,000 898,250 |
Financial Instruments (Tables)
Financial Instruments (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Derivative Instruments And Hedging Activities Disclosure [Abstract] | |
Reconciliation of Cash and Cash Equivalents and Restricted Cash | A reconciliation of cash and cash equivalents on the consolidated balance sheets to cash, cash equivalents and restricted cash presented on the consolidated statements of cash flows is as follows: As of December 31, 2020 2019 Cash and cash equivalents presented in the consolidated balance sheets $ 268,345 $ 50,443 Restricted cash — 2,505 Cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows $ 268,345 $ 52,948 |
Information Related to Recurring Fair Value Measurement of Derivative Financial Instruments in the Consolidated Balance Sheet | Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2020 is as follows: Asset Derivatives Liability Derivatives Hedge Designation Fair Value Hierarchy Balance Sheet Location Fair Value Balance Sheet Location Fair Value Net Asset/ (Liabilities) Foreign currency derivatives Cash flow hedge Level 2 Other current assets $ 1,513 Other current liabilities $ — $ 1,513 Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2019 is as follows: Asset Derivatives Liability Derivatives Hedge Designation Fair Value Hierarchy Balance Sheet Location Fair Value Balance Sheet Location Fair Value Net Asset/ (Liabilities) Foreign currency derivatives Cash flow hedge Level 2 Other current assets $ 1,242 Other current liabilities $ — $ 1,242 |
Information Related to Effect of Derivative Instruments in the Consolidated Statements of Income | Information related to the effect of derivative instruments in the consolidated statements of income is as follows: Year Ended December 31, Location 2020 2019 Foreign currency derivatives Cost of sales $ (1,629 ) $ 1,976 Other comprehensive income 272 1,151 Foreign currency loss (118 ) (46 ) Total foreign currency derivatives $ (1,475 ) $ 3,081 |
Reclassifications Out of Accu_2
Reclassifications Out of Accumulated Other Comprehensive Income (Loss) (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Equity [Abstract] | |
Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Income (Loss) | Reclassification adjustments and other activities impacting accumulated other comprehensive income (loss) during the years ended December 31, 2020, 2019 and 2018 are as follows: Defined Benefit Pension Plans Foreign Currency Translation Adjustments Foreign Currency Hedge Derivatives Total Balance at December 31, 2019 $ (3,371 ) $ (39,879 ) $ 895 $ (42,355 ) Other comprehensive (loss) income before reclassifications (328 ) 27,147 (1,751 ) 25,068 Income tax effect of other comprehensive income before reclassifications 117 95 381 593 Amounts reclassified from accumulated other comprehensive loss into net income 131 2,023 a 2,154 Income taxes reclassified into net income — (442 ) (442 ) Net current period other comprehensive (loss) income (80 ) 27,242 211 27,373 Balance at December 31, 2020 $ (3,451 ) $ (12,637 ) $ 1,106 $ (14,982 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income. Defined Benefit Pension Plans Foreign Currency Translation Adjustments Foreign Currency Hedge Derivatives Total Balance at December 31, 2018 $ (2,339 ) $ (37,157 ) $ (4 ) $ (39,500 ) Other comprehensive (loss) income before reclassifications (1,264 ) (2,329 ) 2,259 $ (1,334 ) Income tax effect of other comprehensive income (loss) before reclassifications 232 (393 ) (493 ) $ (654 ) Amounts reclassified from accumulated other comprehensive loss into net income — — (1,108 ) a $ (1,108 ) Income taxes reclassified into net income — — 241 $ 241 Net current period other comprehensive (loss) income (1,032 ) (2,722 ) 899 (2,855 ) Balance at December 31, 2019 $ (3,371 ) $ (39,879 ) $ 895 $ (42,355 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income. Defined Benefit Pension Plans Foreign Currency Translation Adjustments Commodity Hedge Derivatives Foreign Currency Hedge Derivatives Total Balance at December 31, 2017 $ (2,366 ) $ (17,555 ) $ 277 $ (800 ) $ (20,444 ) Cumulative effect of accounting change due to adoption of ASU 2018-02 (49 ) — 9 — (40 ) Other comprehensive income (loss) before reclassifications 18 (19,212 ) — 1,342 (17,852 ) Income tax effect of other comprehensive loss before reclassifications (15 ) (390 ) — (337 ) (742 ) Amounts reclassified from accumulated other comprehensive loss into net income 73 — (218 ) a (246 ) a (391 ) Income taxes reclassified into net income — — (68 ) 37 (31 ) Net current period other comprehensive income (loss) 27 (19,602 ) (277 ) 796 (19,056 ) Balance at December 31, 2018 $ (2,339 ) $ (37,157 ) $ — $ (4 ) $ (39,500 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income. |
Accounting for Stock Based Co_2
Accounting for Stock Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |
Summary of Stock Option Activity | The following table summarizes stock option activity during the years ended December 31, 2020, 2019 and 2018: Options Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2017 2,652,142 $ 35.34 4.76 $ 6,964 Granted — — Exercised (615,358 ) 24.01 Forfeited (383,784 ) 39.59 Outstanding at December 31, 2018 1,653,000 $ 38.53 4.28 $ 3,610 Granted — — Exercised (428,250 ) 38.66 Forfeited (355,750 ) 39.99 Outstanding at December 31, 2019 869,000 $ 37.87 3.51 $ 5,172 Granted — — Exercised (434,250 ) 38.12 Forfeited (6,750 ) 38.05 Outstanding at December 31, 2020 428,000 $ 37.61 3.20 $ 11,815 Exercisable at December 31, 2020 338,625 $ 37.87 3.11 $ 9,261 |
Restricted Stock Activity | The following table summarizes restricted stock activity during the years ended December 31, 2020, 2019 and 2018: Unvested Restricted Shares Shares Weighted-Average Grant Date Fair Value Outstanding at December 31, 2017 282,100 $ 38.06 Granted 21,681 35.00 Vested (130,684 ) 38.62 Forfeited (36,531 ) 37.60 Outstanding at December 31, 2018 136,566 $ 37.16 Granted 19,920 40.16 Vested (91,566 ) 37.09 Forfeited (30,000 ) 38.05 Outstanding at December 31, 2019 34,920 $ 38.31 Granted 32,406 39.96 Vested (32,420 ) 38.33 Forfeited — — Outstanding at December 31, 2020 34,906 $ 39.82 |
SARs Activity | The following table summarizes SARs activity during the years ended December 31, 2020, 2019 and 2018: Stock Appreciation Rights Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2017 1,192,350 $ 38.17 4.36 $ 2,278 Granted — — Exercised (204,250 ) 26.35 Forfeited — — Outstanding at December 31, 2018 988,100 $ 40.61 3.57 $ 2,064 Granted — — Exercised (179,500 ) 32.84 Forfeited (254,350 ) 42.63 Outstanding at December 31, 2019 554,250 $ 39.41 2.84 $ 2,981 Granted — — Exercised (342,150 ) 38.22 Forfeited (40,500 ) 44.39 Outstanding at December 31, 2020 171,600 $ 40.60 2.44 $ 4,224 Exercisable at December 31, 2020 131,350 $ 41.39 2.22 3,131 |
RSU | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |
Restricted Stock Activity | The following table summarizes restricted stock unit activity during the years ended December 31, 2020, 2019 and 2018: Performance-Based Awards Unvested Restricted Stock Units Time Vesting Shares ROIC Target Shares TSR Target Shares Total Outstanding at December 31, 2017 — — — — Granted 86,392 64,785 64,792 215,969 Vested — — — — Forfeited — — — — Outstanding at December 31, 2018 86,392 64,785 64,792 215,969 Granted 107,391 56,380 56,375 220,146 Vested (23,956 ) — — (23,956 ) Forfeited (28,086 ) (26,124 ) (26,128 ) (80,338 ) Outstanding at December 31, 2019 141,741 95,041 95,039 331,821 Granted 132,864 77,967 77,967 288,798 Vested (50,953 ) — — (50,953 ) Forfeited (14,747 ) (15,090 ) (15,090 ) (44,927 ) Outstanding at December 31, 2020 208,905 157,918 157,916 524,739 The total intrinsic value of restricted stock units vested during the years ended December 31, 2020, 2019 and 2018 was $2,214, $1,000 and $0, respectively. |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
(Loss) Earnings Before Income Taxes | The income tax provisions were calculated based upon the following components of (loss) earnings before income tax for the years ended December 31, 2020, 2019 and 2018: Year Ended December 31, 2020 2019 2018 (Loss) earnings before income tax: Domestic $ (11,374 ) $ 74,531 $ 10,092 Foreign 92,930 (15,380 ) 48,027 Earnings before income tax $ 81,556 $ 59,151 $ 58,119 |
Provision for Income Taxes | The components of the provision for income taxes for the years ended December 31, 2020, 2019 and 2018 are summarized as follows: Year Ended December 31, 2020 2019 2018 Current income tax expense (benefit): Federal $ 784 $ 262 $ 340 State and local 83 94 (71 ) Foreign 20,150 17,672 9,224 Total current income tax expense 21,017 18,028 9,493 Deferred income tax expense (benefit): Federal (2,302 ) (2,490 ) (1,422 ) State and local 32 (1 ) 20 Foreign 3,119 (5,252 ) 8,129 Total deferred income tax expense 849 (7,743 ) 6,727 Total income tax expense $ 21,866 $ 10,285 $ 16,220 |
Deferred Tax Assets and Deferred Tax Liabilities | The deferred tax assets and deferred tax liabilities and related valuation allowance were comprised of the following as of December 31, 2020 and 2019: December 31, 2020 2019 Deferred tax assets: Net operating losses $ 22,658 $ 17,881 Intangible assets 29,145 33,743 Research and development credits 10,773 9,752 Depreciation 7,426 7,223 Valuation reserves and accrued liabilities 7,131 7,196 Stock compensation 4,200 3,485 Defined benefit obligation 1,974 2,027 Inventory 1,571 1,284 Other credits 12,068 11,753 Unrealized foreign currency exchange loss 1,431 — Other 64 113 Total deferred tax asset 98,441 94,457 Valuation allowance (17,197 ) (17,316 ) Deferred tax liabilities: Unrealized foreign currency exchange gains — (674 ) Undistributed profits of subsidiary (5,727 ) (4,629 ) Property and equipment (2,758 ) (3,366 ) Other (572 ) (733 ) Total deferred tax liability (9,057 ) (9,402 ) Net deferred tax asset $ 72,187 $ 67,739 |
Reconciliations Between Statutory Federal Income Tax Rate and Effective Rate | Reconciliations between the statutory Federal income tax rate and the effective rate of income tax expense for the years ended December 31, 2020, 2019 and 2018 are as follows: Year Ended December 31, 2020 2019 2018 Statutory Federal income tax rate 21.0 % 21.0 % 21.0 % Increase (decrease) resulting from: Change in valuation allowance (0.4 )% 11.5 % (6.6 )% Effect of different tax rates of foreign jurisdictions (4.7 )% (24.8 )% (6.6 )% Audit settlements and statute expirations 3.9 % 0.6 % (1.1 )% US tax reform items 2.5 % 4.3 % 10.8 % Research and development credits (1.4 )% (2.3 )% (2.5 )% Non-deductible expenses 2.1 % 2.1 % 3.4 % Foreign, state and local tax, net of Federal benefit 1.4 % 1.7 % 1.8 % Tax effects of intercompany transfers 1.4 % 1.5 % 0.8 % Undistributed profit of subsidiaries 0.9 % 1.2 % 1.2 % Other 0.1 % 0.6 % 5.7 % Effective rate 26.8 % 17.4 % 27.9 % |
Net Operating Loss Carryforwards | The Company has Net Operating Loss (“NOL”) carryforwards as follows: Jurisdiction Amount as of December 31, 2020 Years of Expiration U.S. state income tax $ 106,987 2021-2040 Foreign $ 7,441 2021-2025 Foreign $ 161,851 Never |
Reconciliation of Unrecognized Tax Benefits | The reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended December 31, 2020 2019 2018 Balance at beginning of year $ 3,795 $ 2,819 $ 3,812 Additions based on tax position related to current year 1,489 661 221 Additions based on tax position related to prior year 179 352 423 Reductions from settlements and statute of limitation expiration (650 ) — (1,469 ) Effect of foreign currency translation 154 (37 ) (168 ) Balance at end of year $ 4,967 $ 3,795 $ 2,819 |
Segment Reporting (Tables)
Segment Reporting (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Segment Reporting [Abstract] | |
Segment Information About Reported Product Revenues and Operating Income | The tables below present segment information about the reported product revenues and operating income of the Company for years ended December 31, 2020, 2019 and 2018. With the exception of goodwill, asset information by segment is not reported since the Company does not manage assets at a segment level. Automotive Medical Corporate Total 2020: Product revenues $ 869,998 $ 43,100 $ — $ 913,098 Depreciation and amortization 37,662 2,366 1,086 $ 41,114 Operating income (loss) 138,410 971 (50,164 ) $ 89,217 2019: Product revenues $ 920,225 $ 51,459 $ — $ 971,684 Depreciation and amortization 40,923 1,621 1,702 $ 44,246 Operating income (loss) 141,206 (5,735 ) (51,211 ) $ 84,260 2018: Product revenues $ 957,824 $ 90,681 $ — $ 1,048,505 Depreciation and amortization 44,246 3,759 2,633 $ 50,638 Operating income (loss) 136,421 (6,900 ) (56,733 ) $ 72,788 |
Segment Information About Reported Segment Product Revenues by Product Category | Automotive and Medical segment product revenues by product category for each of the years ended December 31, 2020, 2019 and 2018 are as follows: Year Ended December 31, 2020 2019 2018 Climate Control Seat (CCS) $ 342,550 $ 359,355 $ 373,945 Seat Heaters 249,665 284,174 305,337 Steering Wheel Heaters 76,272 65,426 69,845 Automotive Cables 73,997 88,031 98,931 Electronics 53,238 47,542 56,783 Battery Performance Solutions (BPS) (a) 50,901 41,498 28,472 Other Automotive 23,375 34,199 24,511 Subtotal Automotive segment 869,998 920,225 957,824 Medical 43,100 36,860 30,108 GPT — 11,181 19,520 CSZ-IC — 3,418 41,053 Subtotal Medical segment 43,100 51,459 90,681 Total Company $ 913,098 $ 971,684 $ 1,048,505 (a) Battery Performance Solutions (BPS) was renamed from Battery Thermal Management (BTM), to better represent our product offerings included within this product category. |
Product Revenues Information by Geographic Area | Revenue (based on shipment destination) by geographic area for each of the years ended December 31, 2020, 2019 and 2018 is as follows: Year Ended December 31, 2020 2019 2018 United States $ 377,577 $ 440,316 $ 488,926 China 101,039 71,461 93,628 South Korea 88,745 63,339 58,717 Germany 58,536 81,315 88,366 Japan 57,785 76,197 62,633 Czech Republic 37,542 38,888 42,665 Other 191,874 200,168 213,570 Total Non-U.S. 535,521 531,368 559,579 Total Company $ 913,098 $ 971,684 $ 1,048,505 |
Percentage of Total Product Revenues Generated from Customers | The table below lists the percentage of total product revenues generated from sales to customers which contributed 10% or more to the Company’s total consolidated product revenue for the years ended December 31, 2020, 2019 and 2018: Year Ended December 31, 2020 2019 2018 Lear 15 % 16 % 17 % Adient 14 % 15 % 16 % |
Schedule of Property and Equipment, Net by Geographic Area | Property and equipment, net, for each of the geographic areas in which the Company operates as of December 31, 2020 and 2019 is as follows: December 31, Property and equipment, net 2020 2019 Macedonia $ 38,273 $ 38,989 Vietnam 21,080 21,452 China 20,375 23,721 United States 19,011 21,280 Mexico 16,034 19,982 Germany 15,641 10,515 Ukraine 9,364 11,727 Hungary 8,401 6,803 Other 4,402 6,136 Total $ 152,581 $ 160,605 |
Overview - Additional Informati
Overview - Additional Information (Detail) | 12 Months Ended |
Dec. 31, 2020 | |
Europe | |
Basis Of Presentation And Accounting Policies [Line Items] | |
Production capacity percentage (impact of COVID-19) | 70.00% |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020USD ($)Segment | Dec. 31, 2019USD ($) | Dec. 31, 2018USD ($) | |
Basis Of Presentation And Accounting Policies [Line Items] | |||
Number of reportable segments | Segment | 2 | ||
capitalized costs to obtain contract | $ 1,805 | $ 1,893 | |
Amortization of capitalized costs into product revenues | 263 | 1,006 | |
Cash and cash equivalents | 268,345 | 50,443 | |
Allowance for doubtful accounts | 1,161 | 1,193 | |
Depreciation expense | $ 31,037 | 33,639 | $ 36,270 |
Operating lease, description | The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. We also have operating leases for office equipment and automobiles. | ||
Operating lease, existence of option to extend | true | ||
Operating lease, options to extend | Excluding land leases, our leases have remaining lease terms ranging from less than 1 year to 11 years and may include options to extend the lease. | ||
Performance Based Restricted Stock Units | |||
Basis Of Presentation And Accounting Policies [Line Items] | |||
Awards vesting period | 3 years | ||
Production Tooling | |||
Basis Of Presentation And Accounting Policies [Line Items] | |||
Reimbursable tooling capitalized within prepaid expenses and other current assets | $ 4,831 | $ 5,347 | |
Concentration of Credit Risk | Accounts receivable | Lear | |||
Basis Of Presentation And Accounting Policies [Line Items] | |||
Concentration risk percentage | 18.00% | 21.00% | |
Concentration of Credit Risk | Accounts receivable | Adient | |||
Basis Of Presentation And Accounting Policies [Line Items] | |||
Concentration risk percentage | 18.00% | 21.00% | |
Foreign Jurisdictions | |||
Basis Of Presentation And Accounting Policies [Line Items] | |||
Cash and cash equivalents | $ 106,598 | $ 35,735 | |
Minimum | |||
Basis Of Presentation And Accounting Policies [Line Items] | |||
Expected period of costs to be realized to recognize assets | 1 year | ||
Operating lease, term of contract | 1 year | ||
Minimum | Production Tooling | |||
Basis Of Presentation And Accounting Policies [Line Items] | |||
Property plant and equipment, estimated useful life | 2 years | ||
Minimum | Ground | |||
Basis Of Presentation And Accounting Policies [Line Items] | |||
Operating lease, term of contract | 40 years | ||
Maximum | |||
Basis Of Presentation And Accounting Policies [Line Items] | |||
Ownership interest | 20.00% | ||
Original maturities of highly liquid investments | 90 days | ||
Operating lease, term of contract | 11 years | ||
Maximum | Production Tooling | |||
Basis Of Presentation And Accounting Policies [Line Items] | |||
Property plant and equipment, estimated useful life | 10 years | ||
Maximum | Ground | |||
Basis Of Presentation And Accounting Policies [Line Items] | |||
Operating lease, term of contract | 42 years |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Summary of Revision of Prior Period Financial Statements (Detail) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Income Statement: | ||||
Earnings before income tax | $ 81,556 | $ 59,151 | $ 58,119 | |
Income tax expense | 21,866 | 10,285 | 16,220 | |
Net income | $ 59,690 | $ 48,866 | $ 41,899 | |
Basic EPS | $ 1.83 | $ 1.48 | $ 1.17 | |
Diluted EPS | $ 1.81 | $ 1.47 | $ 1.16 | |
Balance Sheet: | ||||
Deferred income tax asset - long term | $ 73,912 | $ 69,096 | ||
Total non-current assets | 364,969 | |||
Total assets | 1,022,839 | 738,832 | ||
Accumulated other comprehensive (loss) income | (14,982) | (42,355) | $ (39,500) | $ (20,444) |
Accumulated earnings | 472,782 | 413,092 | ||
Total liabilities and shareholders’ equity | $ 1,022,839 | 738,832 | ||
As Reported | ||||
Income Statement: | ||||
Earnings before income tax | 59,151 | |||
Income tax expense | 21,645 | |||
Net income | $ 37,506 | |||
Basic EPS | $ 1.13 | |||
Diluted EPS | $ 1.13 | |||
Balance Sheet: | ||||
Deferred income tax asset - long term | $ 57,650 | |||
Total non-current assets | 353,523 | |||
Total assets | 727,386 | |||
Accumulated other comprehensive (loss) income | (42,441) | |||
Accumulated earnings | 401,732 | |||
Total liabilities and shareholders’ equity | 727,386 | |||
Adjustment | ||||
Income Statement: | ||||
Income tax expense | (11,360) | |||
Net income | $ 11,360 | |||
Basic EPS | $ 0.35 | |||
Diluted EPS | $ 0.34 | |||
Balance Sheet: | ||||
Deferred income tax asset - long term | $ 11,446 | |||
Total non-current assets | 11,446 | |||
Total assets | 11,446 | |||
Accumulated other comprehensive (loss) income | 86 | |||
Accumulated earnings | 11,360 | |||
Total liabilities and shareholders’ equity | $ 11,446 |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail) | 12 Months Ended |
Dec. 31, 2020 | |
Leasehold Improvements | |
Property Plant And Equipment [Line Items] | |
Property plant and equipment, estimated useful life | Term of lease |
Minimum | Buildings and Improvements | |
Property Plant And Equipment [Line Items] | |
Property plant and equipment, estimated useful life | 2 years |
Minimum | Plant and Equipment | |
Property Plant And Equipment [Line Items] | |
Property plant and equipment, estimated useful life | 1 year |
Minimum | Production Tooling | |
Property Plant And Equipment [Line Items] | |
Property plant and equipment, estimated useful life | 2 years |
Minimum | Information Technology | |
Property Plant And Equipment [Line Items] | |
Property plant and equipment, estimated useful life | 1 year |
Maximum | Buildings and Improvements | |
Property Plant And Equipment [Line Items] | |
Property plant and equipment, estimated useful life | 50 years |
Maximum | Plant and Equipment | |
Property Plant And Equipment [Line Items] | |
Property plant and equipment, estimated useful life | 20 years |
Maximum | Production Tooling | |
Property Plant And Equipment [Line Items] | |
Property plant and equipment, estimated useful life | 10 years |
Maximum | Information Technology | |
Property Plant And Equipment [Line Items] | |
Property plant and equipment, estimated useful life | 10 years |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies - Fair Value and Corresponding Useful Lives for Acquired Intangibles Assets (Detail) | 12 Months Ended |
Dec. 31, 2020 | |
Customer Relationships | Minimum | |
Finite Lived Intangible Assets [Line Items] | |
Acquired intangible assets useful life | 6 years |
Customer Relationships | Maximum | |
Finite Lived Intangible Assets [Line Items] | |
Acquired intangible assets useful life | 15 years |
Technology | Minimum | |
Finite Lived Intangible Assets [Line Items] | |
Acquired intangible assets useful life | 4 years |
Technology | Maximum | |
Finite Lived Intangible Assets [Line Items] | |
Acquired intangible assets useful life | 8 years |
Product Development Costs | Minimum | |
Finite Lived Intangible Assets [Line Items] | |
Acquired intangible assets useful life | 1 year |
Product Development Costs | Maximum | |
Finite Lived Intangible Assets [Line Items] | |
Acquired intangible assets useful life | 15 years |
Acquisitions and Divestitures -
Acquisitions and Divestitures - Additional Information (Detail) - USD ($) $ in Thousands | Apr. 01, 2019 | Feb. 01, 2019 | Dec. 31, 2019 | Dec. 31, 2018 |
Business Acquisition [Line Items] | ||||
Asset impairment charges | $ 21,206 | $ 11,476 | ||
Impairment on assets held for sale | 2,190 | |||
Goodwill impairment charges | 6,151 | |||
Other intangible impairment charges | 3,135 | |||
Pre-tax gain (loss) on sale of business | (1,587) | |||
GPT | ||||
Business Acquisition [Line Items] | ||||
Asset impairment charges | 21,206 | |||
Impairment on assets held for sale | 16,720 | |||
Impairment of equity method investment held for sale | 4,486 | |||
GPT and CSZ-IC | ||||
Business Acquisition [Line Items] | ||||
Asset impairment charges | 11,476 | |||
Impairment on assets held for sale | 2,190 | |||
Goodwill impairment charges | 6,151 | |||
Other intangible impairment charges | $ 3,135 | |||
CSZ-IC | ||||
Business Acquisition [Line Items] | ||||
Total cash proceeds | $ 47,500 | |||
Escrow deposit | $ 2,500 | |||
Pre-tax gain (loss) on sale of business | 4,298 | |||
GPT | ||||
Business Acquisition [Line Items] | ||||
Pre-tax gain (loss) on sale of business | (5,885) | |||
Uncollectible amount | 1,500 | |||
Stihler Electronic GmbH | ||||
Business Acquisition [Line Items] | ||||
Net assets acquired | $ 15,476 | |||
Business combination future contingent consideration milestone payment | 653 | |||
Acquisition related costs | $ 324 | |||
Goodwill, recognized deductible for income tax purpose | $ 2,524 | |||
Stihler Electronic GmbH | Other intangible assets | ||||
Business Acquisition [Line Items] | ||||
Estimated useful life | 9 years |
Acquisitions and Divestitures_2
Acquisitions and Divestitures - Summary of Purchase Price Allocation (Detail) - USD ($) $ in Thousands | Apr. 01, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2020 |
Business Acquisition [Line Items] | ||||
Purchase price, cash consideration, net of cash acquired | $ 14,823 | $ 15 | ||
Goodwill | $ 64,572 | $ 68,024 | ||
Stihler Electronic GmbH | ||||
Business Acquisition [Line Items] | ||||
Purchase price, cash consideration, net of cash acquired | $ 14,823 | |||
Purchase price, fair value of contingent consideration | 653 | |||
Total purchase price, net of cash acquired | 15,476 | |||
Accounts receivable | 883 | |||
Inventory | 1,698 | |||
Prepaid expenses and other assets | 241 | |||
Operating lease right-of-use assets | 263 | |||
Property and equipment | 260 | |||
Other intangible assets | 4,380 | |||
Goodwill | 9,816 | |||
Assumed liabilities | (2,065) | |||
Net assets acquired | $ 15,476 |
Restructuring - Additional Info
Restructuring - Additional Information (Detail) | 12 Months Ended | ||
Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Dec. 31, 2018USD ($)Facility | |
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | $ 5,803,000 | $ 12,919,000 | $ 14,772,000 |
Impairment loss | 21,206,000 | 11,476,000 | |
Manufacturing Footprint Rationalization | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | 7,137,000 | ||
Other restructuring costs | 332,000 | ||
Manufacturing Footprint Rationalization | Minimum | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring and related cost expected total cost | 16,000,000 | ||
Manufacturing Footprint Rationalization | Maximum | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring and related cost expected total cost | 19,000,000 | ||
Advanced Research and Development Rationalization and Site Consolidation | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | 4,669,000 | ||
Impairment loss | 425,000 | ||
GPT and CSZ-IC | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | 2,303,000 | ||
Employee Separation Costs | Manufacturing Footprint Rationalization | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | (832,000) | 4,863,000 | |
Restructuring reserve accelerated depreciation | 687,000 | ||
Restructuring reserve accelerated depreciation | 2,087,000 | ||
Employee Separation Costs | Manufacturing Footprint Rationalization | Minimum | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring and related cost expected total cost | 6,500,000 | ||
Employee Separation Costs | Manufacturing Footprint Rationalization | Maximum | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring and related cost expected total cost | 7,500,000 | ||
Employee Separation Costs | Other Restructuring Activities | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | 5,382,000 | 2,942,000 | 6,598,000 |
Employee Separation Costs | Advanced Research and Development Rationalization and Site Consolidation | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | 1,094,000 | ||
Employee Separation Costs | GPT and CSZ-IC | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | 251,000 | 757,000 | |
Cash Expenditures | Manufacturing Footprint Rationalization | Minimum | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring and related cost expected total cost | 13,000,000 | ||
Cash Expenditures | Manufacturing Footprint Rationalization | Maximum | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring and related cost expected total cost | 16,000,000 | ||
Restructuring Capital Expenditures | Manufacturing Footprint Rationalization | Minimum | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring and related cost expected total cost | 3,500,000 | ||
Restructuring Capital Expenditures | Manufacturing Footprint Rationalization | Maximum | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring and related cost expected total cost | 4,500,000 | ||
Accelerated Depreciation and Impairment | Manufacturing Footprint Rationalization | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring and related cost expected total cost | 3,000,000 | ||
Other Restructuring | Manufacturing Footprint Rationalization | Minimum | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring and related cost expected total cost | 3,000,000 | ||
Other Restructuring | Manufacturing Footprint Rationalization | Maximum | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring and related cost expected total cost | 4,000,000 | ||
Other Restructuring | Other Restructuring Activities | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | $ 234,000 | 1,360,000 | 2,869,000 |
Other Restructuring | Advanced Research and Development Rationalization and Site Consolidation | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | 643,000 | ||
Other Restructuring | GPT and CSZ-IC | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | $ 991,000 | 304,000 | |
Loss on the Sale of Battery Management Systems | Advanced Research and Development Rationalization and Site Consolidation | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | 1,107,000 | ||
Asset Disposal Costs | Advanced Research and Development Rationalization and Site Consolidation | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | $ 1,400,000 | ||
Facility Closing | Advanced Research and Development Rationalization and Site Consolidation | |||
Restructuring Cost And Reserve [Line Items] | |||
Number of leased facilities vacated | Facility | 2 |
Restructuring - Summary of Rest
Restructuring - Summary of Restructuring Expense by Reportable Segment (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | $ 5,803 | $ 12,919 | $ 14,772 |
Operating Segments | Automotive Segments | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | 5,075 | 9,353 | 5,548 |
Operating Segments | Medical Segments | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | 112 | 1,838 | 5,607 |
Operating Segments | Corporate Segments | |||
Restructuring Cost And Reserve [Line Items] | |||
Restructuring expenses | $ 616 | $ 1,728 | $ 3,617 |
Restructuring - Summary of Re_2
Restructuring - Summary of Restructuring Activity for All Restructuring Initiatives (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Restructuring Cost And Reserve [Line Items] | ||
Balance, beginning of period | $ 6,065 | $ 2,547 |
Additions, charged to restructuring expenses | 8,203 | 12,919 |
Change in estimate | (2,400) | |
Cash payments | (5,809) | (6,754) |
Non-cash utilization | (687) | (2,512) |
Reclassification to lease liability | (112) | |
Currency translation | 255 | (23) |
Balance, end of period | 5,627 | 6,065 |
Employee Separation Costs | ||
Restructuring Cost And Reserve [Line Items] | ||
Balance, beginning of period | 5,994 | 2,079 |
Additions, charged to restructuring expenses | 6,932 | 8,056 |
Change in estimate | (2,382) | |
Cash payments | (5,052) | (4,118) |
Currency translation | 135 | (23) |
Balance, end of period | 5,627 | 5,994 |
Accelerated Depreciation and Impairment | ||
Restructuring Cost And Reserve [Line Items] | ||
Additions, charged to restructuring expenses | 687 | 2,512 |
Non-cash utilization | (687) | (2,512) |
Other Restructuring | ||
Restructuring Cost And Reserve [Line Items] | ||
Balance, beginning of period | 71 | 468 |
Additions, charged to restructuring expenses | 584 | 2,351 |
Change in estimate | (18) | |
Cash payments | (757) | (2,636) |
Reclassification to lease liability | (112) | |
Currency translation | $ 120 | |
Balance, end of period | $ 71 |
Details of Certain Financial _3
Details of Certain Financial Statement Components (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Inventory: | |||
Raw materials, net of reserve | $ 68,362 | $ 61,323 | |
Work in process, net of reserve | 8,247 | 7,444 | |
Finished goods, net of reserve | 45,792 | 49,712 | |
Total inventory, net | 122,401 | 118,479 | |
Current Assets: | |||
Notes receivable | 19,200 | 9,963 | |
Income tax and other tax receivable | 10,514 | 17,057 | |
Billable tooling | 4,831 | 5,194 | |
Prepaid expenses | 3,930 | 7,022 | |
Other | 2,713 | 3,490 | |
Total other current assets | 41,188 | 42,726 | |
Property and equipment: | |||
Machinery and equipment | 142,833 | 137,813 | |
Buildings and improvements | 99,011 | 90,675 | |
Information technology | 30,338 | 27,697 | |
Production tooling | 22,783 | 19,906 | |
Leasehold improvements | 11,762 | 11,116 | |
Construction in progress | 8,968 | 2,856 | |
Total property and equipment | 315,695 | 290,063 | |
Less: accumulated depreciation | (163,114) | (129,458) | |
Total property and equipment, net | 152,581 | 160,605 | |
Other current liabilities: | |||
Accrued employee liabilities | 26,612 | 26,019 | |
Liabilities from discounts and rebates | 22,910 | 16,593 | |
Income tax and other taxes payable | 14,714 | 3,693 | |
Restructuring | 5,627 | 6,065 | |
Accrued warranty | 2,391 | 4,596 | $ 4,514 |
Other | 9,155 | 9,617 | |
Total other current liabilities | $ 81,409 | $ 66,583 |
Goodwill and Other Intangible_2
Goodwill and Other Intangibles - Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Goodwill [Line Items] | ||
Balance, beginning of period | $ 64,572 | |
Balance, end of period | 68,024 | $ 64,572 |
Operating Segments | ||
Goodwill [Line Items] | ||
Balance, beginning of period | 64,572 | 55,311 |
Stihler acquisition | 9,816 | |
Exchange rate impact | 3,452 | (555) |
Balance, end of period | 68,024 | 64,572 |
Automotive Segments | Operating Segments | ||
Goodwill [Line Items] | ||
Balance, beginning of period | 36,938 | 37,533 |
Exchange rate impact | 2,557 | (595) |
Balance, end of period | 39,495 | 36,938 |
Medical Segments | Operating Segments | ||
Goodwill [Line Items] | ||
Balance, beginning of period | 27,634 | 17,778 |
Stihler acquisition | 9,816 | |
Exchange rate impact | 895 | 40 |
Balance, end of period | $ 28,529 | $ 27,634 |
Goodwill and Other Intangible_3
Goodwill and Other Intangibles - Summary of Other Intangible Assets and Accumulated Amortization Balances (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Intangible Assets [Line Items] | ||
Gross Carrying Value | $ 155,264 | $ 138,895 |
Accumulated Amortization | (108,843) | (89,112) |
Net Carrying Value | 46,421 | 49,783 |
Net Carrying Value | 46,421 | 49,783 |
Customer Relationships | ||
Intangible Assets [Line Items] | ||
Gross Carrying Value | 97,815 | 89,208 |
Accumulated Amortization | (63,432) | (50,687) |
Net Carrying Value | 34,383 | 38,521 |
Technology | ||
Intangible Assets [Line Items] | ||
Gross Carrying Value | 30,615 | 25,106 |
Accumulated Amortization | (24,075) | (19,866) |
Net Carrying Value | 6,540 | 5,240 |
Product Development Costs | ||
Intangible Assets [Line Items] | ||
Gross Carrying Value | 22,164 | 19,911 |
Accumulated Amortization | (21,336) | (18,559) |
Net Carrying Value | 828 | 1,352 |
Tradenames | ||
Intangible Assets [Line Items] | ||
Net Carrying Value | $ 4,670 | $ 4,670 |
Goodwill and Other Intangible_4
Goodwill and Other Intangibles - Additional Information (Detail) - USD ($) $ in Thousands | Jun. 19, 2020 | Feb. 28, 2020 | Dec. 31, 2020 | Dec. 31, 2018 | Dec. 31, 2019 |
Goodwill And Other Intangible Assets [Line Items] | |||||
Gain on sale of intangible assets | $ 1,978 | ||||
Intangible assets | 46,421 | $ 49,783 | |||
Other intangible assets | 9,226 | $ 14,043 | 10,068 | ||
Impairment on assets held for sale | 2,190 | ||||
Goodwill impairment charges | 6,151 | ||||
Other intangible impairment charges | $ 3,135 | ||||
Patents and Intellectual Property | |||||
Goodwill And Other Intangible Assets [Line Items] | |||||
Proceeds from sale of intangible assets | $ 2,055 | ||||
Patents and Intellectual Property | Other Income | |||||
Goodwill And Other Intangible Assets [Line Items] | |||||
Gain on sale of intangible assets | $ 1,978 | ||||
Customer Relationship | |||||
Goodwill And Other Intangible Assets [Line Items] | |||||
Intangible assets | 34,383 | 38,521 | |||
Technology | |||||
Goodwill And Other Intangible Assets [Line Items] | |||||
Intangible assets | 6,540 | $ 5,240 | |||
Development Stage Technology Company | |||||
Goodwill And Other Intangible Assets [Line Items] | |||||
Automotive patents and technology acquired | $ 3,141 | ||||
Defensive intangible assets, useful life | 6 years | ||||
Stihler Electronic GmbH | Customer Relationship | |||||
Goodwill And Other Intangible Assets [Line Items] | |||||
Intangible assets | $ 3,420 | ||||
Acquired intangible assets useful life | 9 years | ||||
Stihler Electronic GmbH | Technology | |||||
Goodwill And Other Intangible Assets [Line Items] | |||||
Intangible assets | $ 538 | ||||
Acquired intangible assets useful life | 7 years |
Goodwill and Other Intangible_5
Goodwill and Other Intangibles - Summary of Estimate of Other Intangible Asset Amortization (Detail) $ in Thousands | Dec. 31, 2020USD ($) |
Finite Lived Intangible Assets Future Amortization Expense [Abstract] | |
2021 | $ 8,316 |
2022 | 7,803 |
2023 | 4,385 |
2024 | 3,245 |
2025 | $ 3,229 |
Leases - Components of Lease Ex
Leases - Components of Lease Expense and Other Information (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Lease cost: | ||
Operating lease cost | $ 6,773 | $ 5,899 |
Short-term lease cost | 1,834 | 3,444 |
Sublease income | (158) | (128) |
Total lease cost | 8,449 | 9,215 |
Operating cash flows for operating leases | 6,817 | 6,059 |
Right-of-use lease assets obtained in exchange for lease obligations, Operating leases | $ 25,161 | 4,111 |
Gain on sale and leaseback transactions, net | $ 207 | |
Weighted-average remaining lease term, Operating leases | 5 years 4 months 24 days | 4 years 6 months |
Weighted-average discount rate, Operating leases | 4.65% | 5.46% |
Leases - Summary of Operating L
Leases - Summary of Operating Leases Under all Non-Cancellable Operating Leases (Detail) $ in Thousands | Dec. 31, 2020USD ($) |
Leases [Abstract] | |
2021 | $ 7,316 |
2022 | 6,033 |
2023 | 4,016 |
2024 | 3,829 |
2025 | 3,648 |
2026 or later | 10,461 |
Total future minimum lease payments | 35,303 |
Less imputed interest | (5,038) |
Total | $ 30,265 |
Summary of Company's Debt (Deta
Summary of Company's Debt (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Debt Instrument [Line Items] | ||
Total debt | $ 192,434 | $ 80,624 |
Current maturities | (2,500) | (2,500) |
Long-term debt, less current maturities | $ 189,934 | $ 78,124 |
U.S. Revolving Note (U.S. Dollar Denominations) | ||
Debt Instrument [Line Items] | ||
Interest Rate | 1.65% | 3.05% |
Total debt | $ 171,500 | $ 50,000 |
U.S. Revolving Note (Euro Denominations) | ||
Debt Instrument [Line Items] | ||
Interest Rate | 1.50% | 1.25% |
Total debt | $ 14,684 | $ 21,874 |
DEG Vietnam Loan | ||
Debt Instrument [Line Items] | ||
Interest Rate | 5.21% | 5.21% |
Total debt | $ 6,250 | $ 8,750 |
Debt - Additional Information (
Debt - Additional Information (Detail) - USD ($) | Jun. 27, 2019 | Jun. 26, 2019 | Jan. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Aug. 07, 2014 |
Debt Instrument [Line Items] | ||||||||
Maximum percentage of stock of non US subsidiaries pledge to secure obligation | 66.00% | 66.00% | ||||||
Amended credit agreement, debt issuance costs | $ 1,278,000 | $ 1,278,000 | ||||||
Federal Funds Rate | Minimum | ||||||||
Debt Instrument [Line Items] | ||||||||
Interest rate | 0.50% | |||||||
Federal Funds Rate | Maximum | ||||||||
Debt Instrument [Line Items] | ||||||||
Interest rate | 0.09% | |||||||
London Interbank Offered Rate | ||||||||
Debt Instrument [Line Items] | ||||||||
Interest rate | 0.14% | |||||||
United State Bank Of America Credit Facility | ||||||||
Debt Instrument [Line Items] | ||||||||
Interest rate | 3.25% | |||||||
Euro Currency Rate Loans | ||||||||
Debt Instrument [Line Items] | ||||||||
Interest rate | 1.00% | |||||||
Euro Currency Rate Loans | Credit Agreement | Minimum | ||||||||
Debt Instrument [Line Items] | ||||||||
Interest rate | 1.25% | |||||||
Euro Currency Rate Loans | Credit Agreement | Maximum | ||||||||
Debt Instrument [Line Items] | ||||||||
Interest rate | 2.25% | |||||||
Base Rate Loans | Credit Agreement | Minimum | ||||||||
Debt Instrument [Line Items] | ||||||||
Interest rate | 0.25% | |||||||
Base Rate Loans | Credit Agreement | Maximum | ||||||||
Debt Instrument [Line Items] | ||||||||
Interest rate | 1.25% | |||||||
DEG Vietnam Loan | ||||||||
Debt Instrument [Line Items] | ||||||||
Semi-annual principal payments earliest date | 2017-11 | |||||||
Semi-annual principal payments latest date | 2023-05 | |||||||
Revolving Credit Facility | Revolving Note (U.S. Dollar) | ||||||||
Debt Instrument [Line Items] | ||||||||
Maximum borrowing capacity | $ 475,000,000 | $ 350,000,000 | $ 350,000,000 | |||||
Line of credit, outstanding amount | 186,184,000 | $ 186,184,000 | ||||||
Debt maturity date | Jun. 27, 2024 | Mar. 17, 2021 | ||||||
Increase in maximum borrowing capacity | $ 169,546,000 | |||||||
Remaining borrowing capacity | 288,776,000 | 288,776,000 | ||||||
Line of credit, repayment amount | 41,180,000 | |||||||
Revolving Credit Facility | Revolving Note (U.S. Dollar) | Subsequent Event | ||||||||
Debt Instrument [Line Items] | ||||||||
Line of credit, repayment amount | $ 80,000,000 | |||||||
Revolving Credit Facility | Revolving Note (U.S. Dollar) | Letters of Credit | ||||||||
Debt Instrument [Line Items] | ||||||||
Maximum borrowing capacity | 15,000,000 | 15,000,000 | ||||||
Line of credit, outstanding amount | 0 | 0 | $ 0 | |||||
Revolving Credit Facility | Revolving Note (U.S. Dollar) | Swing Line Loans | ||||||||
Debt Instrument [Line Items] | ||||||||
Maximum borrowing capacity | $ 40,000,000 | $ 40,000,000 |
Principal Maturities of Debt (D
Principal Maturities of Debt (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Debt Instrument [Line Items] | ||
Debt maturing in 2021 | $ 2,500 | |
Debt maturing in 2022 | 2,500 | |
Debt maturing in 2023 | 1,250 | |
Debt maturing in 2024 | 186,184 | |
Total debt | 192,434 | $ 80,624 |
DEG Vietnam Loan | ||
Debt Instrument [Line Items] | ||
Debt maturing in 2021 | 2,500 | |
Debt maturing in 2022 | 2,500 | |
Debt maturing in 2023 | 1,250 | |
Total debt | 6,250 | $ 8,750 |
US and Euro Denominated Revolving Note | ||
Debt Instrument [Line Items] | ||
Debt maturing in 2024 | 186,184 | |
Total debt | $ 186,184 |
Pension and Other Post Retire_3
Pension and Other Post Retirement Benefit Plans - Components of Net Periodic Benefit Cost for Company's Defined Benefit Plans (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
United States | |||
Net periodic benefit cost: | |||
Interest cost | $ 85 | $ 127 | $ 114 |
Amortization of prior service cost and actuarial loss | 7 | ||
Net periodic benefit cost | $ 92 | $ 127 | $ 114 |
Assumptions: | |||
Discount rate | 2.40% | 3.65% | 2.95% |
German Plan | |||
Net periodic benefit cost: | |||
Interest cost | $ 88 | $ 147 | $ 147 |
Expected return on plan assets | (121) | (126) | (130) |
Amortization of prior service cost and actuarial loss | 124 | 72 | 73 |
Net periodic benefit cost | $ 91 | $ 93 | $ 90 |
Assumptions: | |||
Discount rate | 1.08% | 1.06% | 2.04% |
Long-term return on assets | 2.90% | 3.10% | 3.40% |
Pension and Other Post Retire_4
Pension and Other Post Retirement Benefit Plans - Reconciliation of Change in Benefit Obligation, Change in Plan Assets and Balance Sheet Classification (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Balance sheet classification: | |||
Pension benefit obligation | $ (8,163) | $ (8,057) | |
United States | |||
Change in projected benefit obligation: | |||
Balance at beginning of year | 3,871 | 3,832 | |
Interest cost | 85 | 127 | $ 114 |
Paid pension distributions | (342) | (342) | |
Actuarial losses | 233 | 254 | |
Balance at end of year | 3,847 | 3,871 | 3,832 |
Change in plan assets: | |||
Underfunded Status | (3,847) | (3,871) | |
Balance sheet classification: | |||
Other current liabilities | (342) | (342) | |
Pension benefit obligation | (3,505) | (3,529) | |
Accumulated other comprehensive loss (pre-tax): | |||
Actuarial losses | $ 701 | $ 476 | |
Discount rate | 1.20% | 2.40% | |
German Plan | |||
Change in projected benefit obligation: | |||
Balance at beginning of year | $ 8,353 | $ 7,529 | |
Interest cost | 88 | 147 | 147 |
Paid pension distributions | (294) | (285) | |
Actuarial losses | 40 | 1,116 | |
Exchange rate impact | 747 | (154) | |
Balance at end of year | 8,934 | 8,353 | 7,529 |
Change in plan assets: | |||
Balance at beginning of year | 3,825 | 3,808 | |
Actual return on plan assets | 121 | 126 | |
Contributions | 294 | 284 | |
Paid pension distributions | (294) | (284) | |
Actuarial losses | (25) | (30) | |
Exchange rate impact | 355 | (79) | |
Balance at end of year | 4,276 | 3,825 | $ 3,808 |
Underfunded Status | (4,658) | (4,528) | |
Balance sheet classification: | |||
Pension benefit obligation | (4,658) | (4,528) | |
Accumulated other comprehensive loss (pre-tax): | |||
Actuarial losses | $ 3,644 | $ 3,398 | |
Discount rate | 1.08% | 1.06% |
Pension and Other Post Retire_5
Pension and Other Post Retirement Benefit Plans - Summary of Pre-tax Amounts in AOCI Expected to Be Recognized in Net Periodic Benefit Cost (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
United States | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Actuarial losses | $ 701 | $ 476 | |
German Plan | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Actuarial losses | $ 3,644 | $ 3,398 | |
Scenario Forecast | United States | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Actuarial losses | $ 26 | ||
Scenario Forecast | German Plan | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Actuarial losses | $ 126 |
Pension and Other Post Retire_6
Pension and Other Post Retirement Benefit Plans - Summary of Accumulated Benefit Obligations (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
United States | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Accumulated benefit obligation | $ 3,847 | $ 3,871 |
German Plan | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Accumulated benefit obligation | $ 8,934 | $ 8,529 |
Pension and Other Post Retire_7
Pension and Other Post Retirement Benefit Plans - Additional Information (Detail) - USD ($) | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Insurance policy value | $ 2,966,000 | $ 2,592,000 | |
401(k) Plan | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Cost recognized for contributions to defined contribution plan | 1,275,000 | $ 1,384,000 | $ 1,471,000 |
United States | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined benefit plan, expected employer contribution in next fiscal year | 0 | ||
German Plan | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined benefit plan, expected employer contribution in next fiscal year | $ 0 |
Pension and Other Post Retire_8
Pension and Other Post Retirement Benefit Plans - Schedule of Future Expected Pension Payments (Detail) - Gentherm GmbH $ in Thousands | Dec. 31, 2020USD ($) |
United States | |
Defined Benefit Plan Disclosure [Line Items] | |
2021 | $ 342 |
2022 | 342 |
2023 | 342 |
2024 | 342 |
2025 | 342 |
2026-2030 | 1,710 |
Total projected pension benefit payments | 3,420 |
German Plan | |
Defined Benefit Plan Disclosure [Line Items] | |
2021 | 296 |
2022 | 291 |
2023 | 301 |
2024 | 295 |
2025 | 287 |
2026-2030 | 2,886 |
Total projected pension benefit payments | $ 4,356 |
Commitments and Contingencies -
Commitments and Contingencies - Reconciliation of Changes in Accrued Warranty Costs (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Loss Contingency [Abstract] | ||
Balance at beginning of year | $ 4,596 | $ 4,514 |
Warranty claims paid | (2,598) | (584) |
Warranty expense for products shipped during the current period | 1,223 | 2,370 |
Adjustments to warranty estimates from prior periods | (893) | (1,660) |
Acquisition of business | 21 | |
Adjustments due to currency translation | 63 | (65) |
Balance at end of year | $ 2,391 | $ 4,596 |
Commitments and Contingencies_2
Commitments and Contingencies - Additional Information (Detail) | 12 Months Ended |
Dec. 31, 2020Agreement | |
Loss Contingencies [Line Items] | |
Number of agreements expire in 2021 | 0 |
Labor agreements expiration period | 2021 |
Labor Agreements | |
Loss Contingencies [Line Items] | |
Percentage of workforce as members of industrial trade unions | 25.00% |
Earnings Per Share (Detail)
Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Earnings Per Share [Abstract] | |||
Net income | $ 59,690 | $ 48,866 | $ 41,899 |
Basic weighted average shares of Common Stock outstanding | 32,666,025 | 33,120,076 | 35,920,782 |
Dilutive effect of stock options, restricted stock awards and restricted stock units | 362,079 | 177,513 | 256,362 |
Diluted weighted average shares of Common Stock outstanding | 33,028,104 | 33,297,589 | 36,177,144 |
Basic earnings per share | $ 1.83 | $ 1.48 | $ 1.17 |
Diluted earnings per share | $ 1.81 | $ 1.47 | $ 1.16 |
Anti-dilutive securities share impact | 12,000 | 214,000 | 898,250 |
Reconciliation of Cash and Cash
Reconciliation of Cash and Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Accounting Policies [Abstract] | ||||
Cash and cash equivalents presented in the consolidated balance sheets | $ 268,345 | $ 50,443 | ||
Restricted cash | 2,505 | |||
Cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows | $ 268,345 | $ 52,948 | $ 39,620 | $ 103,172 |
Financial Instruments - Additio
Financial Instruments - Additional Information (Detail) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Derivative [Line Items] | ||
Maximum length of time to hedges exposure to foreign currency exchange risk | 12 months | |
Foreign Currency Derivatives | ||
Derivative [Line Items] | ||
Notional Value | $ 13,299,000 | $ 14,449,000 |
Interest Rate Swap | ||
Derivative [Line Items] | ||
Hedge Ineffectiveness Incurred | $ 0 | $ 0 |
Information Related to Recurrin
Information Related to Recurring Fair Value Measurement of Derivative Financial Instruments in the Consolidated Balance Sheet (Detail) - Fair Value, Inputs, Level 2 - Foreign Currency Derivatives - Designated as Hedging Instrument - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Derivatives Fair Value [Line Items] | ||
Net Asset/ (Liabilities) | $ 1,513 | $ 1,242 |
Other Current Assets | ||
Derivatives Fair Value [Line Items] | ||
Asset Derivatives, Fair Value | $ 1,513 | $ 1,242 |
Information Related to Effect o
Information Related to Effect of Derivative Instruments in the Consolidated Statements of Income (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Derivative Instruments Gain Loss [Line Items] | ||
Gain (loss) on derivatives | $ (1,475) | $ 3,081 |
Other comprehensive income | Foreign Currency Derivatives | ||
Derivative Instruments Gain Loss [Line Items] | ||
Gain (loss) on derivatives | 272 | 1,151 |
Cost of sales | Foreign Currency Derivatives | ||
Derivative Instruments Gain Loss [Line Items] | ||
Gain (loss) on derivatives | (1,629) | 1,976 |
Foreign currency loss | Foreign Currency Derivatives | ||
Derivative Instruments Gain Loss [Line Items] | ||
Gain (loss) on derivatives | $ (118) | $ (46) |
Fair Value Measurement - Additi
Fair Value Measurement - Additional Information (Detail) - USD ($) | Dec. 31, 2020 | Dec. 31, 2019 |
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Carrying value | $ 192,434,000 | $ 80,624,000 |
DEG Vietnam Loan | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Carrying value | 6,250,000 | 8,750,000 |
Fair value | 6,360,000 | 8,785,000 |
Fair Value, Recurring Basis | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Financial assets, fair value | 0 | 0 |
Financial liabilities, fair value | 0 | 0 |
Fair Value, Nonrecurring Basis | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Financial assets, fair value | 0 | 0 |
Financial liabilities, fair value | 0 | $ 0 |
Fair Value, Nonrecurring Basis | Level 3 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Estimated fair value related to other intangible assets | $ 4,380,000 |
Equity - Additional Information
Equity - Additional Information (Detail) - USD ($) $ in Thousands | Dec. 11, 2020 | Jun. 30, 2018 | Dec. 31, 2016 | Dec. 31, 2020 | Dec. 31, 2019 |
Class Of Stock [Line Items] | |||||
Common Stock, shares authorized | 55,000,000 | 55,000,000 | |||
Preferred stock, shares authorized | 4,991,000 | ||||
Common Stock, shares issued | 32,921,341 | 32,674,354 | |||
Common Stock, shares outstanding | 32,921,341 | 32,674,354 | |||
Preferred stock, shares issued | 0 | ||||
Preferred stock, shares outstanding | 0 | ||||
Stock repurchase program period | 3 years | ||||
Stock repurchase program, authorized amount | $ 100,000 | ||||
Authorized increase and extension in stock repurchase program amount | $ 300,000 | ||||
Stock repurchase program extended expiration date | 2020-12 | ||||
Shares repurchased | 9,092 | ||||
Remaining authorized repurchase amount | $ 74,226 | ||||
2020 Stock Repurchase Program | |||||
Class Of Stock [Line Items] | |||||
Stock repurchase program period | 3 years | ||||
Stock repurchase program expiration date | Dec. 15, 2023 | ||||
Maximum | |||||
Class Of Stock [Line Items] | |||||
Shares issued | 59,991,000 | ||||
Maximum | 2020 Stock Repurchase Program | |||||
Class Of Stock [Line Items] | |||||
Stock repurchase program, authorized to repurchase amount | 150,000,000 |
Schedule of Reclassification Ad
Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | ||
Accumulated Other Comprehensive Income Loss [Line Items] | ||||
Beginning Balance | $ (42,355) | $ (39,500) | $ (20,444) | |
Cumulative effect of accounting change due to ASU 2018-02 | (40) | |||
Other comprehensive income (loss) before reclassifications | 25,068 | (1,334) | (17,852) | |
Income tax effect of other comprehensive income (loss) before reclassifications | 593 | (654) | (742) | |
Amounts reclassified from accumulated other comprehensive loss into net income | 2,154 | (1,108) | (391) | |
Income taxes reclassified into net income | (442) | 241 | (31) | |
Other comprehensive income (loss), net of tax | 27,373 | (2,855) | (19,056) | |
Ending Balance | (14,982) | (42,355) | (39,500) | |
Defined Benefit Pension Plans | ||||
Accumulated Other Comprehensive Income Loss [Line Items] | ||||
Beginning Balance | (3,371) | (2,339) | (2,366) | |
Cumulative effect of accounting change due to ASU 2018-02 | (49) | |||
Other comprehensive income (loss) before reclassifications | (328) | (1,264) | 18 | |
Income tax effect of other comprehensive income (loss) before reclassifications | 117 | 232 | (15) | |
Amounts reclassified from accumulated other comprehensive loss into net income | 131 | 73 | ||
Other comprehensive income (loss), net of tax | (80) | (1,032) | 27 | |
Ending Balance | (3,451) | (3,371) | (2,339) | |
Foreign Currency Translation Adjustments | ||||
Accumulated Other Comprehensive Income Loss [Line Items] | ||||
Beginning Balance | (39,879) | (37,157) | (17,555) | |
Other comprehensive income (loss) before reclassifications | 27,147 | (2,329) | (19,212) | |
Income tax effect of other comprehensive income (loss) before reclassifications | 95 | (393) | (390) | |
Other comprehensive income (loss), net of tax | 27,242 | (2,722) | (19,602) | |
Ending Balance | (12,637) | (39,879) | (37,157) | |
Commodity Hedge Derivatives | ||||
Accumulated Other Comprehensive Income Loss [Line Items] | ||||
Beginning Balance | 277 | |||
Cumulative effect of accounting change due to ASU 2018-02 | 9 | |||
Amounts reclassified from accumulated other comprehensive loss into net income | [1] | (218) | ||
Income taxes reclassified into net income | (68) | |||
Other comprehensive income (loss), net of tax | (277) | |||
Foreign Currency Hedge Derivatives | ||||
Accumulated Other Comprehensive Income Loss [Line Items] | ||||
Beginning Balance | 895 | (4) | (800) | |
Other comprehensive income (loss) before reclassifications | (1,751) | 2,259 | 1,342 | |
Income tax effect of other comprehensive income (loss) before reclassifications | 381 | (493) | (337) | |
Amounts reclassified from accumulated other comprehensive loss into net income | [1] | 2,023 | (1,108) | (246) |
Income taxes reclassified into net income | (442) | 241 | 37 | |
Other comprehensive income (loss), net of tax | 211 | 899 | 796 | |
Ending Balance | $ 1,106 | $ 895 | $ (4) | |
[1] | The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instrument`s on our consolidated statements of income. |
Accounting for Stock Based Co_3
Accounting for Stock Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands | May 21, 2020 | May 19, 2017 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | May 16, 2013 |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Performance based restricted stock units outstanding | 34,906 | 34,920 | 136,566 | 282,100 | |||
Shareholder Return Award Performance Measurement Period | 3 years | ||||||
Unrecognized compensation cost related to non-vested options, restricted stock, restricted stock units and PSUs | $ 13,604 | $ 13,168 | |||||
Unrecognized share-based compensation cost recognition period | 2 years | ||||||
Share based compensation expense | $ 14,323 | 8,589 | $ 12,177 | ||||
Deferred tax benefit | $ 3,002 | $ 1,573 | $ 2,434 | ||||
Granted, Shares | 0 | 0 | 0 | ||||
Total intrinsic value of options exercised | $ 5,317 | $ 1,681 | $ 5,061 | ||||
Total fair value of restricted shares vested | $ 1,499 | $ 3,697 | $ 4,599 | ||||
Performance Based Restricted Stock Units | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Performance based restricted stock units outstanding | 315,834 | ||||||
These awards vesting period | 3 years | ||||||
Stock option achieving minimum threshold | 50.00% | ||||||
Stock option achieving maximum threshold | 200.00% | ||||||
RSU | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Performance based restricted stock units outstanding | 524,739 | 331,821 | 215,969 | ||||
Total intrinsic value of restricted stock units vested | $ 2,214 | $ 1,000 | $ 0 | ||||
Stock Appreciation Rights (SARs) | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Total intrinsic value of options exercised | $ 4,164 | $ 1,588 | $ 3,532 | ||||
ROIC | Performance Based Restricted Stock Units | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Performance based restricted stock payment condition | one-half | ||||||
TSR | Performance Based Restricted Stock Units | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Performance based restricted stock payment condition | one-half | ||||||
Employee and Consultants | Minimum | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Share based compensation, requisite service period | 3 years | ||||||
Employee and Consultants | Maximum | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Share based compensation, requisite service period | 4 years | ||||||
Director | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Share based compensation, requisite service period | 1 year | ||||||
2013 Plan | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Number of shares authorized for grant | 3,021,451 | ||||||
Number of shares authorized for grant | 3,500,000 | ||||||
Number of increased shares available for grant | 2,450,000 | 2,000,000 | |||||
Equity Incentive Plan Twenty Eleven and Two Thousand and Six | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Number of shares authorized for grant | 0 |
Accounting for Stock Based Co_4
Accounting for Stock Based Compensation - Summarizes Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ||||
Stock Options Outstanding, beginning balance, Shares | 869,000 | 1,653,000 | 2,652,142 | |
Granted, Shares | 0 | 0 | 0 | |
Exercised, Shares | (434,250) | (428,250) | (615,358) | |
Forfeited, Shares | (6,750) | (355,750) | (383,784) | |
Stock Options Outstanding, ending balance, Shares | 428,000 | 869,000 | 1,653,000 | 2,652,142 |
Stock Options Exercisable, Shares | 338,625 | |||
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price | $ 37.87 | $ 38.53 | $ 35.34 | |
Exercised, Weighted-Average Exercise Price | 38.12 | 38.66 | 24.01 | |
Forfeited, Weighted-Average Exercise Price | 38.05 | 39.99 | 39.59 | |
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price | $ 37.61 | $ 37.87 | 38.53 | $ 35.34 |
Exercisable, Weighted-Average Exercise Price | $ 37.87 | |||
Stock Options Outstanding, Weighted-Average Remaining Contractual Term | 3 years 2 months 12 days | 3 years 6 months 3 days | 4 years 3 months 10 days | 4 years 9 months 3 days |
Exercisable, Weighted-Average Remaining Contractual Term | 3 years 1 month 9 days | |||
Stock Options Outstanding, Aggregate Intrinsic Value | $ 11,815 | $ 5,172 | $ 3,610 | $ 6,964 |
Exercisable, Aggregate Intrinsic Value | $ 9,261 |
Accounting for Stock Based Co_5
Accounting for Stock Based Compensation - Summarizes Restricted Stock Activity (Detail) - $ / shares | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |||
Outstanding at beginning of period, Shares | 34,920 | 136,566 | 282,100 |
Granted, Shares | 32,406 | 19,920 | 21,681 |
Vested, Shares | (32,420) | (91,566) | (130,684) |
Forfeited, Shares | (30,000) | (36,531) | |
Outstanding at end of period, Shares | 34,906 | 34,920 | 136,566 |
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value | $ 38.31 | $ 37.16 | $ 38.06 |
Granted, Weighted-Average Grant Date Fair Value | 39.96 | 40.16 | 35 |
Vested, Weighted-Average Grant Date Fair Value | 38.33 | 37.09 | 38.62 |
Forfeited, Weighted-Average Grant Date Fair Value | 38.05 | 37.60 | |
Outstanding at end of period, Weighted-Average Grant Date Fair Value | $ 39.82 | $ 38.31 | $ 37.16 |
Accounting for Stock Based Co_6
Accounting for Stock Based Compensation - Summarizes Restricted Stock Unit Activity (Detail) - shares | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Outstanding at beginning of period, Shares | 34,920 | 136,566 | 282,100 |
Granted, Shares | 32,406 | 19,920 | 21,681 |
Vested, Shares | (32,420) | (91,566) | (130,684) |
Forfeited, Shares | (30,000) | (36,531) | |
Outstanding at end of period, Shares | 34,906 | 34,920 | 136,566 |
RSU | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Outstanding at beginning of period, Shares | 331,821 | 215,969 | |
Granted, Shares | 288,798 | 220,146 | 215,969 |
Vested, Shares | (50,953) | (23,956) | |
Forfeited, Shares | (44,927) | (80,338) | |
Outstanding at end of period, Shares | 524,739 | 331,821 | 215,969 |
RSU | Time Vesting Shares [Member] | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Outstanding at beginning of period, Shares | 141,741 | 86,392 | |
Granted, Shares | 132,864 | 107,391 | 86,392 |
Vested, Shares | (50,953) | (23,956) | |
Forfeited, Shares | (14,747) | (28,086) | |
Outstanding at end of period, Shares | 208,905 | 141,741 | 86,392 |
RSU | ROIC Target Shares [Member] | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Outstanding at beginning of period, Shares | 95,041 | 64,785 | |
Granted, Shares | 77,967 | 56,380 | 64,785 |
Forfeited, Shares | (15,090) | (26,124) | |
Outstanding at end of period, Shares | 157,918 | 95,041 | 64,785 |
RSU | TSR Target Shares [Member] | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Outstanding at beginning of period, Shares | 95,039 | 64,792 | |
Granted, Shares | 77,967 | 56,375 | 64,792 |
Forfeited, Shares | (15,090) | (26,128) | |
Outstanding at end of period, Shares | 157,916 | 95,039 | 64,792 |
Accounting for Stock Based Co_7
Accounting for Stock Based Compensation - Summarizes Stock Appreciation Rights (SARs) Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Stock Options Outstanding, beginning balance, Shares | 869,000 | 1,653,000 | 2,652,142 | |
Granted, Shares | 0 | 0 | 0 | |
Exercised, Shares | (434,250) | (428,250) | (615,358) | |
Forfeited, Shares | (6,750) | (355,750) | (383,784) | |
Stock Options Outstanding, ending balance, Shares | 428,000 | 869,000 | 1,653,000 | 2,652,142 |
Exercisable, Ending Balance | 338,625 | |||
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price | $ 37.87 | $ 38.53 | $ 35.34 | |
Exercised, Weighted-Average Exercise Price | 38.12 | 38.66 | 24.01 | |
Forfeited, Weighted-Average Exercise Price | 38.05 | 39.99 | 39.59 | |
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price | $ 37.61 | $ 37.87 | 38.53 | $ 35.34 |
Exercisable, Weighted Average Exercise Price | $ 37.87 | |||
Stock Options Outstanding, Weighted-Average Remaining Contractual Term | 3 years 2 months 12 days | 3 years 6 months 3 days | 4 years 3 months 10 days | 4 years 9 months 3 days |
Exercisable, Weighted-Average Remaining Contractual Term | 3 years 1 month 9 days | |||
Outstanding, Aggregate Intrinsic Value | $ 11,815 | $ 5,172 | $ 3,610 | $ 6,964 |
Exercisable, Aggregate Intrinsic Value | $ 9,261 | |||
Stock Appreciation Rights (SARs) | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Stock Options Outstanding, beginning balance, Shares | 554,250 | 988,100 | 1,192,350 | |
Exercised, Shares | (342,150) | (179,500) | (204,250) | |
Forfeited, Shares | (40,500) | (254,350) | ||
Stock Options Outstanding, ending balance, Shares | 171,600 | 554,250 | 988,100 | 1,192,350 |
Exercisable, Ending Balance | 131,350 | |||
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price | $ 39.41 | $ 40.61 | $ 38.17 | |
Exercised, Weighted-Average Exercise Price | 38.22 | 32.84 | 26.35 | |
Forfeited, Weighted-Average Exercise Price | 44.39 | 42.63 | ||
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price | $ 40.60 | $ 39.41 | 40.61 | $ 38.17 |
Exercisable, Weighted Average Exercise Price | $ 41.39 | |||
Stock Options Outstanding, Weighted-Average Remaining Contractual Term | 2 years 5 months 8 days | 2 years 10 months 2 days | 3 years 6 months 25 days | 4 years 4 months 9 days |
Exercisable, Weighted-Average Remaining Contractual Term | 3 years 1 month 2 days | |||
Outstanding, Aggregate Intrinsic Value | $ 4,224 | $ 2,981 | $ 2,064 | $ 2,278 |
Exercisable, Aggregate Intrinsic Value | $ 3,131 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Income Taxes [Line Items] | ||||
Undistributed earnings offsetting with dividend received deduction percent | 100.00% | |||
Income tax holiday, amount of corporate income tax savings realized | $ 21,866 | $ 10,285 | $ 16,220 | |
Total unrecognized tax benefits | $ 4,967 | 3,795 | 2,819 | $ 3,812 |
Macedonia | ||||
Income Taxes [Line Items] | ||||
Income tax holiday, description | The government of Macedonia granted the Company a tax holiday that released the Company from the obligation to pay corporate income taxes for a ten year period, subject to certain limitations. | |||
Income tax holiday, period | 10 years | |||
Income tax holiday, amount of corporate income tax savings realized | $ 0 | $ 0 | $ 0 | |
U.S. State | Earliest Tax Year | ||||
Income Taxes [Line Items] | ||||
Operating loss carryforward, year of expiration | 2021 | |||
U.S. State | Latest Tax Year | ||||
Income Taxes [Line Items] | ||||
Operating loss carryforward, year of expiration | 2040 | |||
Non-U.S. Subsidiaries | ||||
Income Taxes [Line Items] | ||||
Operating loss carryforward, amount | $ 169,293 | |||
Operating loss valuation allowance | 5,787 | |||
Foreign Jurisdictions | ||||
Income Taxes [Line Items] | ||||
Operating loss carryforward, amount | $ 7,441 | |||
Foreign Jurisdictions | Earliest Tax Year | ||||
Income Taxes [Line Items] | ||||
Operating loss carryforward, year of expiration | 2021 | |||
Foreign Jurisdictions | Latest Tax Year | ||||
Income Taxes [Line Items] | ||||
Operating loss carryforward, year of expiration | 2025 | |||
Indefinite | ||||
Income Taxes [Line Items] | ||||
Operating loss carryforward, amount | $ 161,851 | |||
Net operating loss carryforward, year of expiration | no expiration date |
Income Taxes - (Loss) Earnings
Income Taxes - (Loss) Earnings Before Income Taxes and Tax Provisions - (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
(Loss) earnings before income tax: | |||
Domestic | $ (11,374) | $ 74,531 | $ 10,092 |
Foreign | 92,930 | (15,380) | 48,027 |
Earnings before income tax | $ 81,556 | $ 59,151 | $ 58,119 |
Income Taxes - Provision for In
Income Taxes - Provision for Income Taxes (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Current income tax expense (benefit): | |||
Federal | $ 784 | $ 262 | $ 340 |
State and local | 83 | 94 | (71) |
Foreign | 20,150 | 17,672 | 9,224 |
Total current income tax expense | 21,017 | 18,028 | 9,493 |
Deferred income tax expense (benefit): | |||
Federal | (2,302) | (2,490) | (1,422) |
State and local | 32 | (1) | 20 |
Foreign | 3,119 | (5,252) | 8,129 |
Total deferred income tax expense | 849 | (7,743) | 6,727 |
Total income tax expense | $ 21,866 | $ 10,285 | $ 16,220 |
Income Taxes - Deferred Tax Ass
Income Taxes - Deferred Tax Assets and Deferred Tax Liabilities (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Deferred tax assets: | ||
Net operating losses | $ 22,658 | $ 17,881 |
Intangible assets | 29,145 | 33,743 |
Research and development credits | 10,773 | 9,752 |
Depreciation | 7,426 | 7,223 |
Valuation reserves and accrued liabilities | 7,131 | 7,196 |
Stock compensation | 4,200 | 3,485 |
Defined benefit obligation | 1,974 | 2,027 |
Inventory | 1,571 | 1,284 |
Other credits | 12,068 | 11,753 |
Unrealized foreign currency exchange loss | 1,431 | |
Other | 64 | 113 |
Total deferred tax asset | 98,441 | 94,457 |
Valuation allowance | (17,197) | (17,316) |
Deferred tax liabilities: | ||
Unrealized foreign currency exchange gains | (674) | |
Undistributed profits of subsidiary | (5,727) | (4,629) |
Property and equipment | (2,758) | (3,366) |
Other | (572) | (733) |
Total deferred tax liability | (9,057) | (9,402) |
Net deferred tax asset | $ 72,187 | $ 67,739 |
Income Taxes - Reconciliations
Income Taxes - Reconciliations Between Statutory Federal Income Tax Rate and Effective Rate (Detail) | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | |||
Statutory Federal income tax rate | 21.00% | 21.00% | 21.00% |
Increase (decrease) resulting from: | |||
Change in valuation allowance | (0.40%) | 11.50% | (6.60%) |
Effect of different tax rates of foreign jurisdictions | (4.70%) | (24.80%) | (6.60%) |
Audit settlements and statute expirations | 3.90% | 0.60% | (1.10%) |
US tax reform items | 2.50% | 4.30% | 10.80% |
Research and development credits | (1.40%) | (2.30%) | (2.50%) |
Non-deductible expenses | 2.10% | 2.10% | 3.40% |
Foreign, state and local tax, net of Federal benefit | 1.40% | 1.70% | 1.80% |
Tax effects of intercompany transfers | 1.40% | 1.50% | 0.80% |
Undistributed profit of subsidiaries | 0.90% | 1.20% | 1.20% |
Other | 0.10% | 0.60% | 5.70% |
Effective rate | 26.80% | 17.40% | 27.90% |
Income Taxes - Net Operating Lo
Income Taxes - Net Operating Loss Carryforwards (Detail) $ in Thousands | 12 Months Ended |
Dec. 31, 2020USD ($) | |
U.S. state income tax | |
Operating Loss Carryforwards [Line Items] | |
Operating loss carryforward, amount | $ 106,987 |
U.S. state income tax | Minimum | |
Operating Loss Carryforwards [Line Items] | |
Operating loss carryforward, year of expiration | 2021 |
U.S. state income tax | Maximum | |
Operating Loss Carryforwards [Line Items] | |
Operating loss carryforward, year of expiration | 2040 |
Foreign | |
Operating Loss Carryforwards [Line Items] | |
Operating loss carryforward, amount | $ 7,441 |
Foreign | Minimum | |
Operating Loss Carryforwards [Line Items] | |
Operating loss carryforward, year of expiration | 2021 |
Foreign | Maximum | |
Operating Loss Carryforwards [Line Items] | |
Operating loss carryforward, year of expiration | 2025 |
Indefinite | |
Operating Loss Carryforwards [Line Items] | |
Operating loss carryforward, amount | $ 161,851 |
Operating loss carryforward, year of expiration | Never |
Income Taxes - Reconciliation o
Income Taxes - Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | |||
Balance at beginning of year | $ 3,795 | $ 2,819 | $ 3,812 |
Additions based on tax position related to current year | 1,489 | 661 | 221 |
Additions based on tax position related to prior year | 179 | 352 | 423 |
Reductions from settlements and statute of limitation expiration | (650) | (1,469) | |
Effect of foreign currency translation | 154 | (37) | (168) |
Balance at end of year | $ 4,967 | $ 3,795 | $ 2,819 |
Revenue Recognition - Additiona
Revenue Recognition - Additional Information (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2020USD ($) | |
Revenue Recognition And Deferred Revenue [Abstract] | |
Aggregate amount of transaction price allocated to material rights that remain unsatisfied under LTAs | $ 181 |
Revenue expected to be recognized in 2021 | 32.00% |
Revenue expected to be recognized in 2022 | 48.00% |
Revenue expected to be recognized in 2023 | 20.00% |
Revenue Recognition - Additio_2
Revenue Recognition - Additional Information (Details 1) | Dec. 31, 2020 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01 | |
Deferred Revenue Arrangement [Line Items] | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01 | |
Deferred Revenue Arrangement [Line Items] | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-01-01 | |
Deferred Revenue Arrangement [Line Items] | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period | 1 year |
Segment Reporting - Segment Inf
Segment Reporting - Segment Information About Reported Product Revenues and Operating Income (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Segment Reporting Information [Line Items] | |||
Product revenues | $ 913,098 | $ 971,684 | $ 1,048,505 |
Type of Revenue [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember |
Depreciation and amortization | $ 41,114 | $ 44,246 | $ 50,638 |
Operating income (loss) | 89,217 | 84,260 | 72,788 |
Automotive Segments | |||
Segment Reporting Information [Line Items] | |||
Product revenues | $ 869,998 | $ 920,225 | $ 957,824 |
Type of Revenue [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember |
Depreciation and amortization | $ 37,662 | $ 40,923 | $ 44,246 |
Operating income (loss) | 138,410 | 141,206 | 136,421 |
Medical Segments | |||
Segment Reporting Information [Line Items] | |||
Product revenues | $ 43,100 | $ 51,459 | $ 90,681 |
Type of Revenue [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember |
Depreciation and amortization | $ 2,366 | $ 1,621 | $ 3,759 |
Operating income (loss) | $ 971 | $ (5,735) | $ (6,900) |
Corporate Segments | |||
Segment Reporting Information [Line Items] | |||
Type of Revenue [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember |
Depreciation and amortization | $ 1,086 | $ 1,702 | $ 2,633 |
Operating income (loss) | $ (50,164) | $ (51,211) | $ (56,733) |
Segment Reporting - Segment I_2
Segment Reporting - Segment Information About Reported Segment Product Revenues by Product Category (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Segment Reporting Information [Line Items] | |||
Product revenues | $ 913,098 | $ 971,684 | $ 1,048,505 |
Automotive Segments | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 869,998 | 920,225 | 957,824 |
Automotive Segments | Climate Control Seat (CCS) | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 342,550 | 359,355 | 373,945 |
Automotive Segments | Seat Heaters | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 249,665 | 284,174 | 305,337 |
Automotive Segments | Steering Wheel Heaters | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 76,272 | 65,426 | 69,845 |
Automotive Segments | Automotive Cables | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 73,997 | 88,031 | 98,931 |
Automotive Segments | Electronics | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 53,238 | 47,542 | 56,783 |
Automotive Segments | Battery Thermal Management (BTM) | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 50,901 | 41,498 | 28,472 |
Automotive Segments | Other Automotive | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 23,375 | 34,199 | 24,511 |
Industrial Segments | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 43,100 | 51,459 | 90,681 |
Industrial Segments | Medical | |||
Segment Reporting Information [Line Items] | |||
Product revenues | $ 43,100 | 36,860 | 30,108 |
Industrial Segments | GPT | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 11,181 | 19,520 | |
Industrial Segments | CSZ-IC | |||
Segment Reporting Information [Line Items] | |||
Product revenues | $ 3,418 | $ 41,053 |
Segment Reporting (Detail)
Segment Reporting (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Segment Reporting Information [Line Items] | |||
Product revenues | $ 913,098 | $ 971,684 | $ 1,048,505 |
Type of Revenue [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember |
United States | |||
Segment Reporting Information [Line Items] | |||
Product revenues | $ 377,577 | $ 440,316 | $ 488,926 |
China | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 101,039 | 71,461 | 93,628 |
South Korea | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 88,745 | 63,339 | 58,717 |
Germany | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 58,536 | 81,315 | 88,366 |
Japan | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 57,785 | 76,197 | 62,633 |
Czech Republic | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 37,542 | 38,888 | 42,665 |
Other | |||
Segment Reporting Information [Line Items] | |||
Product revenues | 191,874 | 200,168 | 213,570 |
Non U.S. | |||
Segment Reporting Information [Line Items] | |||
Product revenues | $ 535,521 | $ 531,368 | $ 559,579 |
Segment Reporting - Percentage
Segment Reporting - Percentage of Total Product Revenues Generated from Customers (Detail) - Sales Revenue, Net - Customer Concentration Risk | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Lear | |||
Segment Reporting Information [Line Items] | |||
Total product revenues in percentage | 15.00% | 16.00% | 17.00% |
Adient | |||
Segment Reporting Information [Line Items] | |||
Total product revenues in percentage | 14.00% | 15.00% | 16.00% |
Segment Reporting - Segment Rep
Segment Reporting - Segment Reporting About Property and Equipment, Net by Geographic Areas (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Segment Reporting Information [Line Items] | ||
Property and equipment, net | $ 152,581 | $ 160,605 |
Macedonia | ||
Segment Reporting Information [Line Items] | ||
Property and equipment, net | 38,273 | 38,989 |
Vietnam | ||
Segment Reporting Information [Line Items] | ||
Property and equipment, net | 21,080 | 21,452 |
China | ||
Segment Reporting Information [Line Items] | ||
Property and equipment, net | 20,375 | 23,721 |
United States | ||
Segment Reporting Information [Line Items] | ||
Property and equipment, net | 19,011 | 21,280 |
Mexico | ||
Segment Reporting Information [Line Items] | ||
Property and equipment, net | 16,034 | 19,982 |
Germany | ||
Segment Reporting Information [Line Items] | ||
Property and equipment, net | 15,641 | 10,515 |
UKRAINE | ||
Segment Reporting Information [Line Items] | ||
Property and equipment, net | 9,364 | 11,727 |
Hungary | ||
Segment Reporting Information [Line Items] | ||
Property and equipment, net | 8,401 | 6,803 |
Other | ||
Segment Reporting Information [Line Items] | ||
Property and equipment, net | $ 4,402 | $ 6,136 |
Valuation and Qualifying Acco_2
Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Allowance for Doubtful Accounts | |||
Valuation And Qualifying Accounts Disclosure [Line Items] | |||
Balance at Beginning of Period | $ 1,193 | $ 851 | $ 973 |
Charged to Costs and Expenses | 1,298 | 969 | 1,005 |
Charged to Other Accounts | 33 | (8) | (121) |
Deductions from Reserves | (1,363) | (619) | (1,006) |
Balance at End of Period | 1,161 | 1,193 | 851 |
Allowance for Deferred Income Tax Assets | |||
Valuation And Qualifying Accounts Disclosure [Line Items] | |||
Balance at Beginning of Period | 17,316 | 9,977 | 27,578 |
Charged to Costs and Expenses | 7,830 | ||
Charged to Other Accounts | 139 | (491) | (14,009) |
Deductions from Reserves | (258) | (3,592) | |
Balance at End of Period | 17,197 | 17,316 | 9,977 |
Reserve for Inventory | |||
Valuation And Qualifying Accounts Disclosure [Line Items] | |||
Balance at Beginning of Period | 6,073 | 6,270 | 7,887 |
Charged to Costs and Expenses | 1,768 | 1,679 | 2,712 |
Charged to Other Accounts | 214 | (56) | (1,047) |
Deductions from Reserves | (914) | (1,820) | (3,282) |
Balance at End of Period | $ 7,141 | $ 6,073 | $ 6,270 |